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General abstract 
In Europe and Northern America, protein intake is high, whilst fibre intake is relatively 
low. With large amounts of protein entering the colon, bacterial proteolysis may have 
some negative effects through potentially toxic end-products. Prebiotics could have the 
potential to reverse negative consequences of gut bacterial protein fermentation. 
 
Single stage, pH controlled, anaerobic, stirred batch culture systems simulating the 
distal colon were applied first with faecal inoculum from both omnivore and vegetarian 
volunteers. Fermentation of different protein sources with and without supplementation 
of inulin type fructans (ITF) were tested. A significant increase of bifidobacteria was 
observed with the addition of the ITF together with lower concentrations of protein 
fermentation metabolites (BCFA and ammonia). 
 
Three-stage continuous colonic model systems simulating the whole colon were then 
studied with both omnivore and vegetarian volunteers. Casein, with and without two 
different doses of ITF were assessed. A significantly higher number of bifidobacteria 
and reduction of bacteroides and Desulfovibrio spp. were found with ITF addition. 
Furthermore, production of metabolites from protein fermentation (BCFA and 
ammonia) was significantly lowered with ITF.  
 
To confirm the health benefit of ITF on high protein population in vivo, 43 volunteers 
were recruited to complete a randomised, double blind, cross over trial. A significant 
increase in bifidobacteria and a decrease in Desulfovibrio spp. was confirmed with the 
addition of prebiotic treatment. Stool frequency was significantly higher with ITF as 
compared to the placebo group, with a trend towards softness as based on the Bristol 
scale. Total bacteria and bifidobacteria changes during interventions were significantly 
correlated with stool frequency. 
 
In conclusion, all three phases of the project found favourable bacterial and metabolic 
changes with ITF supplementation. ITF had inhibitory effects on colonic microbial 
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proteolysis, and could exert health benefit for high protein consumers, especially those 
who also consume low fibre diet.  
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Chapter 1  
1.1 Prebiotic Ingredients in Probiotic Dairy Products  
 
X. Wang and R.A. Rastall 
 
 
1.1.1 Introduction 
 
The human body functions as a complex ecosystem with more micro-organisms being 
present than human cells. The gastrointestinal tract is the biggest and most important 
habitat for micro-organisms due to the abundance of nutrients in the form of digesta 
that flows through the lumen without being absorbed by the small intestine. According 
to several human intestinal metagenomic studies, the most widely represented phyla of 
micro-organisms in the human gut are Firmicutes, Bacteroidetes, Actinobacteria, 
Proteobacteria, Verrucomicrobia, Fusobacteria, and Euryarchaeota methanogens 
(Arumugam et al., 2011, Eckburg et al., 2005). The gastrointestinal tract’s 
physiochemical status affects the microbiota to a large extent. Due to the low pH of the 
stomach, only a few microorganisms can survive there. Although pH fluctuates in the 
small intestine as a result of the secretion of alkaline pancreatic juices and acid bile, 
numbers of bacteria increase gradually and reach high number in large intestine. On the 
other hand, the microbiota composition and metabolism affect host health in various 
ways, for instance by influencing immunity, mineral absorption, energy intake 
regulation and lipid metabolism. A good symbiosis between the human body and its 
microbiota is essential for human health, whereas dysbiosis, which can be caused by 
antibiotic therapy, drugs, diseases, injury, surgery, stress, or aging, is problematic. Diet 
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plays an important role on the gut microbiota, therefore food ingredients and 
supplements that can promote beneficial bacteria can confer health benefits.  
Prebiotics are defined as “selectively fermented ingredients that result in 
specific changes, in the composition and/or activity of the gastrointestinal microbiota, 
thus conferring benefit upon host health” (Gibson et al. (2010). Prebiotics not only 
boost the growth of beneficial bacteria in the gastrointestinal (GI) tract, but also have 
the potential to inhibit pathogens, improve mineral absorption, increase satiety and 
improve wellbeing. 
 
1.1.2 Criteria for an ingredient to be classified as a prebiotic 
 
Prebiotics were originally defined by Gibson and Roberfroid (1995) as “a non-
digestible food ingredient that beneficially affects the host by selectively stimulating 
the growth and/or activity of one or a limited number of bacteria in the colon, and thus 
improves host health”. Since then the definition has been revisited several times and 
criteria have been proposed to qualify a compound as prebiotic. There are three criteria 
as proposed by Gibson et al. (2004):  
• Non-digestibility: resistant to gastric acid, hydrolysate enzymes, and 
gastrointestinal absorption. 
• Fermentable by gut microbiota. 
• Selectivity: selectively boost the growth or/and the activity of beneficial colonic 
bacteria. 
Current recognised prebiotics are all carbohydrates: non-digestible 
oligosaccharides that contain different oligomers of saccharides with different degree 
of polymerisation.  
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Inulin-type fructans are oligo- or poly-saccharides composed principally of 
fructose. D-fructose molecules are linked by β (2→1) linkages and the chain is 
terminated by a D-glucose molecule bonded with fructose by an α(12) linkage; inulin 
often refers to molecules with more than 10 degrees of polymerisation (DP) whereas 
fructooligosaccharide (FOS) or oligofructose (OF) often refers to molecules with 2~10 
DP. Inulin is naturally present in many plants such as chicory, artichoke, leek, banana, 
asparagus, and onion. Fructooligosaccharides also occur in natural food as well as being 
produced from sucrose or inulin. These molecules can stay intact until reaching the 
colon, where they principally simulate the growth of bifidobacteria (Kelly, 2008).  
Galactooligosaccharides (GOS) are oligosaccharides with DP less than 10 that 
consist of one or more galactose residues and a terminal glucose, or they are 
disaccharides of galactose (Gosalbes et al.). Galactooligosaccharides can be produced 
from lactose and in the GI tract can enhance the growth of bifidobacteria while 
supressing the growth of clostridia; this has been shown both in vitro and in vivo 
(Rycroft et al., 2001, Vulevic et al., 2013, Giovannini et al., 2014). 
Other carbohydrates that have been investigated as candidate prebiotics 
include human milk oligosaccharides, resistant starch (RS), isomaltooligosaccharides, 
lactosucrose, xylooligosaccharides (XOS), lactulose, soya/soybean oligosaccharides, 
glucooligosaccharides, arabinoxylan, arabinogalactans, pectin/pectic oligosaccharides, 
seaweeds/microalgae and β-glucans. 
 
1.1.3 Health benefits of prebiotics and their mechanisms of action 
 
Commensal bacteria in the human gut can utilise undigested carbohydrates or proteins 
as energy sources. Microbial breakdown of carbohydrates produces short chain fatty 
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acids (SCFA) (e.g. acetate, propionate, and butyrate), ethanol, formate, lactate, 
succinate, carbon dioxide, methane and hydrogen through various pathways. Protein 
fermentation also generates SCFA, ethanol, gases and other organic acids together with 
branched chain fatty acids (BCFA), such as iso-butyrate and iso-valerate, ammonia 
(NH3), and amines. Fermentation of aromatic amino acids leads to the production of 
phenolic and indolic compounds, whereas fermentation of sulphur containing amino 
acids often generates hydrogen sulphide (H2S). In general, SCFA are believed to be 
involved in various health benefits (Russell et al., 2013); however NH3, phenolic and 
indolic compounds, and H2S are believed to have a negative impact on human cells, as 
indicated by various in vitro cell studies (Windey et al., 2012). Commensal bacteria in 
the human gut can be saccharolytic, proteolytic or both. Consumption of prebiotics 
usually promotes increased growth of beneficial saccharolytic bacteria and an increase 
in saccharolytic activity of the gut microbiota, resulting in increased SCFA production 
 
1.1.3.1 Short chain fatty acids (SCFA) and human metabolism 
 
Bacteria are present throughout the gastrointestinal tract; however they are more 
abundant in the large intestine than the small intestine. This coincides with the SCFA 
concentration within the human body: SCFA are at low concentrations in the terminal 
ileum and high in the colon, which confirms the role of colonic bacteria in SCFA 
production (Cummings et al., 1987). Within the colon, SCFA are produced primarily 
in the ascending colon where substrates are abundant and to a lesser extent in the 
descending colon where most substrates have been utilised by the bacteria in the early 
part of the colon and are scarce.  Although the concentration of SCFA in the human gut 
varies between individuals, the ratio of acetate, propionate, butyrate and BCFA is 
generally around 50:20:20:10 (Cummings et al., 1987, Macfarlane and Macfarlane, 
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2003). Whether considering the amount of substrates reaching the lower gut and then 
being fermented, or the requirement to sustain the survival of colonic bacteria, the 
amount of SCFA produced in the human colon is considerable, however, human faecal 
output contains only low amounts of SCFA (Cummings, 1981). This is due to SCFA 
absorption in the colon, which not only happens in humans but also in other mammalian 
species such as rat, horse, and pig. McNeil et al. (1978) studied 46 human subjects’ 
rectal SCFA absorption by connecting dialysis bags filled with different testing 
solutions to the volunteers’ rectum. The fluid in the dialysis bags was measured before 
and one hour after connecting: this showed that absorption of SCFA occurs together 
with the excretion of bicarbonate and that absorption of SCFA is not related to the pH 
level in the lumen.  
After absorption by the colon, butyrate is present in low concentrations in 
portal blood due to utilisation of butyrate as an energy source by colonic epithelial cells. 
The remaining SCFA are transported to the liver (Cummings et al., 1987). Colonocytes 
oxidise acetate, propionate, butyrate, glucose and glutamine to generate energy; 
however butyrate is the preferred substrate for colonocytes. The presence of butyrate 
inhibits the oxidation of other energy sources with the preference order being: 
butyrate>acetate>propionate>glucose>glutamine (Clausen and Mortensen, 1995). 
After being absorbed by the colon, SCFA are transported to the liver via portal blood. 
Most propionate and butyrate is metabolised by the liver, however, acetate is further 
transported by the venous blood to peripheral tissues (Bloemen et al., 2009). In venous 
blood, more than 90% of SCFA is acetate, which can join the tricarboxylic acid cycle 
in peripheral tissues by forming acetyl-CoA and then providing energy (Cummings et 
al., 1987). Around one third of the acetate absorbed from the colon will be taken by the 
cells in peripheral tissues providing energy (Cummings et al., 1987).  
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1.1.3.2 Mineral absorption 
 
Prebiotic consumption can directly lead to an increase in mineral absorption. Feeding 
rats with FOS can improve the absorption by the gut of multiple minerals including 
calcium, magnesium, and iron (Ohta et al., 1995, Delzenne et al., 1995). 
Supplementation with prebiotics, such as GOS, lactulose and other resistant 
carbohydrates, to rats also revealed similar findings: calcium absorption by the gut was 
enhanced (Brommage et al., 1993, Chonan et al., 1995) The GOS study also measured 
bone ash and found that rats fed with GOS had higher levels, implying that prebiotics 
can improve bone health (Chonan et al., 1995). 
Most studies on prebiotics and mineral absorption have focussed on calcium 
as it is crucial for bone health, especially in children and women. Most calcium in the 
human body is distributed in bones and the adult calcium levels are maintained by a 
dynamic equilibrium of calcium deposition and resorption. Bone calcium in elderly 
people decreases, particularly in postmenopausal women. Calcium deficiency in 
children causes rickets, while low bone mass in the elderly causes osteoporosis and 
elevated risk of fracture (Greer et al., 2006, Jackson et al., 2006). Calcium is absorbed 
by both active absorption, which is vitamin D dependent, and in the small intestine by 
passive absorption.  
Many human trials have been carried out and these have confirmed that 
prebiotics stimulate mineral absorption. Such studies have investigated FOS, inulin, 
GOS and lactulose or have targeted specific groups (male and female adolescents, and 
postmenopausal women), (van den Heuvel et al., 2009, van den Heuvel et al., 1999b, 
van den Heuvel et al., 2000, Whisner et al., 2013, van den Heuvel et al., 1999a). 
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The mechanism underlying prebiotic stimulation of mineral absorption is not 
fully known; however, it may involve protonation of the minerals which increases 
passive absorption across cell membranes. A feeding study involving 10 ileostomy 
subjects fed with FOS, inulin and sucrose did not show changes in mineral absorption 
indicating that the effect of prebiotics occurs in the large intestine (Ellegard et al., 
1997).  
  
1.1.3.3 Energy intake and appetite regulation 
 
There is increasing interest in the potential role of the microbiome in human energy 
metabolism. In an acute study that used inulin as a fat replacer in a sausage patty, a 
significant decrease of 1521kJ energy intake was seen (P=0.039) compared to the full-
fat patty; this was similar to results obtained in a study using inulin in yoghurt (Archer 
et al., 2004, Perrigue et al., 2009). Twenty one volunteers had two consecutive days of 
FOS and β-glucan supplement and did not show any difference in satiety compared 
with the control intervention (Peters et al., 2009). However, five volunteers who were 
on a supplementation of 16 g of FOS for 2 weeks showed an enhancement of satiation 
compared with another 5 volunteers who had placebo (Cani et al., 2006). 
It is hard to quantify satiety and satiation; however, gut hormones that regulate 
energy intake can be quantified. There are a number of hormones that are secreted by 
the gastrointestinal tract that can affect energy intake and satiety. They are produced by 
different cells and have various functions on satiety regulation. Table 1.1 shows a list 
of gut hormones and how they affect satiety. 
Table 1.1 Gastrointestinal hormones 
Name  Secretion site Produced by Hormone 
signals 
targeting organ  
Effect on 
food intake 
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Ghrelin Stomach Gastric 
oxyntic cells 
Vagus and 
hypothalamus 
Increase 
Cholecystokinin 
(CCK) 
Small 
intestine 
I-cells Vagus and 
brainstem 
Decrease 
Glucagon-Like 
Peptide-1 
(GLP-1) 
Ileum and 
colon 
L-cells Vagus and 
brainstem 
Decrease 
Polypeptide YY 
(PYY) 
Ileum and 
colon 
L-cells Hypothalamus Decrease 
Oxyntomodulin  Ileum and 
colon 
L-cells Hypothalamus Decrease 
Table compiled from Cummings & Overduin (2007). 
 
Bioactive glucagon-like peptide-1 (GLP-1) has two forms: GLP-1(7-37) and 
GLP-1(7-36), which can both be obtained from the biologically inactive 37 amino acid 
peptide GLP-1(1-37) by cleavage of the peptide chain. Both forms of bioactive GLP-1 
have alanine at position 2, so they can be inactivated by dipeptidyl peptidase-4 which 
breaks down alanine containing peptides. The molecules can then be cleared through 
the kidneys. Glucagon-like peptide-1 (GLP-1) is produced in L-cells in the gut, but the 
receptor for GLP-1 is present in pancreatic islets mainly β cells, kidney, lung, heart and 
nervous system. In addition, GLP-1 can increase gastric emptying time by 
communicating with the nervous system. Glucagon-like peptide-1 not only increases 
insulin secretion, but also enhances the storage of insulin and stimulates insulin gene 
expression; it can also mediate glucose levels by glucagon secretion inhibition and 
activation of glucose disposal sensors (Drucker, 2006). Seven days of FOS 
supplementation significantly increased gastric transit time and higher plasma GLP-1 
levels in nine gastroesophageal reflux disease patients (Piche et al., 2003). A placebo 
controlled study with 48 volunteers on a 12 weeks’ intervention confirmed FOS can 
regulate energy intake, decrease ghrelin and increase plasma peptide YY (PYY) 
(Parnell and Reimer, 2009).  
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Gut hormones involved in energy homeostasis can be regulated by prebiotics 
via metabolites, such as SCFA. Infusion of SCFA directly into rat colon increased PYY, 
and in pigs both PYY and GLP-1 reached higher concentration after SCFA infusion 
(Cherbut et al., 1998, Cuche et al., 2000). Short chain fatty acids also have their own 
receptors, which can affect energy uptake and storage. G protein receptor 40 (GPR40), 
GPR41, GPR43 are also known as free fatty acid receptor 1 (FFA1), FFA3, FFA2. Free 
fatty acid 1 is activated by long chain fatty acids; however, FFA2 and FFA3 can be 
activated by SCFA. Both of these SCFA receptors are expressed in a variety of human 
tissues including the colon (Tazoe et al., 2009, Karaki et al., 2008). Free fatty acid 2 is 
more highly expressed in immune cells, and FFA3 has the highest expression in adipose 
tissues (Brown et al., 2003). For FFA2, the agonist strength is propionate = butyrate = 
acetate > valerate, while for FFA3, propionate = valerate = butyrate > acetate (Brown 
et al., 2003). Free fatty acid 2 is expressed in colon L cells and can activate PYY 
secretion, while FFA3 stimulates the secretion of leptin in adipose tissues (Karaki et 
al., 2008, Xiong et al., 2004).  
Propionate and its potential for energy regulation were observed in a human 
study: inulin-propionate ester (10 g d-1) was fed to 60 overweight adults recruited on a 
randomised, double-blind, placebo-controlled, parallel study. Acute measurements 
revealed that inulin-propionate ester significantly increased plasma concentration of 
PYY and GLP-1 after 6 hours compared to inulin; after 24 weeks supplementation, the 
inulin-propionate ester group gained less weight and had less low density lipoprotein 
(LDL) -cholesterol and total cholesterol compared to the inulin group (Chambers et al., 
2015).  
 
1.1.3.4 Lipid metabolism 
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High concentrations of LDL-cholesterol and triacylglycerol in the blood are risk factors 
for cardiovascular disease. Triacylglycerol levels can be reduced by prebiotics partly 
by their regulation of gut hormones and fat intake. Short chain fatty acid receptor FFA2 
is involved in mediating plasma fatty acid level by inhibiting lipolysis and simulating 
adipogenesis (Stoddart et al., 2008). Prebiotics can modulate microbiota composition 
with a bifidogenic effect, and anaerobic growth of lactobacilli and bifidobacteria can 
assimilate cholesterol with bile salts (Pereira and Gibson, 2002b). In rats prebiotic 
supplementation can inhibit hepatic lipogenesis by downregulating lipogenesis 
enzymes (Kok et al., 1996). Intervention with FOS resulted in  reduction of blood 
glucose and LDL-cholesterol in 18 diabetic subjects compared to 10 diabetic subjects 
who received sucrose (Yamashita et al., 1984). Other studies, mainly on inulin type 
fructans, have produced inconsistent results where reduction of LDL-cholesterol or 
triacylglycerol was not always observed. These studies, however, targeted different 
groups and used different doses of prebiotics (Canzi et al., 1996, Davidson et al., 1998, 
Pedersen et al., 1997)  
 
1.1.3.5 Immune function modulation of prebiotics 
 
An immune system that functions properly is able to protect the human body from 
invasion of pathogens and other antigens; however, immunity disorders can lead to 
problems, such as allergy, and inflammatory disease. Prebiotics can modulate immune 
function from two perspectives: they enhance the defence against pathogenic infections 
and reduce unwanted inflammatory events. Short chain fatty acids receptors, which are 
discussed in Section 1.1.3.4, may help to modulate immunity in the human body: FFA2 
expression is highest in immune cells which indicates SCFA may be involved in host 
defences (Le Poul et al., 2003).  
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Prebiotic defence against pathogens can prevent acute gastroenteritis or 
shortens its duration. Two research groups have studied two different prebiotics for 
their effect on travellers’ diarrhoea: GOS had significant improvement on both the 
occurrence (P<0.05) and the length of travellers’ diarrhoea (P<0.05); however, a study 
on FOS improved the general wellbeing of volunteers but did not show improvement 
on diarrhoea (Cummings et al., 2001, Drakoularakou et al., 2010). Another study used 
a synbiotic containing FOS and two strains of probiotics also failed to find any impact 
on traveller’s diarrhoea (Virk et al., 2013). The rationale behind any effect is that 
prebiotics often shorten gastrointestinal transit time resulting in excretion of pathogens 
before they have had time to grow. Furthermore, supplementation with prebiotics 
boosts the growth of beneficial bacteria that compete with the pathogens.  
Inflammatory bowel disease (IBD) describes two gastrointestinal disorders 
ulcerative colitis (UC) and Crohn’s disease (CD), which present as abnormal 
inflammation. These disorders are believed to be related to gut microbiota dysbiosis, 
therefore by modulating gut bacteria composition, prebiotics have the potential to 
improve wellbeing or even ease the symptoms of IBD. Fructooligosaccharides (15 g 
daily) reduced CD activity in 10 patients was observed by Lindsay et al. (2006); 
however, there was no significant finding with another study feeding 103 patients 15 g 
FOS daily (Benjamin et al., 2011). Fourteen UC patients and seventeen CD patients 
received 10 g lactulose every day for 4 months, and although no disease parameter 
improved, quality of life scores increased with lactulose compared to before the 
intervention (Hafer et al., 2007). A synbiotic with FOS, inulin and ‘Bifidobacterium 
longum/Synergy 1’ (presumed to be Bifidobacterium longum subsp. longum/Synergy 
1) resulted in a significant improvement in disease parameters in a randomised placebo 
controlled trial with 18 UC patients (Furrie et al., 2005). There are not many human 
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trials into the effects of prebiotics on IBD, and those trials that had positive results did 
not have high number of patients, more research needs to be done.  
Atopic dermatitis is an allergic skin disease that mostly happens in early 
infancy and childhood. There is evidence that feeding infants with mixed prebiotics can 
reduce incidence of atopic dermatitis; however, the severity of ongoing atopic 
dermatitis was not improved by GOS as indicated by the results of a randomised control 
trial with 107 infants (Bozensky et al., 2015, Moro et al., 2006, Gruber et al., 2010)  
 
1.1.3.6 Colorectal cancer risk and prebiotics 
 
Since prebiotics can benefit human gut health in many aspects, their effects on 
colorectal cancer have also been investigated. Feeding colon cancer patients with 
prebiotic for 12 weeks did not result in any significant difference in cancer related 
biomarkers compared to control group (Rafter et al., 2007). However, an observational 
study with a large population and a 9 year follow up revealed that dietary fibre 
consumption and colorectal cancer risk were negatively correlated (Bingham et al., 
2003). Direct studies of the mechanism by which prebiotics may lower human 
colorectal cancer risk are few in number, but many in vitro or animal studies have been 
done. Three groups of mice had six weeks supplementation of inulin, FOS or cellulose 
were then challenged with carcinogen, and abnormal crypt foci were significantly lower 
in the prebiotic group compared to the control group (Buddington et al., 2002). 
Prebiotics may not be able to cure colon cancer, but they show potential for reducing 
the risk of colorectal cancer incidence. Two mouse studies found FOS, long chain 
inulin, and a mixture of both could affect the onset of colon cancer by inducing 
apoptosis (Hughes and Rowland, 2001, Femia et al., 2002). Burns and Rowland (2004) 
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found that fermentation by probiotics and faecal genotoxic water with FOS or inulin 
helped human cells resist genotoxicity.  
Prebiotics may reduce the genotoxicity of faecal water by modulating the 
metabolism of the gut microbiota. Proteolysis by gut bacteria can generate carcinogens 
or co-carcinogens. Fermentation of aromatic amino acids, for instance, generates 
indolic or phenolic compounds, which are generally considered as carcinogens. 
Supplementation of prebiotics can shift the microbiota to a more saccharolytic one by 
increasing the number of bifidobacteria and lactobacilli, thereby reducing production 
of such carcinogenic compounds. The primary bile acids are synthesised in the liver 
from cholesterol, and some of them can escape intestinal absorption to be metabolised 
by colonic bacteria. Secondary bile acids are produced by bacterial groups, such as 
bacteroides, clostridia, lactobacilli, bifidobacteria, and Eubacterium, by deconjugation 
and dihydroxylation (Ridlon et al., 2006). Secondary bile acids can lead to a loss of 
mucosal cells in the colon due to disruption of the cell membrane and, furthermore, 
induce hyper-proliferation of mucosal cells that helps the development of colon cancer 
(Nagengast et al., 1995). Prebiotics can possibly reduce secondary bile acids production 
by changing microbial metabolism and reducing colonic transit time. Glucuronidation 
is one of the most important and widely present detoxification pathways in human body. 
β-glucuronidase activity of some bacteria, which can deconjugate toxins, leads to a 
longer transit time of toxins; this leads to an increase of cytotoxicity and genotoxicity.   
Prebiotics possibly exert apoptosis induction by SCFA production. In healthy 
subjects, colonic epithelial cells, which are derived from stem cells, start from the 
bottom of crypts. They move to the proliferation region and then move upwards until 
undergoing programmed cell death at the top of crypts; epithelial cells become 
increasingly more differentiated during this process towards apoptosis. Short chain fatty 
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acids are believed to enhance cell differentiation and cell apoptosis, with butyrate being 
the most effective (Hague et al., 1995). Butyrate can act as a histone deacetylase 
inhibitor, which can selectively modulate gene expressions involved with the cell cycle 
(Boffa et al., 1978, Sambucetti et al., 1999).  
 
1.1.3.7 Gut permeability  
 
The gut forms a semipermeable barrier preventing the translocation of antigens, 
proinflammatory compounds and toxins from the digestive lumen to the sterile organs 
and tissues; reduced gut barrier function is related to infection, carcinogenesis and other 
chronic diseases. Supplementation with FOS for 2 weeks did not result in improvement 
in gut barrier function among 34 healthy volunteers (Ten Bruggencate et al., 2006). 
However, a human study feeding volunteers with inulin enriched pasta for 5 weeks 
revealed decreased gut permeability (Russo et al., 2012). An in vitro study indicated 
that a prebiotic along with a probiotic exerted better improvement of barrier function 
compared to the prebiotic alone (Commane et al., 2005).  
The mechanism behind this could be SCFA modulation of cell signalling 
pathways. The colonic mucosa has a layer of cells joined by tight junctions composed 
of specific proteins, for instance, claudins and occludin, which forms a physical barrier. 
Direct application of mixed SCFA to rat intestinal wall resulted in reduced permeability 
with higher concentrations of acetate exerting better effects (Suzuki et al., 2008). 
Butyrate is believed to be an epithelial cell differentiation inducer and differentiated 
mature epithelial cells have enhanced expression of tight junction proteins. Bordin et 
al. (2004) found that butyrate treatment of several cell lines resulted in an increase in 
tight junction protein expression. 
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1.1.3.8 Colon motility and faecal bulking with application to constipation 
 
Generally, prebiotics increase faecal weight, colon motility and decrease colonic transit 
time which can exert benefits, such as soothing constipation. Short chain fatty acids 
produced by fermentation may also play crucial roles in colon motility: propionate 
increased muscle contraction frequency in rats possibly linked to the SCFA receptors 
FFA2 and FFA3 (Tazoe et al., 2008), and reported studies on colon motility in relation 
to prebiotic food supplementation are shown in Table 1.2.  
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Table 1.2 Human studies of colon motility and faecal bulking with prebiotic supplementation 
Prebiotics and control 
or placebo 
Duration of the 
treatment 
Targeted group and 
subjects number 
Results References 
Low RS (5 g) and 
high RS (39 g) 
3 weeks - a 
crossover study 
11 healthy human 
subjects 
Increased faecal 
weight 
Phillips et al. (1995) 
GOS (9 g d-1) 2 weeks - a 
crossover study 
14 elderly females 
suffering 
constipation 
Increased 
defecation 
frequency 
Teuri and Korpel 
(1998) 
GOS (15 g d-1) 2 weeks - 
before and after 
treatment 
12 healthy human 
subjects 
Increased 
defecation 
frequency 
Teuri et al. (1998) 
Control diet, wheat 
bran diet and wheat 
bran + RS diet 
3 weeks - a 
crossover study 
12 healthy human 
subjects with 
family history of 
colorectal cancer 
Increased faecal 
weight and 
defecation 
frequency 
Muir et al. (2004) 
Inulin (13 g d-1) 3 weeks - a 
crossover study 
15 wheelchair 
bound adults 
Increased faecal 
weight and no 
difference in 
defecation 
frequency 
Dahl et al. (2005) 
Inulin (20 g) and 
resistant maltodextrin  
20 d - a placebo 
controlled parallel 
study 
32 constipation 
sufferers 
Increased 
defecation 
frequency and 
improvement of 
constipation  
Roman et al. (2008) 
Polydextrose (8 g d-1) 3 weeks - a 
placebo controlled 
parallel study 
45 healthy human 
subjects 
Increased 
defecation 
frequency and no 
difference in faecal 
weight 
Hengst et al. (2009) 
Inulin (20 g d-1) 3 weeks - a 
crossover study 
12 healthy male 
subjects 
No difference in 
both faecal weight 
and defecation 
frequency 
Slavin and Feirtag 
(2011) 
Inulin and guar gum 
mixture (15 g) 
3 weeks - a 
placebo controlled 
parallel study 
60 female 
constipation 
sufferers  
Increased 
defecation 
frequency but no 
difference between 
control and 
prebiotic groups 
Linetzky Waitzberg 
et al. (2012) 
Abbreviations:- GOS = galactooligosaccharides; RS = resistant starch. 
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1.1.4 Inulin-type fructans as prebiotics 
 
Inulin type fructans, which include FOS with DP 2-10 and inulin with DP>10, are 
comprised of a number of fructose residues sometimes with a glucose at the terminal: 
D-fructose molecules are linked by β (2→1) linkages and when there is a glucose, the 
chain is terminated by a D-glucose molecule bonded with fructose by an α (12) 
linkage (see Fig. 1.1). Fructan is a generic term used for all molecules that contain one 
or more fructosyl-fructose links such as inulin and laevan, which mainly has β (2→6) 
linkages. In this section, inulin type fructans are discussed.  
Figure 1.1 The chemical structure of FOS (n=2-9) and inulin (n>9) 
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Both inulin and FOS are widely present in nature and have been in the human 
diet for a very long time. Due to variations in dietary habits, people consuming Western 
diets obtain 1-10 g of inulin type fructans, while people consuming an American diet 
obtain 5.1 g on average with 2.6 g of inulin and 2.5 g of FOS (van Loo et al., 1995, 
Moshfegh et al., 1999). The occurrence of these fructans in the human diet is mainly in 
plant-based foods, especially onion, Jerusalem artichoke, chicory and asparagus. Table 
1.3 shows a list of plant foods that are rich in inulin in the Western diet. In addition, 
people from India, Japan, and other parts of the world also consume dahlia tuber and 
thistles roots, which also contain inulin type fructans (van Loo et al., 1995).  
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Table 1.3 Inulin rich plant foods in the Western diet and their inulin content 
Name Inulin content (100 
g-1) 
Degrees of 
polymerisation 
of its inulin 
Characteristics 
Onion 1.1-7.5 g 2-12 Depolymerise 
during storage 
Asparagus 2-3 g --- --- 
Jerusalem 
artichoke 
16-20 g 2-50 --- 
Leek 3 g 12 --- 
Rye flour 0.5-1 g --- Resistant to baking 
Garlic 9.8-16 g 2-50 --- 
Dandelion  12-15 g --- --- 
Artichokes globe 2.5-9.5 g ≥ 19 High DP range 
Barley 0.5-1 g --- --- 
Banana  0.3-0.7 g --- --- 
Wheat 1-4 g 50% of its inulin 
≤5 
Resistant to baking 
Chicory root 15-20 g 2-65 Resistant to 
roasting: > 70% of 
its inulin is still 
present after 
roasting 
Footnote: --- = data was not reported. 
Data adapted from van Loo et al. (1995). 
 
The degree of polymerisation of these plant fructans is relatively low with a 
maximum DP<200 and they also tend to be less branched, whereas fructans from 
bacterial origin can be both highly branched and highly polymerised with a maximum 
DP up to 100 000 (Roberfroid, 2005b). The food industry uses chicory root to produce 
inulin and its derivatives because the dry weight of chicory root contains > 70% of 
inulin (van Loo et al., 1995).  
 
1.1.4.1 Determination of inulin type fructans 
 
Both capillary gas chromatography (CGC) and high pressure liquid chromatography 
(HPLC) can be used for the determination of short chain fructans, such as FOS. Sample 
preparation for HPLC is quick and straightforward as diluted samples can be injected 
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into the HPLC. van Loo et al. (1995) used two packed Aminex HPX87K columns with 
water (H2O) (pH 9.5 adjusted by potassium hydroxide - KOH) as eluent and the 
separation was performed at 85°C. Sample preparation for CGC included adding 
internal standard, dilution with water, drying, formation of oxime by hydroxylamine-
HCl, derivatisation with trimethylsilylimidazole (TSIM), extraction of silylated 
fructans by addition of isooctane, and centrifugation; separation was performed by a 
capillary column together with a flame-ionisation detector with an helium gas flow of 
9 mL min-1 (van Loo et al., 1995). The American Official Association of Chemists 
(AOAC) validated two methods to quantify fructans: AOAC method 997.08 and AOAC 
method 999.03, analysis by high performance anion exchange chromatography with 
pulsed amperometric detection (HPAEC-PAD) and spectrophotometry, respectively. 
Both depend on enzymatic treatment to hydrolyse the polysaccharide and release sugars 
for analysis. Method 997.08 of the AOAC needs three chromatography readings from 
one sample to quantify fructans: the quantity after direct hot water extraction, quantity 
after amyloglucosidase treatment of the first extraction and quantity after fructozyme 
treatment of the second extraction (Hoebregs, 1997). Method 999.03 of the AOAC 
contains two enzymatic treatments: hydrolysis of starch and sucrose by a mixture of 
enzymes followed by reduction with borohydride, then hydrolysis of fructans by a 
fructanase mixture followed by spectrophotometric determination of the reducing 
sugars with para-hydroxybenzoic acid hydrazide (McCleary et al., 2000).  
 
1.1.4.2 Production of inulin type fructans 
 
As discussed above, chicory roots are the main raw material for inulin production on 
an industrial scale. The extraction of inulin from chicory roots is carried out by diffusion 
in hot water, purification and then spray drying, in a process similar to extraction of 
21 
 
sucrose from sugar beet. The inulin produced by simple extraction is native inulin or 
standard inulin which has DP from 2 to 65 and average DP 12, such as Orafti® ST from 
Beneo in Belgium. Native inulin can be refined by physical separation to obtain high 
polymerised inulin (inulin HP) with DP 10-60 and average DP 25, such as Orafti® HP 
from Beneo in Belgium.  
The partial enzymatic hydrolysis of inulin can produce FOS with DP 2-7 and 
an average DP of 4, by means of an endoinulinase (EC 3.2.1.7) or an exo-inulinase (EC 
3.2.1.80) together with the endoinulinase (Roberfroid, 2007, Roberfroid, 2005a). 
Fructooligosaccharides can also be synthesised from sucrose by fructosyltranferases 
(EC 3.2.1.99 and EC 3.2.1.100), which catalyse the transfer of fructofuranosyl residues 
from sucrose (Gibson et al., 2006). The transfer of fructofuranosyl residue from sucrose 
to sucrose, the growing fructan chain, or water, can produce GF2 (where G represents 
glucose, F represents fructose, and 2 represents the number of fructose moieties), extend 
the fructan chain, or breakdown sucrose respectively. The yield of FOS from synthesis 
is around 55%-60% and separation is needed to obtain purified FOS (Gibson et al., 
2006).  
Long chain inulin and short chain FOS may exert different health benefits, 
therefore, Beneo provide a product known as Synergy 1®, which is a mixture of short 
chain FOS and long chain inulin HP.  
 
1.1.4.3 Physical and chemical characteristic of inulin type fructans and application in the 
food industry  
 
Chicory root inulins are white odourless powders, while FOS can be a powder obtained 
by spray drying or a viscous syrup with 75 g 100 g-1 dry matter obtained by evaporation 
(Franck, 2002). Inulin type fructans do not possess any off flavour or aftertastes; FOS 
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and native inulin have a slightly sweet taste due to the small amount of glucose, fructose 
and sucrose present. Water solubility negatively correlates with inulin chain length: at 
25°C, more than 75% of FOS can dissolve in water, whereas only 2.5% of inulin HP 
can dissolve in water. Although inulin and FOS can resist general food processing, such 
as heat, the linkage between fructoses can breakdown at very low pH. Dissolving inulin 
in water or any other liquid results in a gel with a creamy structure that can be used as 
a fat replacer (Franck, 2002). Inulin can support most gelling agents, stabilise foam and 
emulsions and improve the taste and texture of bakery and cereal products (Franck, 
2002). It has been used in many foods, such as baked goods, baby food, beverages, 
breakfast cereals, candy, dairy products, frozen desserts, soups and sauces and table 
spreads.  
 
1.1.4.4 Prebiotic effects of inulin type fructans 
 
One of the main characteristics of prebiotics is their resistance to digestion in the GI 
tract. Humans and other mammals lack the enzyme to breakdown the β (2→1) linkages 
within inulin and FOS. Human studies have confirmed that most inulin and FOS are 
not absorbed by the small intestine: 88% of FOS and 89% of inulin were recovered in 
the ileostomy effluent of 10 ileostomy patients (Ellegard et al., 1997). However, gut 
bacteria do possess enzymes that hydrolyse β (2→1) linkages. and McKellar and 
Modler (1989) found that three strains of bifidobacteria have cell associated β-
fructosidases that hydrolyse inulin type fructans, although different strains may have 
different preference for chain length. Enrichment culture of different species of 
bifidobacteria also revealed their growth by metabolisation of FOS (Gibson and Wang, 
1994). Twenty-eight strains of lactobacilli, bifidobacteria, and Streptococcus 
thermophilus were examined in MRS agar together with FOS: 12 out of 16 strains of 
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lactobacilli, 6 out of 7 strains of bifidobacteria, and none of the Streptococcus 
thermophilus strains were capable of utilising FOS (Kaplan and Hutkins, 2000). 
Bifidogenic effects of inulin and FOS were observed by Wang and Gibson (1993) in an 
in vitro single vessel fermentation simulating the human colon, which was achieved by 
inoculation with human faecal slurries. A number of human studies have been carried 
out with different dosages, treatment durations, numbers of volunteers and different 
target groups to investigate the microbiota composition changes associated with inulin 
or FOS supplementation. All of the studies found there was an elevated bifidobacterial 
count, which in some cases was significant (Hidaka, 1991, Williams et al., 1994, 
Gibson et al., 1995, Buddington et al., 1996, Kleessen et al., 1997, Bouhnik et al., 1999, 
Kruse et al., 1999). Gibson et al. (1995) put eight volunteers on a controlled diet for 45 
d, feeding them with 15 g sucrose for the first 15 d, then 15 d with 15 g FOS. Four 
volunteers continued to complete another intervention for 15 d with 15 g inulin. The 
authors did not observe any change in total faecal bacteria; however, both FOS and 
inulin boosted growth of bifidobacteria significantly. Furthermore, decreased level of 
bacteroides, clostridia, and fusobacteria were seen in this diet-controlled study.  
 
1.1.4.5 Health benefits of inulin type fructans 
 
Inulin type fructans are the best studied prebiotics and many human studies have been 
carried out to investigate various health benefits, such as increased mineral absorption, 
effect on energy regulation, effect on lipid metabolism, improvement of immunity, 
potential to prevent colorectal cancer and gut function improvement.  
Most of the mineral absorption studies have focused on calcium intake with an 
emphasis on postmenopausal women and girls. Supplementation of inulin or FOS in 
postmenopausal women resulted in increased in absorption and bone health (based on 
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bone turnover markers and other biomarkers) in different studies using various 
methods, dosage of inulin or FOS and products (Tahiri et al., 2003, Holloway et al., 
2007, Adolphi et al., 2009, Slevin et al., 2014, Kruger et al., 2015). Inulin type fructans 
have also been shown to increase calcium absorption in adolescents, both male and 
female (van den Heuvel et al., 1999a, Griffin et al., 2002, Griffin et al., 2003, Abrams 
et al., 2005, Abrams et al., 2007a). However, one study showed contradictory results: 
10 g d-1 of FOS for 36 d did not reveal any improvement in calcium absorption, but 
subjects in this study were girls low calcium intake (van den Heuvel et al., 2009). A 
further two studies have been carried out in healthy adults and these resulted in 
improvement of calcium absorption (Coudray et al., 1997, Abrams et al., 2007b). 
Enhancement of magnesium absorption by inulin type fructans was observed in both 
postmenopausal women and young girls (Tahiri et al., 2001, van den Heuvel et al., 
2009).  
As discussed in Section 1.1.3.4, satiety and energy intake regulation is another 
possible health benefit from prebiotics. Inulin type fructans showed improvement of 
satiation in some human intervention studies and some studies have measured 
hormones, which are related to energy regulation and revealed enhancement of satiation 
(Cani et al., 2006, Antal et al., 2008, Parnell and Reimer, 2009, Tarini and Wolever, 
2010, Russo et al., 2011a). Although inulin and FOS showed potential to regulate 
energy intake, 8 g d-1 of FOS for 12 weeks failed to reduce weight in overweight and 
obese children (Liber and Szajewska, 2014), therefore, the long term effects on weight 
management needs further investigation.  
Lipid lowering effects of inulin type fructans were studied in 18 subjects with 
diabetes: reductions of blood glucose, total cholesterol, and LDL-cholesterol were seen 
in those who received 8 g d-1 of FOS for 14 d (Yamashita et al., 1984). Two studies 
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with 4 week interventions of FOS or inulin did not find any difference in the lipid 
profiles of healthy subjects (Luo et al., 1996, Pedersen et al., 1997). Seventeen healthy 
volunteers had either placebo or a mixture of inulin and FOS for 6 months and this 
resulted in only a trend for total cholesterol and LDL-cholesterol reduction in the inulin 
study group (Forcheron and Beylot, 2007). Many other studies in different target 
groups, such as healthy subjects, hypercholesterolemia and individuals with type 2 
diabetes, found that inulin significantly improved lipid profile, at different doses, study 
durations and monitored parameters (Davidson et al., 1998, Brighenti et al., 1999, 
Jackson et al., 1999, Causey et al., 2000, Letexier et al., 2003, Russo et al., 2008, 
Dehghan et al., 2013).  
Elderly people tend to have weaker immune function, hence there is an interest 
in improving their health by prebiotic supplementation. Nineteen elderly individuals 
were recruited in a study supplementing 8 g d-1 of FOS for 3 weeks and their immunity 
was compared before and after the intervention: there was a reduction of phagocytic 
activity after the treatment, however, a decrease of IL-6 was observed with FOS 
supplementation (Guigoz et al., 2002). Another cross-over study had 43 elderly subjects 
being given a synbiotic comprising the probiotic ‘Bif. longum’ (presumed to be Bif. 
longum subsp. longum; Mattarelli et al., 2008) and FOS enriched inulin. Pro-
inflammatory cytokines were significantly lower in the synbiotic treatment group 
(Macfarlane et al., 2013). This inhibition of pro-inflammatory cytokines was also seen 
in healthy adult volunteers aged 18-24 supplemented given a combination of xylose 
oligosaccharides (XOS) and inulin (Lecerf et al., 2012a). FOS enriched inulin improved 
seasonal influenza vaccination in middle aged-humans, as seen by increased antibody 
titres after vaccination (Lomax et al., 2015). However, supplementation of FOS in 
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infant cereal did not show any change in subjects’ immune function (Duggan et al., 
2003).  
A synbiotic featuring ‘Bif. longum’ (presumed to be Bif. longum subsp. longum) 
and FOS enriched inulin not only reduced UC patients’ inflammatory cytokines, but 
also improved epithelial tissue regeneration (Furrie et al., 2005). Studies on Crohn’s 
disease have not shown any change (Lindsay et al., 2006, Benjamin et al., 2011). Apart 
from these studies on inflammatory bowel diseases, one study showed that intervention 
with 24 g d-1 of inulin for 3 weeks decreased inflammation in patients who had ileal 
pouch-anal anastomosis (Welters et al., 2002).  
Some animal models have suggested that inulin can reduce cancer risk, and 
Pool-Zobel (2005) reviewed data from animal models that investigated the effects of 
inulin type fructans on colorectal cancer risk. Inulin type fructans can reduce faecal 
water genotoxicity and reduce secondary bile acid production in humans (Klinder et al., 
2004, Boutron-Ruault et al., 2005). However, experimental results with human 
colorectal cancer patients are controversial: different studies have monitored 
genotoxicity, proliferation, immune parameters or aberrant crypt foci. Only a limited 
number of studies with inulin type fructans have shown significant changes in colorectal 
cancer patients (Rafter et al., 2007, Roller et al., 2007, Limburg et al., 2011). 
 
1.1.5 Galactooligosaccharides (GOS) as prebiotics 
 
Studies of infant faecal microbiota composition found different patterns depending on 
feeding regime: (a) bifidobacteria tend to be higher in breastfed infants compared to 
formula-fed or formula-breast mixed fed infants, (b) clostridia and some facultative 
microbes are lower in breastfed infants, and (c) proteolytic metabolism is less active in 
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breastfed infants (Stark and Lee, 1982, Benno et al., 1984, Mevissenverhage et al., 
1987, Harmsen et al., 2000b, Heavey et al., 2003). This led to the identification and 
isolation of bifidogenic compounds in human milk. Human milk contains more 
oligosaccharides compared to cow’s milk, and some of them have a galactose-glucose 
structure (Kobata and Ginsburg, 1969, Kobata and Ginsburg, 1972, Yamashit.K and 
Kobata, 1974, Yamashita et al., 1976b, Yamashita et al., 1976a, Yamashita et al., 
1977b, Yamashita et al., 1977a). The ability of GOS to act as a substitute for these 
human oligosaccharides has attracted interest in further researching into their prebiotic 
and health beneficial effects.  
Galactooligosaccharides or trans-GOS are oligosaccharides comprised of a 
number of galactose monomers with a glucose molecule at the terminus with DP 3-10 
and disaccharides comprising of two galactose monomers. Galactoses are often linked 
by β (1→4) and β (1→6) linkage, while β (1→2) and β (1→3) linkages occur less 
frequently in GOS (Fig. 1.2).  
Figure 1.2 Chemical structure of GOS (n=1-8) 
 
1.1.5.1 Production and determination of galactooligosaccharides 
 
The GOS are synthesised by transgalactosylation in an enzymatic catalysis from lactose 
by β-galactosidase (EC 3.2.1.23). β-Galactosidase catalyses the transfer of a galactosyl 
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residue from lactose to a sugar chain or water, and can either extend the sugar chain 
and produce GOS or break down lactose, respectively. During enzymatic 
transgalactosylation, the GOS production rate is influenced by the enzyme source, 
substrate concentration and reaction conditions (temperature and pH). Generally, GOS 
production is favoured by high substrate concentration although different enzyme 
sources have different reaction condition preferences and can form different glycoside 
linkages.  
Various organisms can produce β-galactosidase, including: Aspergillus 
oryzae, Kluyveromyces marxianus subsp. lactis, and Cryptococcus laurentii in 
eukaryotic organisms; Sulfolobus solfataricus and Pyrococcus furiosus in Archaea; 
Bifidobacterium spp., Lactobacillus spp., Bacillus spp., Str. thermophilus, Escherichia 
coli and Enterobacter cloacae in bacteria. Table 1.4 shows the main characteristics of 
some GOS products in the market. 
Table 1.4 Commercially available galactooligosaccharides (GOS) products 
Name Format GOS content 
(g 100 g-1 -
dry weight) 
Enzyme source Glycoside bond Reference 
Cup Oligo H-70 Syrup ≥70 Cryptococcus 
laurentii 
β (1→4) (Ohtsuka et al., 
1990) 
Cup Oligo P Powder ≥70 Cry. laurentii  β (1→4)  (Ohtsuka et al., 
1990)  
OLIGOMATE® 
55N 
Syrup ≥55 Sporobolomyces 
singularis and 
Kluyveromyces 
marxianus subsp. 
lactis 
β (1→4) and 
β(1→6) 
(Asp et al., 
1980, Gorin et 
al., 1964) 
OLIGOMATE® 
55NP 
Powder ≥55 Spo. singularis and 
K. marxianus 
subsp. lactis  
β (1→4) and 
β(1→6)  
(Asp et al., 
1980, Gorin et 
al., 1964)  
Vivinal® GOS  Syrup ≥59 Bacillus circulans β (1→4) (Yanahira et al., 
1995) Syrup (easy 
drying syrup) 
≥72 
Powder ≥69 
Bimuno Syrup ≥57 Bifidobacterium 
bifidum 
β (1→3)  (Rabiu et al., 
2001) Powder ≥80 
Purimune™ 
BIOLIGO GL 5700 
IMF GOS 
Syrup 65 B. circulans β (1→4) (Yanahira et al., 
1995) 
Floraid® GOS 
Syrup 
Syrup 39 Aspergillus oryzae β (1→6) (Toba et al., 
1985) 
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Floraid® GOS Powder 39  A. oryzae β (1→6) Culhane & 
Tanugraha 
(2013)  
 
The AOAC published a validated method (method 2001.02) to determine GOS 
by HPAEC-PAD. This method requires enzymatic treatment with β-galactosidase to 
hydrolyse the oligosaccharides and release sugars for analysis. Before the enzymatic 
reaction, an initial solution is taken and heated to 100°C for 10 min to deactivate the 
enzyme. This is then analysed by HPAEC-PAD to determine the concentration of 
lactose and monosaccharides. The remaining solution with active β-galactosidase is 
incubated at 60°C for 30 min, and then sugar analysis is performed by HPAEC-PAD 
(Slegte, 2002). Galactooligosaccharide content can be calculated by subtracting the 
initial galactose and lactose concentrations from the final galactose concentration. This 
method needs efficient deactivation of β-galactosidase in the initial solution to avoid 
underestimating GOS concentration. 
 
1.1.5.2 Application of galactooligosaccharide in the food industry  
 
Galactooligosaccharide is categorised as Generally Regarded As Safe (Boudry et al.) 
in the United States of America (USA) and regarded as a Food for Specific Health Use 
(FOSHU) in Japan. It has been used in infant formula to enhance bifidobacteria growth 
in an attempt to provide a functional mimic to human milk oligosaccharides (Boehm et 
al., 2002). Galactooligosaccharide is slightly sweet without aftertaste, resistant to heat, 
and can retain moisture. It is also not digested or absorbed by the human small intestine, 
therefore it can be used as a sugar substitute that has reduced calories. Examples of 
GOS application in dairy products are fermented milk, lactic acid bacteria beverages, 
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ice-cream and milk beverages. Apart from dairy products, GOS can be used in 
beverages, sweets, dessert, bakery, jams and other food products. 
 
1.1.5 3 The prebiotic effect of galactooligosaccharide 
 
The non-digestibility of GOS was demonstrated by van Loo et al. (1999) and they 
concluded that more than 90% of GOS can be recovered in the colon. However, there 
is no in vivo human study showing non-digestibility, which is normally done by 
analysing digesta from ileostomy volunteers after feeding the prebiotic.  
Tanaka et al. (1983) carried out a human study to observe the changes in faecal 
microbiota composition by associated with GOS supplementation: Bifidobacterium 
spp. increased while Bacteroidaceae spp. decreased. Other human studies have shown 
similar results, that GOS can modulate human colonic bacteria by increasing 
bifidobacteria (Ito, 1993, Bouhnik et al., 1997). One study that recruited 37 volunteers 
(who were more than 50 years old) revealed an increase in faecal Bifidobacterium spp. 
after a 3-week intervention, of the ten bacteria groups that were monitored (Walton et 
al., 2012). A study with elderly people and another with overweight volunteers both 
found an increase of bifidobacteria, and decrease of Bacteroides spp., Clostridium 
histolyticium, and Desulfovibrio spp. (Vulevic et al., 2008, Vulevic et al., 2013). 
Consuming 2.5 g d-1 of GOS can affect microbiota changes within one week. A parallel 
study with 8 volunteers in each group that tested interventions with 2.5 g, 5 g, 7.5 g and 
10 g d-1 of GOS did not show any dose-dependent effect (Bouhnik et al., 2004). 
However, another study with 18 volunteers consuming different doses of GOS for 3 
weeks, showed a dose-dependent change of faecal bifidobacteria (Davis et al., 2010). 
Galactooligosaccharides produced from various enzymatic sources differ in their 
bifidogenic effect. A cross-over study with 59 healthy human subjects found intake of 
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GOS produced from Bifidobacterium spp. was more effective for enhancing 
bifidobacteria growth (Depeint et al., 2008).  
 
1.1.5.4 Infant nutrition and galactooligosaccharides 
 
Infants are free of bacteria before delivery. The infant gut is first inoculated with 
microbes resulting from contact with the mother during delivery. The maternal 
microbiota is transferred to the infant during natural delivery, therefore modulation of 
the mother’s microbiota while pregnant should help infant health by passing on a 
healthier microbiota. Sixteen expectant mothers received prebiotic treatment with 9 g 
d-1 of 9:1 of GOS/FOS for 15 weeks before their delivery; these women showed higher 
number of faecal bifidobacteria compared to the placebo group (n=17). However, 
bifidobacteria of the neonates did not differ significantly between the two groups 
(Shadid et al., 2007). 
Breast and formula feeding shape the infant microbiome in different ways: 
bifidobacteria tend to be higher in breastfed infants compared to formula-fed infants. 
After the introduction of solid food, children acquire more microbes and the microbial 
ecology of the gut starts to become similar to that of adults. Before this, bifidobacteria 
are the dominant bacterial group in breastfed infants. It is believed that human milk 
oligosaccharides play an important role in bifidobacterial colonisation in the infant 
colon. Researchers have investigated the addition of prebiotics to infant formula with 
the aim of boosting bifidobacteria and exerting health benefits to the infants. The most 
widely studied prebiotic combination for infant formula is a mixture of 90% GOS and 
10% FOS. This combination has both low molecular weight GOS and inulin, which is 
believed to have a similar health benefit as human milk oligosaccharides (Boehm et al., 
2002).  
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As many as 1032 infants have been enrolled in various studies investigating 
infant tolerance of GOS with diverse targeted groups, such as premature infants, full 
term infants and infants born from human immunodeficiency virus positive mothers. 
Safety and tolerance were evaluated in terms of weight gain, length gain, digestive 
tolerance and adverse events, and no safety issues were found with GOS or GOS/FOS 
combination as supplement in infant formula (Boehm et al., 2002, Chouraqui et al., 
2008, Fanaro et al., 2009, Holscher et al., 2012, Ribeiro et al., 2012, da Costa Ribeiro 
et al., 2015, Lee le et al., 2015).  
Studies investigating infant formula, prebiotic supplemented formula, and 
human milk showed a higher number of bifidobacteria, improved stool consistency and 
lower faecal pH in the infants fed the prebiotic formula or human milk compared to the 
infants given non-supplemented formula. The organic acid profile of the infant’s faecal 
water was also different with higher concentrations of acetate and lactate with the 
prebiotic formula and human milk fed infants (Boehm et al., 2002, Bakker-Zierikzee et 
al., 2005, Knol et al., 2005, Ben et al., 2008).  
Apart from gastrointestinal function, other studies have focused on other 
health benefits of prebiotics given to infants, such as improvement of lipid profile. 
Alliet et al. (2007) investigated lipid profile differences among breastfed infants, 
prebiotic supplemented formula and non-supplemented formula; they found that total 
cholesterol and LDL were higher in breastfed infants compared to the formula fed 
infants. There was no difference between two different formulae in terms of the infants’ 
lipid profile.  
Many studies have looked at various parameters regarding the prebiotic effects 
on immune function in infants. Faecal secretory IgA levels were higher in 19 infants 
who had 6 g L-1 9:1 GOS/FOS supplemented formula for 16 weeks compared to 19 
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infants given control formula, indicating a better host defence against pathogens 
(Bakker-Zierikzee et al., 2006). The feeding of 8 g L-1 9:1 GOS/FOS formula to infants 
for 6 months did not affect their diphtheria, tetanus, polio (DTP) vaccination response; 
however, a significant reduction of immunoglobulins relating to cow’s milk allergy 
were observed with prebiotic formula (van Hoffen et al., 2009). Fifty-five new-born 
premature infants, who consumed prebiotic supplement for 30 d, had the same level of 
proinflammatory cytokines as the control group (Westerbeek et al., 2011). Without a 
control formula group, Bocquet et al. (2013) failed to find any significant difference 
between a prebiotic-fed group and a probiotic-fed group (Bifidobacterium animalis 
subsp. lactis) in terms of infection incidence. Another recent study did not find any 
significant difference in IgA secretion, infection incidence and allergic incidence 
between infants who had GOS until they were 1-year-old, when compared to a control 
group (Sierra et al., 2015). A summary of human studies of infant health feed containing 
GOS is shown in Table 1.5.  
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Table 1.5 Some reported human studies of infant health with galactooligosaccharides (GOS) supplementation 
Treatments and dosage Formula and subjects number Targeted group Duration Results References 
10 g L-1 9:1 
GOS/fructooligosaccharide
s (FOS)  
Prebiotic formula (n=15) 
Control formula (n-15) 
Human milk (n-12) 
Premature infants 28 d Higher number of 
bifidobacteria; 
improved stool 
consistency 
(Boehm et 
al., 2002) 
6 g L-1 9:1 GOS/FOS or 
Bifidobacterium animalis 
BB-121 (6 x 1010 colony 
forming units (cfu) L-1) 
Prebiotic formula (n=19) 
Probiotic formula (n=19) 
Control formula (n=19) 
Human milk (n=63) 
New born infants 
starting the study at 
day 5 after delivery 
16 weeks Higher acetate and 
lactate; lower pH 
(Bakker-
Zierikzee et 
al., 2005) 
8 g L-1 9:1 GOS/FOS Prebiotic formula (n=15) 
Control formula (n=19) 
Human milk (n=19) 
Infants with average 
age of 7.7 weeks at 
enrolment 
6 weeks Higher number of 
bifidobacteria; 
higher acetate and 
lactate; lower pH 
(Knol et al., 
2005) 
4.5 g d-1 9:1 GOS/FOS Prebiotic formula (n=11) 
Placebo (n=9) 
Weaning infants 
aged 4-6 months 
6 weeks Higher number of 
bifidobacteria 
(Scholtens 
et al., 2006) 
2.4 g L-1 GOS  Prebiotic formula (n=37) 
Prebiotic formula and  
    human milk (n=58) 
Human milk (n=24) 
Control formula (n=45) 
Term infants 3 months Higher number of 
bifidobacteria and 
lactobacilli; higher 
acetate; lower pH 
(Ben et al., 
2008) 
5 g L-1 GOS Prebiotic formula (n=77) 
Control formula (n=82) 
Infants with age of 
4-6 months 
12 weeks Higher number of 
bifidobacteria; 
improved stool 
consistency 
(Fanaro et 
al., 2009) 
4 g L-1 1:1 polydextrose 
(PDX)/GOS, 
4 g L-1 3:2:1  
PDX/GOS/lactulose (LOS) 
and  
8 g L-1 3:2:1  
PDX/GOS/LOS 
  
Prebiotic formula (n=27) 
Prebiotic formula (n=27) 
 
Prebiotic formula (n=25) 
Human milk (n=30) 
Control formula (n=25) 
Term infants 28 days Human milk group 
had better stool 
consistency. No 
other significant 
difference was 
observed 
(Nakamura 
et al., 2009) 
4 g L-1 9:1 GOS/FOS Prebiotic formula (n=53) 
Control formula (n=59) 
Human milk (n=57) 
Infants aged no 
more than 30 d at 
enrolment 
Until 
infants 
reach 4-
month old 
Higher number of 
bifidobacteria; 
improved stool 
consistency  
(Vivatvakin 
et al., 2010) 
9:1 GOS/FOS Prebiotic formula (n=36) 
Control formula (n=33) 
Human milk (n=33) 
Term infants aged 2-
8 weeks at 
enrolment 
6 weeks Higher number of 
bifidobacteria; lower 
pH; no difference 
with stool 
consistency 
(Holscher 
et al., 2012) 
4 g L-1 1:1 PDX/GOS Prebiotic formula (n=78) 
Control formula (n=81) 
Human milk (n=71) 
Infants aged 21-30 
days at enrolment 
60 days Higher number of 
bifidobacteria;  
(Scalabrin 
et al., 2012) 
4 g L-1 GOS  Prebiotic formula (n=83) 
Control formula (n=80) 
Human milk (n=199) 
New born infants 
starting the study at 
day 15 after delivery 
Before 
complemen
tary feeding 
Higher number of 
bifidobacteria and 
lower number of 
clostridia;  
(Giovannini 
et al., 2014) 
3 g L-1 GOS  Prebiotic formula (n=9) 
Control formula (n=13) 
Term infants 2 weeks Higher number of 
bifidobacteria; no 
difference with 
SCFA and faecal pH 
(Matsuki et 
al., 2016) 
1 ‘Bifidobacterium animalis BB-12 (presumed to be Bifidobacterium animalis subsp. lactis BB-12 (Anonymous, 2013). 
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1.1.5.5 Health benefit of galactooligosaccharides 
 
Rat studies on GOS found enhanced absorption of calcium, iron, magnesium and zinc; 
furthermore, two studies that monitored bone health parameters confirmed 
improvement of bone health with GOS supplementation (Chonan et al., 1995, Chonan 
et al., 1996, Chonan and Watanuki, 1996, Weaver et al., 2011, Takasugi et al., 2013). 
Unlike with inulin, the effect of GOS supplementation on mineral absorption is not well 
studied in human trials. Healthy males are not the main target group for mineral 
absorption improvement. Two studies with females of different age ranges found 
mineral absorption enhancement associated with GOS: ingesting 20 g d-1 for 9 days 
significantly increased true calcium absorption in 12 postmenopausal women in a 
crossover design study (van den Heuvel et al., 2000). Another crossover study looked 
at how two different doses of GOS (5 g and 10 g d-1 for 3 weeks) affected calcium 
absorption in adolescent girls compared to the control, GOS improved calcium 
absorption significantly without any dose-dependent effect (Whisner et al., 2013). 
Though mineral absorption was analysed in these studies, no further analysis on bone 
mass density and other bone health parameters was done to confirm the health benefit.  
Lipid profile improvement associated with intervention with 5.5 g d-1 of GOS 
for 12 weeks was seen in overweight adult subjects, but not in generally healthy young 
adults who had 15 g d-1 of GOS (van Dokkum et al., 1999, Vulevic et al., 2008). Various 
studies with healthy subjects, overweight subjects, UC patients and elderly subjects 
have investigated the effect of GOS on immune function in terms of reduction of pro-
inflammatory cytokines, improvement of host defence against pathogens and 
improvement in the wellbeing of chronic inflammatory disease patients (see Table 1.6).  
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Table 1.6 Human studies of adult health with galactooligosaccharides (GOS) supplementation 
Treatments and dosage Study design 
and subjects 
number 
Targeted 
group 
Duration  Result Reference 
15 g d-1 Inulin  
15 g d-1 
fructooligosaccharide 
(FOS)  
15 g d-1 GOS  
Cross-over 
study (n=12) 
Healthy male 
with an 
average age 
of 23 
3 weeks Inulin and GOS increased faecal acetate 
concentration; inulin increased faecal 
valerate concentration; inulin and FOS 
decreased secondary bile acids 
concentration; GOS and inulin 
decreased β-glucuronidase activity; no 
significant difference was found with 
lipid profile 
(van Dokkum et 
al., 1999) 
5.6 g d=1 GOS  Cross-over 
study (n=44) 
Elderly 
subjects 
10 weeks Higher number of bifidobacteria; 
increased natural killer (NK) cell 
activity and anti-inflammatory 
cytokines; decreased proinflammatory 
cytokines; no difference of lipid profile 
(Vulevic et al., 
2008) 
Probiotic strains 
(Lactobacillus 
rhamnosus GG, Lb. 
rhamnosus LC705, 
Propionibacterium 
freudenreichii subsp. 
shermanii JS, and 
Bifidobacterium breve 
BB-99) (2×1010 colony 
forming units   
       (cfu) d-1) 
3.8 g d-1 GOS  
120 g d-1 Whole grain 
rye bread  
Sequential 
intervention  
(n=18) 
Healthy male 6 weeks Probiotic lactobacilli, propionibacteria 
and GOS increased the counts of 
bifidobacteria and decreased β-
glucuronidase activity 
(Kekkonen et 
al., 2011) 
Bif. breve (3 ×  
     109 cfu d-1) and 5.5 g 
d-1  
     GOS  
 
Parallel study 
(n=44) 
Ulcerative 
colitis 
1 year Colonoscopy showed better condition; 
decreased myeloperoxidase indicating 
decreased severity of ulcerative colitis 
(UC); decreased Bacteroidaceae and 
faecal pH 
(Ishikawa et al., 
2011) 
8 g d-1 GOS  Cross-over 
study (n=39) 
Healthy 
subjects aged 
more than 50 
3 weeks Increased counts of bifidobacteria; No 
difference of faecal water genotoxicity 
(Walton et al., 
2012) 
5.5 g d-1 GOS  Cross-over 
study (n=45) 
Overweight 
adults 
12 weeks Increased number of bifidobacteria and 
decreased number of bacteroides and 
Clostridium histolyticum; no difference 
of blood cytokines; faecal calprotectin 
and plasma C-reactive protein decreased 
indicating decrease inflammation; 
Increased faecal secretory IgA; 
decreased plasma insulin; decreased 
total cholesterol, and total 
cholesterol/high density lipoprotein 
(HDL)-cholesterol ratio; triglyceride 
reduction was only significant in male 
(Vulevic et al., 
2013) 
7.5 g d-1 GOS  
Amoxicillin (1125 mg d-
1)  
        for 5 days 
Parallel study 
(n=12) 
Healthy 
adults  
12 days  Restored bifidobacteria from antibiotic 
treatment and increased butyrate 
concentration 
(Ladirat et al., 
2014) 
6, 12, 18 g d-1 α-GOS  Parallel study 
(n=88) 
Overweight 
adults 
14 days Improvement of appetite with dose-
dependent effect; reduced energy intake; 
lipopolysaccharides reduced dose-
dependently; decreased plasma C-
reactive protein  
(Morel et al., 
2015) 
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1.1.6 Resistant starch and other glucose based non digestible carbohydrates 
 
Resistant starch (RS) refers to those types of starch that are not hydrolysed and absorbed in the 
small intestine. Type 1 RS is physically surrounded by other material that makes digestion 
impossible; type 2 RS represents natural uncooked starches, such as potato starch, green banana 
starch and high amylose maize starch; type 3 RS is retrograded amylose and starch; type 4 
resistant starches are chemically modified starches.  
The non-digestibility of RS was confirmed by Englyst et al. (1996) with 9 ileostomy 
subjects: more than 90% of tested RS 2 and RS 3 were recovered in ileostomy effluent. 
Microbiota changes associated with RS have not been conclusive in human intervention 
studies, which may be due to the different resistant starch types having different physiological 
effects. Two recent studies using RS 4 as supplementary treatment did not find any 
bifidobacterial changes; one of them found significantly higher number of Bacteroides spp. 
and Ruminococcus spp. with RS 4 (Upadhyaya et al., 2016, Dahl et al., 2016). An increase of 
Ruminococcus spp. was also seen in another two human intervention studies with RS 2 (Abell 
et al., 2008, Venkataraman et al., 2016). Twenty healthy young adults who had RS 2 for 3 
weeks, and 24 volunteers who had RS 3 had higher numbers of faecal bifidobacteria after these 
treatments (Venkataraman et al., 2016, Costabile et al., 2016). Resistant starch has been studied 
in numerous human intervention trials, with an emphasis on insulin sensitivity, glycaemic 
homeostasis, appetite, satiety and weight management; however, many of these studies did not 
investigate if health benefits correlated with any change in the gut microbiota.  
 
1.1.7 Xylooligosaccharides (XOS) 
 
Xylooligosaccharides and xylan are xylose based oligo- or poly-saccharides. They are 
produced by hydrolysis of hemicellulose following by purification. Nine species of 
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bifidobacteria were tested in pure culture fermentation with different carbon sources, and one 
species (Bifidobacterium catenulatum) preferred XOS over FOS (Palframan et al., 2003). 
There are two in vivo studies on the effect of XOS in the human colon (Finegold et al., 2014, 
Lecerf et al., 2012a). Xylooligosacchardides (4.2 g d-1 for 4 weeks) reduced constipation 
severity in constipated pregnant women (Tateyama et al., 2005).  
 
1.1.8 Other potential prebiotics candidates and summary 
 
There are many other emerging carbohydrates that may have prebiotic effect, such as human 
milk oligosaccharides, isomaltooligosaccharides, lactosucrose, lactulose, soya/soybean 
oligosaccharides, pyrodextrins, polydextrose, arabinogalactans, pectin/pectic oligosaccharides, 
and seaweeds/microalgae (Gibson et al., 2004). Many of them are under investigation by 
scientists. 
Gut bacteria are involved in various metabolic activities, and these activities affect 
human health in different ways. It is becoming apparent that it is not only gut health that is 
related to colonic bacteria activity; there is an increasingly interest in the gut-brain axis, gut-
kidney axis, and gut-heart axis (Cryan and Dinan, 2012, Meijers and Evenepoel, 2011, Tang et 
al., 2013). Serotonin is a key neurotransmitter, and a recent study found that gut bacteria 
regulate serotonin biosynthesis through signalling by host colon enterochromaffin cells (Yano 
et al., 2015). Production of p-cresol and indole by gut bacteria from protein fermentation 
contributes to serum p-cresyl sulphate and indoxyl sulphate levels, which are risk factors for 
chronic kidney disease (Meijers et al., 2010). Metabolism of L-carnitine and 
phosphatidylcholine by some gut bacteria produces trimethylamine, which can be further 
oxidised to trimethylamine-N-oxide; the latter is a promoter of cardiovascular disease, such as 
atherosclerosis (Koeth et al., 2013, Wang et al., 2011). With more host-microbiome 
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interactions to be elucidated, prebiotics may apply to more health areas by their modulation of 
the gut bacteria composition and associated health benefits.  
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1.2 Proteolysis by gut bacteria  
1.2.1 Protein consumption and human gut bacteria metabolism 
Protein supply worldwide is increasing annually, and reached 81.23g/capita/d in 2013(FAO, 
2017). After ingestion, proteins are partially hydrolysed by stomach acid, which involves 
cleavage of amino acids from the N terminal. This is then followed by enzymatic protease 
breakdown in the small intestine (Fuller and Tome, 2005). Proteins are not always fully 
digested and absorbed allowing colonic delivery. Moreover, endogenous proteins are excreted 
into the digestive tract, such as secretions from digestive organs, sloughed epithelial cells and 
debris, and mucosal content (Fuller and Tome, 2005). From various ileostomy studies, protein 
digestibility in the diet is influenced by protein source, quantity of the protein and other dietary 
components (Gibson et al., 1976, Chacko and Cummings, 1988, McBurney and Thompson, 
1989). Enhanced protein absorption by thermal treatment was observed in two studies using 
egg protein (Evenepoel et al., 1999, Evenepoel et al., 1998). Silvester and Cummings (1995) 
found similar nitrogen outputs in various protein diets in volunteers ileal efflux, and a strong 
correlation between ileal nitrogen and total dietary protein consumption. Two recent 
endogenous composition studies suggested that endogenous proteins are 69.2% bacterial 
proteins, 16.9% mucin, 7.65% enzymes, and 6.2% mucosal cells (Miner-Williams et al., 2012, 
Miner-Williams et al., 2014). Absorption of amino acids in the large intestine is limited 
comparing to the small intestine, with various bacteria being able to utilise them.  
 
Metabolism of protein by gut bacteria firstly involves breakdown of peptides into amino acids, 
and then further metabolism of amino acids producing different metabolites. Smith and 
Macfarlane (1997) studied amino acid fermentation by colonic bacteria, and end products 
include CO2, NH3 and SCFA. Branched chain amino acid utilisation by bacteria generates 
branched chain fatty acids: valine is the main source of iso-butyrate production; leucine from 
iso-valerate production; catabolism of iso-leucine produces 2-methyl-butyrate and valine. 
Microbial degradation of aromatic amino acids (tyrosine, phenylalanine, and tryptophan) leads 
to the production of phenolic and indolic compounds: tyrosine is degraded by bacteria and 
generates phenol and p-cresol, phenylalanine triggers the production of phenylacetate, and 
main tryptophan end products are indole and skatole. Among amino acids, acetate, propionate 
and butyrate production rates differ: glutamate, histidine, cysteine, glycine, serine, and proline 
have acetate as the highest SCFA produced; aspartate, methionine, alanine, and threonine have 
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propionate as the highest SCFA; metabolism of lysine produces more butyrate, followed by 
acetate, and trace amount of propionate (Smith and Macfarlane, 1997).  
 
In healthy adult humans, the proximal colon is approximately pH 5.5 which increases gradually 
to around pH 6.7 in the distal colon (Fallingborg, 1999). At different stages, microbes would 
have various substrates to ferment. Metabolites from protein fermentation are found more in 
the distal colon, where carbohydrates are limited and transit is slowest (Macfarlane et al., 
1992b).  
1.2.2 Proteolysis metabolites in the gut and their possible health effects 
1.2.2.1 Ammonia and amines 
Deamination of amino acids in the gut generates ammonia, and alimentary protein consumption 
is correlated with its production (Geypens et al., 1997). By investigating Caco-2 cell lines after 
treatment of ammonia, permeability was significantly increased without affecting occludin 
expression, suggesting change of barrier function (Hughes et al., 2008). Lin and Visek (1991) 
found, in rats, that ammonia promoted cell proliferation and shortened the lifespan of mucosal 
cells. In another rat study using N-methyl-N'-nitro-N-nitrosoguanidine as the carcinogen, 
ammonia treatment had more adenocarcinomas generated suggesting cancer promoting 
property (Clinton et al., 1988).  
Amines are produced from decarboxylation of amino acids, and gut mucosa detoxify amines 
by oxidation (Windey et al., 2012). Dietary polyamines contribute more than those of bacterial 
origin from a rat study comparing conventional rats with antibiotic treated rats (Loser et al., 
1999). Main sources of carcinogenic N-nitrosamines are from diet, occupational exposure, 
cigarette smoking, and other minor sources, however, bacteria enzymes and amines can 
promote the formation of N-nitrosamines (Tricker, 1997). A human trial with 21 male subjects 
revealed that dietary haem from red meat, but not protein, promoted endogenous N-
nitrosation(Cross et al., 2003).  
1.2.2.2 Hydrogen sulphide 
Apart from dissimilatory sulphate reduction, bacterial degradation of sulphur containing amino 
acids such as cysteine and methionine can form hydrogen sulphide. With both rat epithelial 
cells and human cell lines, hydrogen sulphide inhibited the oxidation of butyrate which lead to 
colonocyte energy deficiency in a dose-dependent manner (Roediger et al., 1993, Leschelle et 
al., 2005). H2S, which is a cellular toxin, was found to affect apoptosis of rat epithelium cells, 
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and dysregulation of cell cycles may trigger ulcerative colitis (Deplancke and Gaskins, 2003). 
Further studies evaluated the genotoxicity of H2S on hamster ovary cells, nontransformed 
human intestinal epithelial cells, and HT29 cell lines: these studies confirmed DNA damage 
caused by H2S, besides, accelerated DNA mutation and free radical DNA damage were found 
with the presence of H2S (Attene-Ramos et al., 2006, Attene-Ramos et al., 2007, Attene-Ramos 
et al., 2010). One animal study confirmed the inhibition of colonocyte energy intake, however 
there was no inflammatory effect (Moore et al., 1997).  
Compared to healthy human subjects, sulphate-reducing bacteria (SRB) isolated from 
ulcerative colitis patients tended to have higher H2S production rates than conventional 
counterparts from the healthy gut (Gibson et al., 1991). Another study showed  that SRB viable 
counts were significantly correlated with ulcerative colitis disease severity (Pitcher et al., 
2000). This study also confirmed that consuming 5-aminosalicylic acid as a treatment for 
ulcerative colitis was related to reduced H2S.  
1.2.2.3 Phenolic and indolic compounds 
Phenol and p-cresol can reduce intestinal epithelial barrier function in vitro, however, the 
carcinogenic effect on human subjects is difficult to resolve (Hughes et al., 2008, McCall et 
al., 2009, Cerini et al., 2004). Indole is a quorum sensing molecule for bacteria, and recently, 
has been found to improve barrier function of epithelial cells and communicate with L cells to 
mediate hormone secretion in the colon (Chimerel et al., 2014, Bansal et al., 2010, Shimada et 
al., 2013). After conjugation of indole and p-cresol, indoxyl sulphate and p-cresol sulphate are 
generated and may be disposed via urine. Incubation of human umbilical vein endothelial cells 
with indoxyl sulphate and p-cresol sulphate under concentrations found in uremic patients, 
revealed inhibitive effects of proliferation and wound repair by these compounds, and inductive 
effect of oxidative stress (Dou et al., 2004, Dou et al., 2007). Serum levels of indoxyl sulphate 
and p-cresol sulphate have been correlated with renal disease progression, and vascular 
dysfunction in chronic kidney diseases (Vanholder et al., 2014, Barreto et al., 2009). Phenol, 
indole and p-cresol are known for their gut bacterial origin from aromatic amino acids 
metabolism. In chronic kidney diseases, there is lack of proof to verify the causal relationship 
of disease progression and uremic toxin accumulation from bacteria (Wikoff et al., 2009, Yap 
et al., 2008).  
1.2.3 Epidemiology studies on protein and host health 
The International Agency for Research on Cancer (IARC), an agency under World Health 
Organization (WHO) published a press release in October 2015, where it classified red meat 
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as “probably carcinogenic to humans”, and processed meat as “carcinogenic to humans”, with 
concerns over colorectal cancer (IARC, 2015). This was supported by various epidemiology 
studies that red meat and processed meat were epidemiologically correlated with colorectal 
cancer (CRC) (Willett et al., 1990, Giovannucci et al., 1994, Norat et al., 2005, Kirkegaard et 
al., 2010). Whether the risk is correlated with protein consumption or other dietary components 
in the meat is unclear. Kato et al. (1997) discovered a correlation between total protein intake 
and CRC risk in New York female populations, meanwhile, an European cohort study revealed 
that heterocyclic amines were related to CRC risk (Rohrmann et al., 2009). 
Bacterial proteolysis may contribute to other colonic inflammatory diseases. Both Japanese 
and French studies concluded that animal protein was associated with increased risk of 
Inflammatory Bowel Disease (IBD) (Shoda et al., 1996, Jantchou et al., 2010). A recent 
systematic review of 19 studies, found that meat consumption, together with total fat, 
polyunsaturated fatty acids, and omega-6 fatty acids were positively related with Crohn’s 
disease and ulcerative colitis(Hou et al., 2011).  
1.2.4 Intervention studies on proteolysis of gut bacteria 
Rats were fed with different amount of beef to determine colon DNA damage after 4 weeks 
treatment, and elevated level of DNA damage was seen in high meat consumption, especially 
red meat (Toden et al., 2007b). High protein consumption was correlated with decreased 
colonocyte membrane height, increased protease activity in the lumen and higher ammonia 
concentration in rats(Andriamihaja et al., 2010). One rat study did not find any difference 
between high protein and high carbohydrate diets, but a lower genotoxicity was observed at 
the end of both treatments. However, baseline dietary protein and carbohydrate were not 
concluded to be the cause of this change (Benassi-Evans et al., 2010). One human intervention 
study fed seven healthy subjects twelve days of high fat, meat, with a low fibre diet, and faecal 
water genotoxicity increased with the intervention(Rieger et al., 1999).  
1.2.5 Possible approaches to prevent the negative effect of the proteolysis by prebiotics 
Prebiotics are “a substrate that is selectively utilised by host microorganisms conferring a 
health benefit” (Gibson et al., 2017). They can modulate the microbiota composition, therefore, 
possibly increasing saccharolytic bacterial populations possibly at the expense of proteolysis. 
Moreover, some prebiotics, such as fructans can reduce colonic transit time which results in 
less protein being catabolised. A placebo controlled crossover study was conducted to study a 
prebiotic FOS enriched inulin, two probiotic strains, and a synbiotic mixture impact on nitrogen 
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metabolism in the gut: with the prebiotic treatment, reduced urinary N excretion occurred, 
together with higher faecal bacterial N fractions (De Preter et al., 2007a). 
Resistant starch (RS) has been studied in various animal trials using rats or piglets to investigate 
the potential of prebiotics on colonic protein fermentation. In both rats and piglets, RS was 
found to decrease urinary excretion of nitrogen, and increase faecal excretion instead (Younes 
et al., 1995, Heijnen and Beynen, 1997). Nitrogen disposal was not sufficient to support the 
protective effects of RS on microbial protein degradation. Three studies looked at different 
dietary protein sources and compared the effect of RS on protein fermentation in rats: red meat, 
casein, white meat, soya protein, and whey protein (Toden et al., 2006, Toden et al., 2007b, 
Toden et al., 2007a). These studies again confirmed that high consumption of dietary protein 
induced colonocyte DNA damage and reduced colonic mucus layer thickness. Addition of RS 
was able to abolish these unfavourable changes. 
Human studies have focused on protein fermentation metabolites. Table 1.7 is a summary of 
prebiotic human studies with protein metabolite analysis.  
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Table 1.7 Human studies of colonic protein metabolism with prebiotic supplementation 
 
Prebiotics treatment Duration and study design Targeted group and number of 
subjects 
Gut proteolysis related 
outcomes 
Reference 
GOS 3 g d-1/10g d-1 
 
1 week—parallel study  Healthy male adults (n=16) Reduction of faecal ammonia 
concentration and urine indican 
secretion 
(Tanaka et al., 1983) 
FOS 8 g d-1 1 month—parallel study Hypercholesterolemia adults 
(n=6) 
Decreased concentration of 
faecal BCFA and phenolic and 
indolic compounds 
(Hidaka, 1991) 
GOS 2.5 g d-1 3 weeks—one arm study Healthy male adults (n=12) Significantly lower amount of 
nitroreductase and indole in 
faeces. Ammonia and p-cresol 
did not differ before and after 
treatment 
(Ito, 1993) 
FOS 15 g d-1 15 days—one arm study Healthy adults (n=8) Increased faecal nitrogen 
secretion 
(Gibson et al., 1995) 
FOS  60 days—parallel study Cirrhotic patients (n=125) Reduction in blood ammonia (Malaguarnera et al., 2010) 
Resistant starch 30g d-1 10 days—crossover study Healthy adults (n=14) Decreased gut ammonia 
production and urinary 
ammonia excretion 
(Wutzke et al., 2010) 
XOS 5g d-1 
XOS and inulin mixture (3g 
inulin+1g XOS per day) 
4 weeks—parallel study Healthy adults (n=60) Lower concentration of p-cresol 
was observed in XOS group, but 
not in XOS and inulin group  
(Lecerf et al., 2012b) 
XOS 5g d-1 3 weeks—crossover study Healthy children aged 8-12 
years (n=29) 
Significant reduction of BCFA 
in faeces 
(Francois et al., 2014) 
A synbiotic combination 
(1.3×1010 d-1 of Lactobacillus 
casei Shirota cells+ 20g d-1 of 
oligofructose- 
enriched inulin) 
4 weeks—one arm study Healthy adults (n=9) Dimethyl trisulfide and ethyl 
benzene were significantly 
lower after the synbiotic 
treatment.  
(De Preter et al., 2011) 
Oligofructose enriched inulin 
20g d-1 
4 weeks—cross over study Healthy adults (n=20) Reduction of urinary N content 
and p-cresol excretion with 
significant changes 
(De Preter et al., 2007a) 
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Chapter 2 In vitro faecal batch culture fermentation of different dietary 
protein sources and influences of prebiotic supplementation 
 
Abstract 
 
Dietary protein levels are high in Western populations. Metabolism of protein can be potentially 
detrimental due to the generation of various toxic metabolites, such as ammonia, p-cresol, and 
indole. Increased consumption of prebiotic carbohydrates allows specific changes, both in the 
composition and/or activity in the gastrointestinal microbiota that confers benefits upon host 
wellbeing and health. Few studies, however, have focused on the impact of prebiotics on 
proteolysis within the gut.  
pH controlled anaerobic stirred batch culture systems were inoculated with omnivore and 
vegetarian volunteers’ faecal samples.  Ten treatments were used in the systems: four different 
protein sources (casein, meat, mycoprotein and soy protein) with and without supplementation 
of inulin/oligofructose mixture (Synergy1), positive control with oligofructose enriched inulin, 
and a negative control without substrate. Bacterial changes during fermentation were 
monitored over 48h by fluorescence in situ hybridisation with flow cytometry. Concentration 
of various fermentation products such as short chain fatty acid (SCFA), ammonia, phenol, 
indole, and p-cresol were monitored. A significant increase of bifidobacteria was observed with 
the addition of the fructan prebiotic Synergy1 (p< 0.05). Branched chain fatty acids (BCFA) 
were lower in fermenters with vegetarians’ faeces, with reduced production by prebiotic 
treatment in donors with high BCFA production on protein substrates. Furthermore, ammonia 
production was lower on Synergy1. Bacterial adaptation to different diets was also observed 
through different patterns of ammonia production between vegetarians and omnivores. In 
volunteer samples with high baseline levels of phenol, indole, p-cresol and skatole, Synergy1 
fermentation led to a complete elimination of these compounds.  
 
Conclusion: Supplementation with a prebiotic resulted in a change in human gut microbiota 
and metabolism, reducing the production of some proteolytic metabolites. In addition, a 
difference was seen in BCFA between omnivores and vegetarians gut microbiota. 
2.1 Introduction 
 
Dietary protein levels are relatively high in western European populations, as high as 105g/d 
according to the Food and Agriculture Organization (FAO, 2017). However, the recommended 
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dietary allowance (RDA) is 56g/d for men and 46g/d for women (Institute of Medicine (U.S.). 
Committee on Use of Dietary Reference Intakes in Nutrition Labeling., 2005). This may result 
in high residual colonic nitrogen, with dietary protein having escaped digestion in the upper 
intestine entering the large gut where it can become a substrate for the colonic microbiota. 
Approximately 16g of protein will reach the colon following ingestion of 105g protein/day of 
which 8g are endogenous and 8g are exogenous (Gibson et al., 1976, Moughan et al., 2005). 
Among the endogenous proteins, there are 69.2% bacterial proteins, 16.9% mucin, 7.65% 
enzymes, and 6.2% mucosal cells (Miner-Williams et al., 2014, Miner-Williams et al., 2012).  
 
Metabolism of carbohydrate by gut bacteria produces short chain fatty acids (SCFA), and gases 
from different pathways. Production of SCFA, mainly acetate, propionate, and butyrate, in the 
lumen is generally believed to mediate health benefits (Russell et al., 2013). Microbial 
breakdown of protein not only generates SCFA and gases, however, but also ammonia, amines, 
indolic and phenolic compounds, and branched chain fatty acids (BCFA) through the 
deamination and decarboxylation of amino acids (Smith and Macfarlane, 1997). In rat and ex 
vivo studies, ammonia at a physiologically relevant dose can harm colon barrier function, 
shorten colonocyte lifespan, and is co-carcinogenic for rats (Clinton et al., 1988, Hughes et al., 
2008, Lin and Visek, 1991). Hydrogen sulphide can be produced from sulphur containing 
amino acids and is toxic to colonocytes by damaging their DNA and blocking utilisation of 
butyrate as an energy source (Attene-Ramos et al., 2010, Attene-Ramos et al., 2007, Attene-
Ramos et al., 2006, Roediger et al., 1993). Metabolism of tyrosine, phenylalanine and 
tryptophan produces phenol, indole, p-cresol and skatole; phenol and p-cresol can reduce 
intestinal epithelial barrier function in vitro (Hughes et al., 2008, McCall et al., 2009, Cerini et 
al., 2004). BCFAs are generated from branched chain amino acids such as valine, leucine, and 
iso-leucine and no physiological role for BCFA is known so far (Verbeke et al., 2015).  
 
Thus, foods entering the colon can have a health impact on the host, possibly by changing gut 
microbiota composition and activity. The International Agency for Research on Cancer 
(IARC), an agency under the World Health Organization (WHO) published a press release in 
October 2015: where it classified red meat as “probably carcinogenic to humans”, and 
processed meat as “carcinogenic to humans”, with concerns over colorectal cancer (IARC, 
2015). Some epidemiological studies found reduced risk of colorectal cancer (CRC) with high 
consumption of dietary fibre, while red meat and processed meat had a positive correlation 
with CRC (Young and Wolf, 1988, Cottet et al., 2005, Willett et al., 1990, Gonzalez and Riboli, 
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2010). Animal protein intake was associated with increased inflammatory bowel disease (IBD) 
risk in two Japanese and French studies (Shoda et al., 1996, Jantchou et al., 2010).  
 
Increased consumption of prebiotics, which can reach the colon resulting in specific changes 
in the composition and/or activity in the gastrointestinal microflora, may counter the negative 
effects of gut microbial proteolysis in persons ingesting high protein diets (Gibson et al., 2017). 
Inulin-type fructans can resist hydrolytic enzymes in the human GI tract and are resistant to 
small intestinal absorption, subsequently they become a food source for the microbiota within 
the large intestine. The impact of inulin on the gut microbiome has been studied using in vitro 
and in vivo approaches (Wang and Gibson, 1993, Kolida et al., 2002).  
2.2 Materials 
2.2.1 Proteins 
Protein substrates used were casein hydrolysate (Sigma-Aldrich, Poole, UK, meat extract for 
microbiology (Sigma-Aldrich, Poole, UK), soy protein acid hydrolysate powder (Sigma-
Aldrich, Poole, UK), and mycoprotein which was extracted from a commercial product 
(QuornTM) purchased from a local supermarket.  
2.2.2 Prebiotic 
Inulin-type fructan was a mixture of oligofructose and inulin: 50%±10% DP (degree of 
polymerisation) 3-9 and 50%±10% DP≥10 (Orafti®Synergy 1, BENEO-Orafti, Tienen, 
Belgium).  
2.3 Methods 
2.3.1 Protein extraction 
Mycoproteins were extracted from QuornTM based on the method described by Williams et al. 
(2001). 500g of QuornTM mince was mixed with 1200ml water and then homogenised in a 
blender. 60ml of formic acid was added after homogenisation and the pH lowered to 1.6. 
Afterwards, 5g pepsin was added and the solution incubated at 37°C for 48 hours. Samples 
were centrifuged at 3000g for 15 minutes and the supernatants freeze-dried for later use. After 
extraction, the nitrogen content of mycoproteins was quantified using the Kjeldahl method 
(Campden BRI, UK) and was found to be 10.3%. The remaining mycoprotein was stored at -
20°C. 
2.3.2 Protein dose determination 
Based on previous validation work from in vitro batch culture experiments and in human trials, 
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the dose of 1 % of substrate (w/v) equates to 5g inulin reaching the colon (Wang and Gibson, 
1993, Buddington et al., 1996). 1% of Synergy1 was used in this study to investigate the 
prebiotic effect on bacterial proteolysis. As described before: 8g endogenous and 8g exogenous 
protein which is approximately 1.846g mucin and 0.612g enzymes apart from bacterial origin 
protein will reach the colon following ingestion of 105g protein/day. The approach used in a 
150ml batch culture experiments is shown in Table 2.1. The amount of casein, meat extract, 
mycoprotein and soy protein was adjusted based on their true protein content which is shown 
in Table 2.2.  
 
 In vitro fermentation dosage 
Dietary protein 2.4g 
Mucin 0.57g 
Digestive enzymes 0.18g 
Note: digestive enzyme is a mixture of 0.107g pepsin, 0.022g pancreatin, and 0.00079g α-amylase based on an in vitro 
digestion simulation paper (Mills et al., 2008) 
Table 2.1 Endogenous and exogenous protein dosage to simulate the in vivo effect of 105g dietary protein per day consumption 
for 150ml batch culture experiment.  
 
Protein Protein content Protein dose 
Casein 68.75% 3.5g 
Soy protein 75% 3.2g 
Meat extract 76% 3.2g 
Mycoprotein 64.2% 3.7g 
Table 2.2 Protein dose that is equivalent to 2.4g dietary protein responding with protein content 
2.3.3 In vitro batch culture fermentation 
2.3.3.1 Faecal Sample Preparation 
Faecal samples were obtained from three healthy meat eating individuals and three healthy 
vegetarian volunteers between the ages of 18 and 60, who had not taken antibiotics for at least 
six months prior to the experiment and had no history of gastrointestinal disorders.  
Faecal samples were diluted 1 in 10 (w/v) using 1M, pH7.4, anaerobically prepared phosphate 
buffered saline (PBS, Oxoid, Hampshire, UK). This solution was homogenised in a stomacher 
(Seward, stomacher 80, Biomaster) for 120 seconds at normal speed. 15mL of this was then 
immediately used to inoculate batch culture vessels. 
2.3.3.2 Batch Culture Basal Nutrient Medium. 
Basal nutrient medium was prepared with chemicals obtained from Sigma-Aldrich, Poole, UK 
unless otherwise stated. In one litre: 2g peptone water, 2g yeast extract (Oxoid, Hampshire, 
UK), 0.1g NaCl, 0.04g K2HPO4 (BDH, Poole, UK), 0.04g KH2PO4 (BDH), 0.01g 
MgSO3.7H2O (Fischer scientific, Loughborough, UK), 0.01g CaCl2.6H2O, 2g NaHCO3 
(Fischer), 0.5g L–cystine HCl, 2mL Tween 80, 10µL vitamin K1, 0.05g haemin, 0.05g bile 
salts (Oxoid), 4ml resazarin (pH7).  
 
81 
 
2.3.3.3 pH controlled, stirred batch culture fermentation 
Vessels with an operating volume of 300mL were set up. 135mL of basal nutrient medium was 
autoclaved (121°C for 15 minutes) and aseptically poured into sterile vessels.  This system was 
left overnight with oxygen free nitrogen pumping the medium at a rate of 15mL/min. After 4 
hours fermentation, nitrogen flow was stopped and gas outlets were clamped to trap gas. pH 
meters (Electrolab pH controller, Tewksbury, UK) were connected to each vessel to regulate 
pH 6.7 to 6.9 with the aid of 0.5M HCl or NaOH.  
 
Each vessel was also temperature controlled at 37°C and stirred using a magnetic stirrer. 1% 
w/v of prebiotic and relative protein treatment were added to the vessels prior to inoculation 
with 15mL of faecal inoculum. For each donor, 10 vessels were prepared for 10 treatments: 
casein, meat extract, Quorn, soy protein, casein+Synergy1, meat extract+Synergy1, 
Quorn+Synergy1, soy protein+Synergy1, Synergy1, and negative control.  
 
Samples were removed from the fermenters after 0, 6, 10, 24 and 48 hours incubation.  
2.3.4 Enumeration of faecal microbial populations by flow cytometry fluorescence in situ 
hybridisation (FISH) 
 
A 750µl sample of batch culture fluid was centrifuged at 11337 × g for 5 minutes and the 
supernatant discarded. The pellet was then suspended in 375µl filtered 1M PBS solution. 
1125µl filtered cold (4°C) 4% paraformaldehyde (PFA) was added and samples were stored at 
4°C for 4 hours. These were then washed thoroughly with PBS to remove PFA and re-
suspended in a mixture containing 300 µl PBS and 300 µl 99% ethanol. Samples were then 
stored at -20°C prior to FISH analysis by flow cytometry. FISH by flow cytometry was carried 
out as described by Grimaldi et al. (2017). The probes used in this study are listed below:
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Table 2.3 Name, sequence, and target group of oligonucleotide probes used in this study for FISH of bacterial enumeration  
 
Probe name 
 
Sequence (5’ to 3’) 
 
Target groups 
 
References 
Non Eub ACTCCTACGGGAGGCAGC Control probe complementary to EUB338  (Wallner et al., 1993) 
Eub338‡ GCTGCCTCCCGTAGGAGT Most Bacteria (Amann et al., 1990) 
Eub338II‡ GCAGCCACCCGTAGGTGT Planctomycetales (Daims et al., 1999) 
Eub338III‡ GCTGCCACCCGTAGGTGT Verrucomicrobiales (Daims et al., 1999) 
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. (Langendijk et al., 1995) 
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus and Enterococcus (Harmsen et al., 1999) 
Bac303 CCAATGTGGGGGACCTT Most Bacteroidaceae and Prevotellaceae, some Porphyromonadaceae (Manz et al., 1996) 
Erec482 GCTTCTTAGTCARGTACCG Most of the Clostridium coccoides-Eubacterium rectale group (Clostridium cluster XIVa 
and XIVb) 
(Franks et al., 1998) 
Rrec584 TCAGACTTGCCGYACCGC Roseburia genus (Walker et al., 2005) 
Ato291 GGTCGGTCTCTCAACCC Atopobium cluster (Harmsen et al., 2000a) 
Prop853 ATTGCGTTAACTCCGGCAC Clostridial cluster IX (Walker et al., 2005) 
Fprau655 CGCCTACCTCTGCACTAC Feacalibacterium prausnitzii and relatives (Suau et al., 2001) 
DSV687 TACGGATTTCACTCCT Desulfovibrio genus Ramsing et al. (1996) 
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium histolyticum group (Clostridium cluster I and II) Franks et al. (1998) 
EC 1531 CAC CGT AGT GCC TCG TCA TCA Escherichia coli BJ4 (Poulsen et al., 1994) 
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2.3.5 Short chain fatty acid (SCFA) analysis by gas chromatography 
Samples were centrifuged at 11337 × g for 10 minutes to remove all particulate matter. 
Supernatants were then filtered through a 0.2 µm polycarbonate syringe filter (VWR, 
Farlington, UK). Extraction was done with some modifications of a method from Richardson 
et al. (1989). 500 µl of sample was transferred into a labelled 100 mm×16 mm glass tube 
(International Scientific Supplies Ltd, Bradford, England) with 25 μl of 2-ethylbutyric acid (0.1 
M, internal standard) (Sigma, Poole, UK). 250 µl concentrated HCl and 1 ml diethyl ether were 
added to each glass tube and samples vortexed for 1 minute. Samples were then centrifuged at 
2000 g for 10 minutes. The diethyl ether (upper) layer of each sample was transferred to a 
labelled clean glass tube. A second extraction was conducted by adding another 0.5 ml diethyl 
ether, followed by vortexing and centrifugation. The diethyl ether layers were pooled. 400 μl 
of pooled ether extract and 50 μl N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide 
(MTBSTFA) (Sigma-Aldrich, Poole, UK) were added into a GC screw-cap vial. Samples were 
left at room temperature for 72 hours to allow lactic acid in the samples to completely derivatise. 
 
An Agilent/HP 6890 Gas Chromatograph (Hewlett Packard, UK) using an HP-5MS 
30m×0.25mm column with a 0.25μm coating (Crosslinked (5%-Phenyl)-methylpolysiloxane, 
Hewlett Packard, UK) was used for analysis of SCFA. Temperatures of injector and detector 
were 275°C, with the column programmed from 63°C for 0 minutes to 190°C at 15°C min-1 
and held at 190°C for 3 minutes. Helium was the carrier gas (flow rate 1.7 ml min-1; head 
pressure 133 KPa). A split ratio of 100:1 was used.  Quantification of the samples was obtained 
through calibration curves of lactic acid and acetic, propionic, butyric, valeric and branched 
SCFA (iso-butyric and iso-valeric) in concentrations between 12.5 and 100 mM.  
 
2.3.6 Volatile organic compounds analysis by GC-MS 
2.3.6.1 Entrapment of volatile compounds 
 
All fermentation samples were adjusted to a pH of 7.0 ± 0.3 using hydrochloric acid or sodium 
chloride prior to volatile entrapment. Each sample (1 g) was placed in a 250mL conical flask 
fitted with a Dreschel head. The flask was placed in a water bath maintained at a temperature 
of 30°C for 1 hour. The flask was attached to oxygen-free nitrogen (40mL/min) which swept 
volatile compounds from the headspace above the sample onto a glass trap (4 mm i.d., 6.35 
mm o.d. x 90 mm long), containing 85mg of Tenax TA poly (a porous polymer absorbent based 
on 2,6-diphenylene-oxide) (Supelco, Poole, UK). Following volatile extraction, 1µL of 1, 2 
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dichlorobenzene in methanol (653ng/µL) was added to each trap as an internal standard and 
the trap was then flushed with oxygen free nitrogen to remove moisture (100mL/min) for 10 
minutes.  
2.3.6.2 Gas Chromatography and Mass spectrometry (GC-MS) 
 
Volatile compounds collected on the Tenax adsorbent were analysed using a Perkin-Elmer 
Claris 500 GC-MS, attached to an automated thermal desorber (Turbomatrix ATD, Perkin 
Elmer, Beaconsfield, UK).  Tenax traps were desorbed at 300°C for 10 min and the volatiles 
cryofocused on the internal cold trap held at -30°C. After desorption, the cold trap was heated 
to 300 °C at 40°C per second to release volatile material onto the GC column. GC separation 
was carried out on a DB-5 non-polar column (60m x 0.32mm id, 1µm film thickness, J&W 
Scientific from Agilent). Helium at 145 kPa was used as the carrier gas. The GC oven 
temperature program was 2min at 40°C followed by an increase at 4°C/min up to 260°C, where 
it was held for 10 min.  All data were collected and stored using Turbomax software (version 
3.5, Perkin Elmer). Compounds were identified from their mass spectra and identities 
confirmed by comparison of retention time (linear retention index, LRI) and mass spectra with 
those of authentic compounds analysed in online library database. Analyses were carried out 
using Agilent 6890/5975 GC-MS system (Agilent Technologies, Palo Alto, CA, USA) fitted 
with a Turbomatrix ATD.  
Indole, p-cresol and phenol (Sigma-Aldrich, Poole, UK) were diluted using the same internal 
standard. Quantification of the samples was obtained through calibration curves of phenol, p-
cresol, indole and skatole in concentrations between 25 and 100 µg/ml 
 
2.3.7 Ammonia Analysis 
Samples at 0, 10 and 24 hours were diluted 1 in 50 v/v prior to analysis. Ammonia concentration 
of diluted fermentation samples was analysed using a FluoroSELECT™ ammonia kit (Sigma-
Aldrich, Poole, UK). Enough reagent was prepared by combining 100 μL assay buffer, 4 μL 
reagent A and 4 μL reagent B in the kit. 10 μL H2O (blank) and 10 μL sample was added to 
each glass vial. Afterwards, 100 μL reagent was added to each tube. Samples were kept in the 
dark for 15 minutes at room temperature before they were read in the fluorometer. Ammonia 
standards were prepared by diluting 20 mmol/L NH4Cl in distilled water and the concentration 
range was 0.25-1 mmol/L).  
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2.4 Results 
2.4.1 Bacterial Enumeration 
 
In order to determine bacterial populations, twelve 16S-rRNA fluorescent in situ hybridisation 
probes were used to follow the changes in population of total bacteria and 11 functionally 
significant faecal microbial groups.  
 
Negative control with omnivore microbiota did not change throughout the fermentation and 
bacteria from vegetarian donors were reduced throughout the whole fermentation from 
8.25±0.38 to 7.67±0.38 log10 bacteria per ml (p=0.04 at 48 hours comparing with 0 hour; Figure 
2.1). Total bacterial counts of omnivore microbiota on 1.5g Synergy1 were higher than counts 
on 2.4g protein, though this effect was not clear with vegetarian microbiota. The combination 
of protein+Synergy1 resulted in higher total bacterial counts than the corresponding protein 
substrate alone in all cases.  
 
Bacterial populations from omnivores and vegetarians responded differently to the proteins: 
faecal bacteria from omnivores had higher counts on meat and casein than on soy protein and 
QuornTM extract, while faecal bacteria from vegetarians had higher counts on soy protein and 
QuornTM extract than meat and casein (Figure 2.1).  
One way ANOVA was performed to compare differences between negative controls and 
various substrates and showed that Synergy1 significantly boosted the growth of bifidobacteria: 
count differences compared to the negative control were casein+Synergy1(p=0.003; Figure 
2.2), meat extract+Synergy1(p=0.005), soy protein+Synergy1(p=0.001), QuornTM 
extract+Synergy1(p=0.001) and Synergy1(p=0.01).  
With faecal samples from vegetarians, bifidobacteria did not increase on protein substrates but 
they decreased after 6 hours fermentation (Figure 2.2). Bifidobacteria did, however, increase 
on Synergy1, even in the presence of protein. After 24 hours, meat extract+Synergy1 and 
QuornTM+Synergy1 supported significant growth of bifidobacteria.  
 
Lactobacilli from both omnivore and vegetarian donors increased on Synergy1 whether alone 
or with protein. With omnivore microbiota, lactobacilli increased significantly with Synergy1 
(Figure 2.2): QuornTM+Synergy1 (p=0.04) and soy protein+Synergy1 (p=0.03) had significant 
growth at 6 hours; Synergy1 caused significant growth of lactobacilli at 10 hours (p=0.004); 
Casein+Synergy1 responded significantly after 24 hours (p=0.01). However, the increase of 
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lactobacilli with vegetarian donors was not statistically significant. In contrast with the growth 
of lactobacilli on Synergy1, those from negative controls with omnivore microbiota decreased 
after 10 hours fermentation, while the count of negative controls with vegetarian microbiota 
decreased from 0 hours of fermentation.  
Stimulation of bifidobacteria and lactobacilli by Synergy1 was more significant with omnivore 
microbiota, however, the vegetarian microbiota had higher bifidobacteria and lactobacilli 
counts (around 7.5 and 5.7 log10 bacteria per ml respectively; Figure 2.2) at the beginning 
compared to omnivore microbiota (around 6.7 and 4.8 log10 bacteria per ml respectively).  
Though there are studies confirming that many Bacteroides spp., are proteolytic (Macfarlane 
et al., 1986), we found no significant changes in Bacteroides. spp. on protein substrates and 
Synergy1 (Figure 2.3). Clostridium coccoides, Eubacterium rectale and Clostridium cluster 
XIVa and XIVb responded to some protein substrates: these bacteria from omnivore donors 
increased on casein and meat while vegetarian microbiota increased with soy protein and 
QuornTM extract. Roseburia did not respond to protein or Synergy1. Atopobium cluster from 
all donors grew on protein substrates but this was only statistically significant on meat extract 
(p=0.006) at 48 hours using faecal inocula from omnivores and on QuornTM (p=0.01) and soy 
protein (p=0.003) at 10 hours using inocula from vegetarians (Figure 2.3). Clostridial cluster 
IX populations in cultures inoculated with samples from vegetarian donors increased on the 
protein substrates, but not significantly (Figure 2.4). Clostridial cluster IX populations in 
cultures inoculated with samples from omnivore donors significantly increased after 24h on 
meat extract, QuornTM extract, soy protein and protein+Synergy1 (p<0.05).  Clostridial cluster 
IX populations dropped and then increased on all protein treatments (Figure 2.4). Clostridium 
clusters I and II also grew more on proteins compared to both the positive and negative controls, 
but only reached statistical significance on soy protein with inocula from omnivores at 24 hours 
(p=0.03; Figure 2.5).  
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Figure 2.1 Total bacterial changes over time as log10 CFU/mL in the single stage batch culture as analysed by FISH. Values are mean values at five time points from 3 omnivore faecal donors’ (A) 
and 3 vegetarian faecal donors’ (B) ± standard deviation. * Mean values were significantly different from 0h fermentation (p<0.05). 
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Figure 2.2 Bif164 (A and B) and Lab158 (C and D) changes over time as log10 CFU/mL in the single stage batch culture as analysed by FISH. Values are mean values at five time points from 3 
omnivore and 3 vegetarian faecal donors’ ± standard deviation. * Mean values were significantly different from 0h fermentation (p<0.05). ** Mean values were highly significantly different from 
0h fermentation (p<0.01). A and C-Omnivores’ microbiota; B and D-Vegetarians’ microbiota  
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Figure 2.3 Bac303 (A and B), Erec482 (C and D) and Rrec584 (E and F) changes over time as log10 CFU/mL in the single 
stage batch culture as analysed by FISH. Values are mean values at five time points from 3 omnivore and 3 vegetarian faecal 
donors ± standard deviation. * Mean values were significantly different from 0h fermentation (p<0.05). A, C and E-Omnivores’ 
microbiota; B, D and F-Vegetarians’ microbiota 
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Figure 2.4 Ato291 (A and B), Prop853 (C and D) and Fprau655 (E and F) changes over time as log10 CFU/mL in the single 
stage batch culture as analysed by FISH. Values are mean values at five time points from 3 omnivore and 3 vegetarian faecal 
donor’s ± standard deviation. * Mean values were significantly different from 0h fermentation (p<0.05). ** Mean values were 
highly significantly different from 0h fermentation (p<0.01).A, C and E-Omnivores’ microbiota; B, D and F-Vegetarians’ 
microbiota 
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Figure 2.5 DSV687 (A and B), Chis150 (C and D) and EC 1531 (E and F) changes over time as log10 CFU/mL in the single 
stage batch culture as analysed by FISH. Values are mean values at five time points from 3 omnivore and 3 vegetarian faecal 
donor’s ± standard deviation. * Mean values were significantly different from 0h fermentation (p<0.05). ** Mean values were 
highly significantly different from 0h fermentation (p<0.01). A, C and E-Omnivores’ microbiota; B, D and F-Vegetarians’ 
microbiota 
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2.4.2 Organic Acids 
 
SCFAs such as acetic, propionic and butyric acid can affect health positively.  
Acetate concentrations increased on Synergy1 (Figure 2.6). The production of acetate from 
omnivores’ gut bacteria had to the highest production on meat extract, while vegetarians’ gut 
bacteria produced the most with soy protein. Acetate is the main SCFA produced by 
bifidobacteria and there was a high concentration on Synergy1.  
 
Propionic acid was also lower in those vessels without Synergy1 (Figure 2.7). Although large 
changes in Bacteroides populations were not seen, propionic acid could be produced by some 
species of Clostridium which increased in vessels containing Synergy1.  
Butyric acid production was low in this study and no significant changes were found (Figure 
2.7); this correlates with the lack of change in population of butyrate-producing bacteria 
(Roseburia and Faecalibacterium prausnitzii) throughout the fermentation.  
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Figure 2.6 Changes in Acetate (A and B) and Lactate (C and D) (mM per mL) of batch culture sample concentration over time. Values are mean values at five time points from 3 omnivore and 3 
vegetarian faecal donor’s ± standard deviation. A and C-Acids production with omnivores’ microbiota; B and D-Acids production with vegetarians’ microbiota. * Mean values were significantly 
different from 0h fermentation (p<0.05). ** Mean values were highly significantly different from 0h fermentation (p<0.01). *** Mean values were highly significantly different from 0h 
fermentation (p<0.001). 
*
*
* ** *
**
*
**
** **
***
**
0
20
40
60
80
100
120
140
160
180
m
M
A
* * * * *
***
*
* *
* ** **
*
*
*
* * *
*
*
**
**
**
** **
** ***
* **
**
*
0
20
40
60
80
100
120
140
160
180
m
M
B
t0
t6
t10
t24
t48
*
*
*
**** *** * * ** *
-10
0
10
20
30
40
50
60
70
m
M
C
*
** *
*
*** * *
-10
0
10
20
30
40
50
60
70
m
M
D t0
t6
t10
t24
t48
94 
 
 
Figure 2.7 Changes in Propionate (A and B) and Butyrate (C and D) (mM per mL) of batch culture sample concentration over time. Values are mean values at five time points from 3 omnivore 
and 3 vegetarian faecal donor’s ± standard deviation. A and C-Acids production with omnivores’ microbiota; B and D-Acids production with vegetarians’ microbiota. * Mean values were 
significantly different from 0h fermentation (p<0.05). ** Mean values were highly significantly different from 0h fermentation (p<0.01). 
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Branched amino acids such as leucine and isoleucine can be metabolised by faecal bacteria to 
produce branched chain fatty acids indicating proteolytic fermentation. Omnivores had much 
higher BCFA production while vegetarians had little production (Figure 2.8). Isovaleric acid 
production was higher than isobutyric acid. In vessels with omnivore microbiota, the presence 
of Synergy1 inhibited production of BCFA indicating that Synergy1 can reduce proteolysis by 
the gut microbiota. 
 
Figure 2.8 Changes in Isobutyrate (A and C) and Isovalerate (B and D) (mM per mL) of batch culture sample concentration 
over time. Values are mean values at five time points from 3 omnivore and 3 vegetarian faecal donor’s ± standard deviation. 
A and B-Acids production with omnivores’ microbiota; C and D-Acids production with vegetarians’ microbiota. * Mean values 
were significantly different from 0h fermentation (p<0.05). ** Mean values were highly significantly different from 0h 
fermentation (p<0.01).   
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2.4.3 Volatile Organic Compounds 
 
This study quantified four potentially detrimental volatile organic compounds (VOCs) which 
were indole, phenol, p-cresol and skatole. Production of these compounds varied individually 
and the effect of prebiotics on VOCs production also varied according to donor diet (Figure 
2.9). The production of these volatile compounds from highest to lowest was indole, phenol, 
p-cresol and skatole in most cases, however with soy protein phenol production was higher 
than indole production. With all donors, comparing negative and positive controls, the 
production of volatile compounds was reduced by Synergy1. However, comparing with 
protein+Synergy1 and the corresponding protein, production of indole, phenol, p-cresol and 
skatole were inhibited by Synergy1 after 48 hours fermentation, only with faecal samples from 
omnivore donor 1, omnivore donor 2 and vegetarian donor 1. These three donors produced 
relatively high levels of VOCs compared with others: the concentration of VOCs was higher 
than 100mM.   There is the possibility that Synergy1 could inhibit production of VOCs in the 
human gut.  
Protein source affected the production of VOCs. According to this study, casein resulted in the 
highest concentration of VOCs in five donors, this was probably because casein is high in 
aromatic amino acids which are the main substrates for bacteria to produce phenolic and indolic 
compounds. Omnivore donor 3 had low phenolic production with casein correlating with this 
donor’s low total bacterial count. 
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Figure 2.9 Changes in Phenolic compounds (µg per mL) of batch culture sample over time. Values are mean values at five 
time points from 3 omnivore and 3 vegetarian faecal donor’s ± standard deviation. A-Omnivore donor1, B-Omnivore donor2, 
C-Vegetarian donor1, D-Omnivore donor3, E-Vegetarian donor2 and F-Vegetarian donor3. 
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2.4.4 Ammonia  
 
Ammonia is considered a major metabolite of protein fermentation by faecal bacteria. 
Ammonia concentrations increased gradually during fermentation on all substrates together 
with the negative control when compared to the positive control (Figure 2.10). Ammonia 
concentrations of Synergy1 treatment, however, remained at low levels (17.55±4.53mM at 48 
hours for omnivores and 25.47±4.55mM for vegetarians) compared with all protein treatments. 
Vessels with Synergy1 had less ammonia production compared to protein treatments, inferring 
that Synergy1 could inhibit the proteolytic activity of faecal bacteria. The host diet also had an 
effect on the selective fermentation of faecal substrates. With faecal samples from omnivores, 
fermentation had higher production of ammonia on casein and meat extract, however, with 
faecal samples from vegetarians, soy protein and Quorn extract produced more ammonia.  
 
 
Figure 2.10 Changes in ammonia concentration (mM) of batch culture sample over time. Values are mean values at five time 
points from 3 omnivore and 3 vegetarian faecal donor’s ± standard deviation. * Mean values were significantly different from 
0h fermentation (p<0.05). A: omnivore donors. B: Vegetarian donors. 
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indicating a preference for polysaccharides by faecal bacteria. Proteins are less favoured than 
carbohydrates by the gut microbiota and this explains why proteolysis mainly happens in the 
distal colon where carbohydrates are depleted. One study testing different protein sources on 
the gut microbiota of weaning piglets revealed that total anaerobes increased on soy protein 
more so than casein and decreased with meat meal (Kellogg, 1964). However, in the present 
study, only a vegetarian microbiota had similar changes to that in this piglet study; the omnivore 
microbiotas were boosted by meat protein and casein rather than soy protein. In addition to 
differences between pigs and humans, host dietary habits may explain the preference of protein 
source. Growth of proteolytic bacteria within the human gut supported this: Clostridium 
coccoides and Eubacterium rectale from omnivore microbiota and vegetarian microbiota grew 
on meat/casein and soy/QuornTM respectively. Ammonia concentrations also indicate that an 
omnivore microbiota and a vegetarian microbiota favour different protein sources based on 
their host diet. A possible reason is the differences of amino acid composition among various 
proteins: bacteria that have adapted to the host diet can breakdown peptides, metabolise amino 
acids or utilise coupled Stickland amino acid fermentation.  
By observing fermentation characteristics of the negative controls only: saccharolytic 
bifidobacterial growth at 6 hours with omnivore faeces occurred indicating that there was a 
small amount of undigested saccharides within the omnivore faecal sample; however, this was 
not seen from the vegetarian donors.  
Even when total bacteria tend to be more saccharolytic, there were some proteolytic bacteria 
present in the gut microbiota. Bacteroides are deemed as having proteolytic activities; however, 
this study did not find any changes in this group of bacteria. Within the genus Bacteroides, 
many saccharolytic and proteolytic species are present. There is the possibility that donors in 
this study carried saccharolytic or weakly proteolytic Bacteroides, and the slight increase in 
Bacteroides from vegetarian microbiota on Synergy1 may prove this.  The genus Clostridium 
contains more than 100 species and these bacteria can be saccharolytic, proteolytic, or both. 
Within Clostridial clusters I and II, there are saccharolytic species such as C. butyricum and C. 
beijerinckii, species that are both saccharolytic and proteolytic such as C. sporogenes and C. 
acetobutylicum, and proteolytic species such as C. limosum and C. histolyticum. This might 
explain why Clostridium numbers dropped and then increased at later times on those protein 
treatments with an omnivore microbiota: saccharolytic types from this genus were likely 
boosted by undigested saccharides within the fermenters at the beginning, and when 
carbohydrates became less abundant the number of saccharolytic clostridia dropped and 
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proteolytic types gradually increased. Vegetarian faeces may not contain as much undigested 
saccharides as omnivore faeces, therefore, the drop of Clostridium after 10 hours and increase 
after 24 hour occurred without any increase after 6 hours.  
Vegetarian donor 1 had the highest production of phenolic and indolic compounds together 
with the highest E. coli population suggesting that E. coli contributes to the production of 
phenolic compounds as suggested by previous studies (Nicholson et al., 2012). Indole and p-
cresol are conjugated as indoxyl sulfate and p-cresol sulphate in the human body; before they 
are excreted via urine, they are toxic to human endothelial cells, can reflect the progression of 
chronic kidney diseases, and increase cardiovascular disease risk for these chronic kidney 
disease patients (Dou et al., 2004, Dou et al., 2007, Aronov et al., 2011, Vanholder et al., 2014).  
Therefore, reduced production of indole and p-cresol can benefit human health in many ways.  
 
A few studies feeding rats with different protein sources did not find higher colonic toxicity of 
casein comparing with soybean, which is contrary to the phenol and p-cresol results in this 
study (Govers et al., 1993, Toden et al., 2007a). Feeding red meat gave higher DNA damage 
than casein in rats (Toden et al., 2006). Similar effects were found in human epidemiological 
research: dairy products were inversely correlated with colorectal cancer in Finnish men and 
New York University women; they speculated that this protective effect may result from other 
nutrients in the dairy products but not from macronutrients such as protein (Pietinen et al., 1999, 
Kato et al., 1997). Mycoprotein is a relatively new protein source from the filamentous fungus 
Fusarium venenatumsource under the trade mark of QuornTM (Wiebe, 2004). QuornTM products 
contain all essential amino acids, is low in fat and high in dietary fibre. However, in terms of 
protein fermentation by gut microbiota, QuornTM did not show any difference compared to 
other proteins.  
 
The use of pH controlled stirred batch culture system allowed rapid analysis of different protein 
fermentations by gut microbiota and the impact of prebiotics. This fermentation system is 
limited: SCFAs would be absorbed in the human colon and digesta supply is continuous. 
 
Some animal studies have revealed an inhibitory effect of proteolysis by resistant starch 
(Younes et al., 1995, Heijnen and Beynen, 1997, Toden et al., 2005). These were investigated 
by analysing indolic/phenolic compounds, or nitrogen secretion in the urine and faeces. One of 
these studies also compared DNA damage with and without resistant starch in rat colonic cells, 
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and found resistant starch protected cells from DNA damage (Toden et al., 2005). One possible 
mechanism of decreased proteolytic fermentation by prebiotics is through growth of 
saccharolytic bacteria that would need more amino acids for reproduction, therefore amino 
acids would not be available for proteolytic bacteria to metabolise.  
 
When concidering fermentation patterns of omnivores and vegetarians omnivores fermentation 
models had higher production of ammonia on casein when fermenting meat extract; on the 
otherhand vegetarians’ models produced more ammonia from soy protein and Quorn extract. 
This could be due to diet protein sources difference: microbiota from vegetarian donors have 
adapted to vegetarian protein sources and can utilise these proteins more efficiently. Besides, 
in this study, lower BCFA production was found with vegetarians’ gut bacteria; this could 
suggest that these vegetarian donors had lower branched chain amino acids in their diet.  
 
Addition of Synergy1 to 48 hour batch culture fermentation changed the microbiota to a more 
saccharolytic nature by stimulation of bifidobacteria and lactobacilli without a significant 
change of Bacteroides, Clostridium and E. coli. Supplementation with Synergy1 also reduced 
the concentration of protein metabolites (ammonia and BCFA); in those donors with high 
production of VOCs, inhibition was also found with Synergy1. Therefore, adding fructan 
prebiotics could potentially reduce or eliminate the negative consequences of ingesting high 
protein diets.  
102 
 
2.6 References 
AMANN, R. I., BINDER, B. J., OLSON, R. J., CHISHOLM, S. W., DEVEREUX, R. & STAHL, D. A. 1990. Combination of 
16s ribosomal-RNA-targeted oligonucleotide probes with flow-cytometry for analyzing mixed microbial-
populations. Applied and Environmental Microbiology, 56, 1919-1925. 
ARONOV, P. A., LUO, F. J. G., PLUMMER, N. S., QUAN, Z., HOLMES, S., HOSTETTER, T. H. & MEYER, T. W. 2011. 
Colonic Contribution to Uremic Solutes. Journal of the American Society of Nephrology, 22, 1769-1776. 
ATTENE-RAMOS, M. S., NAVA, G. M., MUELLNER, M. G., WAGNER, E. D., PLEWA, M. J. & GASKINS, H. R. 2010. 
DNA Damage and Toxicogenomic Analyses of Hydrogen Sulfide in Human Intestinal Epithelial FHs 74 Int 
Cells. Environmental and Molecular Mutagenesis, 51, 304-314. 
ATTENE-RAMOS, M. S., WAGNER, E. D., GASKINS, H. R. & PLEWA, M. J. 2007. Hydrogen sulfide induces direct 
radical-associated DNA damage. Molecular Cancer Research, 5, 455-459. 
ATTENE-RAMOS, M. S., WAGNER, E. D., PLEWA, M. J. & GASKINS, H. R. 2006. Evidence that hydrogen sulfide is a 
genotoxic agent. Molecular Cancer Research, 4, 9-14. 
BUDDINGTON, R. K., WILLIAMS, C. H., CHEN, S. C. & WITHERLY, S. A. 1996. Dietary supplement of neosugar alters 
the fecal flora and decreases activities of some reductive enzymes in human subjects. American Journal 
of Clinical Nutrition, 63, 709-716. 
CERINI, C., DOU, L., ANFOSSO, F., SABATIER, F., MOAL, S., GLORIEUX, G., DE SMET, R., VANHOLDER, R., DIGNAT-
GEORGE, F., SAMPOL, J., BERLAND, Y. & BRUNET, P. 2004. P-cresol, a uremic retention solute, alters the 
endothelial barrier function in vitro. Thrombosis and Haemostasis, 92, 140-150. 
CLINTON, S. K., BOSTWICK, D. G., OLSON, L. M., MANGIAN, H. J. & VISEK, W. J. 1988. Effects of ammonium acetate 
and sodium cholate on N-methyl-N'-nitro-N-nitrosoguanidine-induced colon carcinogenesis of rats. 
Cancer Research, 48, 3035-3039. 
COTTET, V., BONITHON-KOPP, C., KRONBORG, O., SANTOS, L., ANDREATTA, R., BOUTRON-RUAULT, M. C., FAIVRE, 
J. & EUROPEAN CANCER PREVENTION ORG, S. 2005. Dietary patterns and the risk of colorectal adenoma 
recurrence in a European intervention trial. European Journal of Cancer Prevention, 14, 21-29. 
DAIMS, H., BRUHL, A., AMANN, R., SCHLEIFER, K. H. & WAGNER, M. 1999. The domain-specific probe EUB338 is 
insufficient for the detection of all Bacteria: Development and evaluation of a more comprehensive 
probe set. Systematic and Applied Microbiology, 22, 434-444. 
DOU, L., BERTRAND, E., CERINI, C., FAURE, V., SAMPOL, J., VANHOLDER, R., BERLAND, Y. & BRUNET, P. 2004. The 
uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney 
International, 65, 442-451. 
DOU, L., JOURDE-CHICHE, N., FAURE, V., CERINI, C., BERLAND, Y., DIGNAT-GEORGE, F. & BRUNET, P. 2007. The 
uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. Journal of Thrombosis and 
Haemostasis, 5, 1302-1308. 
FAO. 2017. Food Balance / Food Balance Sheets [Online]. Food and Agriculture Organization. Available: 
http://faostat3.fao.org/browse/FB/FBS/E. 
FRANKS, A. H., HARMSEN, H. J., RAANGS, G. C., JANSEN, G. J., SCHUT, F. & WELLING, G. W. 1998. Variations of 
bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 
16S rRNA-targeted oligonucleotide probes. Applied and Environmental Microbiology, 64, 3336-45. 
GIBSON, G. R., HUTKINS, R., SANDERS, M. E., PRESCOTT, S. L., REIMER, R. A., SALMINEN, S. J., SCOTT, K., STANTON, 
C., SWANSON, K. S., CANI, P. D., VERBEKE, K. & REID, G. 2017. Expert consensus document: The 
International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the 
definition and scope of prebiotics. Nature reviews. Gastroenterology & hepatology. 
GIBSON, J. A., SLADEN, G. E. & DAWSON, A. M. 1976. Protein absorption and ammonia production: the effects 
of dietary protein and removal of the colon. British Journal of Nutrition, 35, 61-65. 
GONZALEZ, C. A. & RIBOLI, E. 2010. Diet and cancer prevention: Contributions from the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study. European Journal of Cancer, 46, 2555-2562. 
GOVERS, M., LAPRE, J. A., DEVRIES, H. T. & VANDERMEER, R. 1993. Dietary soybean protein compared with casein 
damages colonic epithelium and stimulates colonic epithelial proliferation in rats. Journal of Nutrition, 
123, 1709-1713. 
GRIMALDI, R., CELA, D., SWANN, J. R., VULEVIC, J., GIBSON, G. R., TZORTZIS, G. & COSTABILE, A. 2017. In vitro 
fermentation of B-GOS: impact on faecal bacterial populations and metabolic activity in autistic and 
non-autistic children. FEMS Microbiology Ecology, 93. 
HARMSEN, H. J. M., ELFFERICH, P., SCHUT, F. & WELLING, G. W. 1999. A 16S rRNA-targeted probe for detection 
of lactobacilli and enterococci in faecal samples by fluorescent in situ hybridization. Microbial Ecology 
in Health and Disease, 11, 3-12. 
103 
 
HARMSEN, H. J. M., WILDEBOER-VELOO, A. C. M., GRIJPSTRA, J., KNOL, J., DEGENER, J. E. & WELLING, G. W. 2000. 
Development of 16S rRNA-based probes for the Coriobacterium group and the Atopobium cluster and 
their application for enumeration of Coriobacteriaceae in human feces from volunteers of different age 
groups. Applied and Environmental Microbiology, 66, 4523-4527. 
HEIJNEN, M. L. A. & BEYNEN, A. C. 1997. Consumption of retrograded (RS3) but not uncooked (RS2) resistant 
starch shifts nitrogen excretion from urine to feces in cannulated piglets. Journal of Nutrition, 127, 1828-
1832. 
HUGHES, R., KURTH, M. J., MCGILLIGAN, V., MCGLYNN, H. & ROWLAND, I. 2008. Effect of colonic bacterial 
metabolites on caco-2 cell paracellular permeability in vitro. Nutrition and Cancer, 60, 245-250. 
IARC 2015. Monographs evaluate consumption of red meat and processed meat. International Agency for 
Research on Cancer, Press release No. 240. World Health Organization  
INSTITUTE OF MEDICINE (U.S.). COMMITTEE ON USE OF DIETARY REFERENCE INTAKES IN NUTRITION LABELING. 
2005. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and 
amino acids. Washington, DC: National Academies Press. 
JANTCHOU, P., MOROIS, S., CLAVEL-CHAPELON, F., BOUTRON-RUAULT, M.-C. & CARBONNEL, F. 2010. Animal 
protein intake and risk of inflammatory bowel disease: the E3N prospective study. American Journal of 
Gastroenterology, 105, 2195-2201. 
KATO, I., AKHMEDKHANOV, A., KOENIG, K., TONIOLO, P. G., SHORE, R. E. & RIBOLI, E. 1997. Prospective study of 
diet and female colorectal cancer: The New York University women's health study. Nutrition and Cancer-
an International Journal, 28, 276-281. 
KELLOGG, T. F. H., V.W.; CATRON, D.V.; QUINN, L.Y.; SPEER, V.C. 1964. Effect of level and source of dietary protein 
on performance and fecal flora of baby pigs. Journal of Animal Science, 23, 1089–1094. 
KOLIDA, S., TUOHY, K. & GIBSON, G. R. 2002. Prebiotic effects of inulin and oligofructose. British Journal of 
Nutrition, 87, S193-S197. 
LANGENDIJK, P. S., SCHUT, F., JANSEN, G. J., RAANGS, G. C., KAMPHUIS, G. R., WILKINSON, M. H. F. & WELLING, 
G. W. 1995. Quantitative fluorescence in-situ hybridization of bifidobacterium spp with genus-specific 
16s ribosomal-RNA-targeted probes and its application in fecal samples. Applied and Environmental 
Microbiology, 61, 3069-3075. 
LIN, H. C. & VISEK, W. J. 1991. Colon mucosal cell-damage by ammonia in rats. Journal of Nutrition, 121, 887-893. 
MACFARLANE, G. T., CUMMINGS, J. H. & ALLISON, C. 1986. Protein-degradation by human intestinal bacteria. 
Journal of General Microbiology, 132, 1647-1656. 
MANZ, W., AMANN, R., LUDWIG, W., VANCANNEYT, M. & SCHLEIFER, K. H. 1996. Application of a suite of 16S 
rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophaga-
flavobacter-bacteroides in the natural environment. Microbiology, 142, 1097-1106. 
MCCALL, I. C., BETANZOS, A., WEBER, D. A., NAVA, P., MILLER, G. W. & PARKOS, C. A. 2009. Effects of phenol on 
barrier function of a human intestinal epithelial cell line correlate with altered tight junction protein 
localization. Toxicology and Applied Pharmacology, 241, 61-70. 
MILLS, D. J., TUOHY, K. M., BOOTH, J., BUCK, M., CRABBE, M. J., GIBSON, G. R. & AMES, J. M. 2008. Dietary 
glycated protein modulates the colonic microbiota towards a more detrimental composition in 
ulcerative colitis patients and non-ulcerative colitis subjects. Journal of applied microbiology, 105, 706-
14. 
MINER-WILLIAMS, W., DEGLAIRE, A., BENAMOUZIG, R., FULLER, M. F., TOME, D. & MOUGHAN, P. J. 2012. 
Endogenous proteins in terminal ileal digesta of adult subjects fed a casein-based diet. American Journal 
of Clinical Nutrition, 96, 508-515. 
MINER-WILLIAMS, W., DEGLAIRE, A., BENAMOUZIG, R., FULLER, M. F., TOME, D. & MOUGHAN, P. J. 2014. 
Endogenous proteins in the ileal digesta of adult humans given casein-, enzyme-hydrolyzed casein- or 
crystalline amino-acid-based diets in an acute feeding study. European Journal of Clinical Nutrition, 68, 
363-369. 
MOUGHAN, P. J., BUTTS, C. A., ROWAN, A. M. & DEGLAIRE, A. 2005. Dietary peptides increase endogenous amino 
acid losses from the gut in adults. American Journal of Clinical Nutrition, 81, 1359-1365. 
NICHOLSON, J. K., HOLMES, E., KINROSS, J., BURCELIN, R., GIBSON, G., JIA, W. & PETTERSSON, S. 2012. Host-Gut 
Microbiota Metabolic Interactions. Science, 336, 1262-1267. 
PIETINEN, P., MALILA, N., VIRTANEN, M., HARTMAN, T. J., TANGREA, J. A., ALBANES, D. & VIRTAMO, J. 1999. Diet 
and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes & Control, 10, 387-396. 
POULSEN, L. K., LAN, F. S., KRISTENSEN, C. S., HOBOLTH, P., MOLIN, S. & KROGFELT, K. A. 1994. Spatial-distribution 
of Escherichia-coli in the mouse large-intestine inferred from ribosomal-RNA in-situ hybridization. 
Infection and Immunity, 62, 5191-5194. 
104 
 
RAMSING, N. B., FOSSING, H., FERDELMAN, T. G., ANDERSEN, F. & THAMDRUP, B. 1996. Distribution of bacterial 
populations in a stratified fjord (Mariager fjord, Denmark) quantified by in situ hybridization and related 
to chemical gradients in the water column. Applied and Environmental Microbiology, 62, 1391-1404. 
RICHARDSON, A. J., CALDER, A. G., STEWART, C. S. & SMITH, A. 1989. Simultaneous determination of volatile and 
non-volatile acidic fermentation products of anaerobes by capillary gas-chromatography. Letters in 
Applied Microbiology, 9, 5-8. 
ROEDIGER, W. E. W., DUNCAN, A., KAPANIRIS, O. & MILLARD, S. 1993. Sulfide impairment of substrate oxidation 
in rat colonocytes: a biochemical basis for ulcerative-colitis. Clinical Science, 85, 623-627. 
RUSSELL, W. R., HOYLES, L., FLINT, H. J. & DUMAS, M.-E. 2013. Colonic bacterial metabolites and human health. 
Current Opinion in Microbiology, 16, 246-254. 
SHODA, R., MATSUEDA, K., YAMATO, S. & UMEDA, N. 1996. Epidemiologic analysis of Crohn disease in Japan: 
Increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased 
incidence of Crohn disease in Japan. American Journal of Clinical Nutrition, 63, 741-745. 
SMITH, E. A. & MACFARLANE, G. T. 1997. Dissimilatory amino acid metabolism in human colonic bacteria. 
Anaerobe, 3, 327-337. 
SUAU, A., ROCHET, V., SGHIR, A., GRAMET, G., BREWAEYS, S., SUTREN, M., RIGOTTIER-GOIS, L. & DORE, J. 2001. 
Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. 
Systematic and Applied Microbiology, 24, 139-145. 
TODEN, S., BIRD, A. R., TOPPING, D. L. & CONLON, M. A. 2005. Resistant starch attenuates colonic DNA damage 
induced by higher dietary protein in rats. Nutrition and Cancer-an International Journal, 51, 45-51. 
TODEN, S., BIRD, A. R., TOPPING, D. L. & CONLON, M. A. 2006. Resistant starch prevents colonic DNA damage 
induced by high dietary cooked red meat or casein in rats. Cancer Biology & Therapy, 5, 267-272. 
TODEN, S., BIRD, A. R., TOPPING, D. L. & CONLON, M. A. 2007. Differential effects of dietary whey, casein and 
soya on colonic DNA damage and large bowel SCFA in rats fed diets low and high in resistant starch. 
British Journal of Nutrition, 97, 535-543. 
VANHOLDER, R., SCHEPERS, E., PLETINCK, A., NAGLER, E. V. & GLORIEUX, G. 2014. The uremic toxicity of indoxyl 
sulfate and p-cresyl sulfate: a systematic review. Journal of the American Society of Nephrology, 25, 
1897-1907. 
VERBEKE, K. A., BOOBIS, A. R., CHIODINI, A., EDWARDS, C. A., FRANCK, A., KLEEREBEZEM, M., NAUTA, A., RAES, 
J., VAN TOL, E. A. F. & TUOHY, K. M. 2015. Towards microbial fermentation metabolites as markers for 
health benefits of prebiotics. Nutrition Research Reviews, 28, 42-66. 
WALKER, A. W., DUNCAN, S. H., LEITCH, E. C. M., CHILD, M. W. & FLINT, H. J. 2005. pH and peptide supply can 
radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from 
the human colon. Applied and Environmental Microbiology, 71, 3692-3700. 
WALLNER, G., AMANN, R. & BEISKER, W. 1993. Optimizing fluorescent in situ hybridization with rRNA-targeted 
oligonucleotide probes for flow cytometric identification of microorganisms. Cytometry, 14, 136-43. 
WANG, X. & GIBSON, G. R. 1993. Effects of the in-vitro fermentation of oligofructose and inulin by bacteria 
growing in the human large-intestine. Journal of Applied Bacteriology, 75, 373-380. 
WIEBE, M. G. 2004. Quorn TM myco-protein - overview of a successful fungal product. Mycologist, 18, 17-20. 
WILLETT, W. C., STAMPFER, M. J., COLDITZ, G. A., ROSNER, B. A. & SPEIZER, F. E. 1990. Relation of meat, fat, and 
fiber intake to the risk of colon cancer in a prospective-study among women. New England Journal of 
Medicine, 323, 1664-1672. 
WILLIAMS, R. J. H., BROWNSELL, V. L. & ANDREWS, A. T. 2001. Application of the plastein reaction to mycoprotein: 
I. Plastein synthesis. Food Chemistry, 72, 329-335. 
YOUNES, H., DEMIGNE, C., BEHR, S. & REMESY, C. 1995. Resistant starch exerts a lowering effect on plasma urea-
by enhancing urea n transfer into the large-intestine. Nutrition Research, 15, 1199-1210. 
YOUNG, T. B. & WOLF, D. A. 1988. Case-control study of proximal and distal colon cancer and diet in Wisconsin. 
International Journal of Cancer, 42, 167-175. 
 
 
 
  
105 
 
Chapter 3 The effect of prebiotic inulin type fructans on bacterial 
metabolism of high protein levels, an in vitro study 
 
Abstract 
Dietary protein levels are generally higher in Western populations than the world average, and 
this can result in microbial generation of various toxic metabolites in the gut. A prebiotic is “a 
substrate that is selectively utilised by host microorganisms conferring a health benefit”. 
Prebiotics may have the potential to reverse the harmful effects of gut bacterial protein 
fermentation.  
 
Three-stage continuous colonic model systems were inoculated with faecal samples from 
omnivore and vegetarian volunteers.  Casein (equivalent to 105g protein consumption per day) 
was used within the systems as a fermentable protein source. Two different doses of inulin type 
fructans (Synergy1) were later added (equivalent to 10g per day in vivo and 15g per day) to 
assess whether this influenced proteolysis. Bacteria were enumerated by fluorescence in situ 
hybridisation-flow cytometry. Metabolites from bacterial fermentation (short chain fatty acid 
(SCFA), ammonia, phenol, indole and p-cresol) were monitored to further analyse proteolysis. 
A significant higher number of bifidobacteria was observed with the addition of Synergy1, 
together with reduction of Bacteroides and Desulfovibrio spp. Furthermore, metabolites from 
protein fermentation such as branched chain fatty acids (BCFA), ammonia production were 
significantly lowered with Synergy1. The higher dose of prebiotic had a more inhibitory effect 
on protein fermentation. 
 
Conclusion: Faecal fermentations of proteins with a prebiotic supplementation resulted in a 
change in the human gut microbiota and inhibited the production of some proteolytic 
metabolites.  
3.1 Introduction 
 
Protein consumption is increasing annually worldwide and 2.5% of British adult males 
consume 136g protein per day according to a recent national dietary survey (FAO, 2017, Food 
Standards Agency, 2016). Most protein is metabolised in the small intestine, but residual 
dietary protein may enter the large intestine where colonic bacteria can utilise it and produce 
various metabolites. Proteolysis gradually increases throughout the colon, being highest in 
distal regions where the carbohydrate is depleted (Macfarlane et al., 1988, Macfarlane et al., 
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1992b). Bacterial degradation of amino acids produces ammonia, amines, CO2, short chain 
fatty acids, branched chain fatty acids, occasionally H2S and aromatic molecules such as indole, 
p-cresol and skatole (Smith and Macfarlane, 1997). These metabolites may interact with the 
host and affect human health in many ways. In cell culture experiments, ammonia at relevant 
lumenal concentrations was found to have a negative effect on barrier function with elevated 
permeability (Hughes et al., 2008). Two animal studies illustrated how ammonia can shorten 
mucosal cell lifespan, and promote colon cancer together with other carcinogens in vivo 
(Clinton et al., 1988, Lin and Visek, 1991). Hydrogen sulphide can be generated from sulphur 
containing amino acids together with reduction of dietary sulphates; both rat and human 
colonocyte cell lines showed that H2S had a negative effect on butyrate and acetate oxidation 
by cells for energy uptake (Roediger et al., 1993, Leschelle et al., 2005). Bacterial H2S 
production rates are higher in ulcerative colitis patients compared to healthy adults which may 
contribute to the pathogenesis of some inflammatory bowel diseases (Gibson et al., 1991). 
Aromatic amino acids such as tyrosine, phenylalanine and tryptophan can be degraded by 
colonic bacteria producing phenol, indole, p-cresol, skatole and other aromatic metabolites. 
Phenol and p-cresol have been shown to damage epithelial barrier function in vitro (Cerini et 
al., 2004, Hughes et al., 2008, McCall et al., 2009). Indole and p-cresol would be transformed 
to indoxyl sulphate and p-cresol sulphate after conjugation in the human body and indoxyl 
sulphate and p-cresol sulphate levels in blood are correlated with renal disease progression and 
vascular dysfunction in chronic kidney disease (Barreto et al., 2009, Vanholder et al., 2014). 
A prebiotic is defined as “a substrate that is selectively utilised by host microorganisms 
conferring a health benefit” by Gibson et al. (2017). One confirmed type of prebiotic is inulin 
type fructans which are carbohydrates comprised of fructose residues, sometimes with a 
glucose at the terminal. The D-fructose molecules are linked by β (2→1) linkages and when 
there is a glucose, the chain is terminated by a D-glucose molecule bonded to fructose by an 
α(12) linkage. A randomised, double-blind, placebo-controlled, cross-over human study 
recently analysed bacterial compositional changes after inulin type fructan intervention by 16S 
rDNA sequencing: bifidobacteria and Anaerostipes increased while Bilophila decreased after 
prebiotic supplementation for 4 weeks, together with an improvement in constipation 
(Vandeputte et al., 2017). Other human intervention studies have investigated various health 
benefits of inulin type fructans such as mineral absorption, energy regulation and lipid lowering 
properties (Holloway et al., 2007, Russo et al., 2011b, Jackson et al., 1999). Metabolism of 
inulin type fructans not only promotes specific bacterial changes in the colon, but also generates 
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short chain fatty acids (SCFA). Bifidobacteria can produce acetate and lactate from 
carbohydrates by the bifid shunt and these two acids are substrates for butyrate producers such 
as Eubacterium rectale and Anaerostipes caccae resulting in enhanced butyrate production in 
the gut (Riviere et al., 2015, Moens et al., 2017). SCFA, especially butyrate, can promote 
epithelial cell differentiation and apoptosis in vitro, therefore they may possibly reduce 
colorectal cancer risk in the human body (Hague et al., 1995).  
Here, prebiotic effects on the possible negative consequence of protein fermentation in the gut 
were studied using an in vitro multiple stage continuous culture system.  
3.2 Materials 
 
3.2.1 Proteins 
Protein substrates used were casein hydrolysates (Sigma-Aldrich, Poole, UK)  
3.2.2 Prebiotic 
Inulin-type fructan was a mixture of oligofructose and inulin: 50% ± 10% degree of 
polymerisation (DP) of 3-9 and 50%±10% DP≥10 (Orafti®Synergy 1, BENEO-Orafti, Tienen, 
Belgium). 
3.3 Methods 
 
3.3.1 Protein and prebiotic dose determination 
 
A miniature gut model system, 33% the size of the version described by Macfarlane et al. (1998) 
was used in this study. Approximate 16g proteins will reach the colon following ingestion of 
105g protein/day of which 8g are endogenous and 8g are exogenous (Gibson et al., 1976, 
Moughan et al., 2005). The in vitro dose required to simulate prebiotic and protein effects in 
vitro was calculated as follows: 
 
 Table 3.1 Protein dosage calculation for continuous gut model fermentation. 
Steady State In vivo In vitro fermentation 
Steady state 2 8g dietary protein per day 2.67g per day 
Steady state 3 8g dietary protein per day 2.67g per day 
10g prebiotic per day 3.33g per day 
Steady state 4 8g dietary protein per day 2.67g per day 
15g prebiotic per day 5g per day 
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3.3.2 In vitro gut model fermentation 
3.3.2.1 Faecal sample preparation 
 
Faecal samples were obtained from three healthy meat eating individuals and three healthy 
vegetarian volunteers between the ages of 18 and 60, who had not taken antibiotics for at least 
six months prior to the experiment and had no history of gastrointestinal disorders.  
Faecal samples were diluted 1 in 20 (w/v) using 1M phosphate buffered saline (PBS, Oxoid, 
Hampshire, UK), pH7.4. This suspension was homogenised in a stomacher (Seward, stomacher 
80, Biomaster) for 120 seconds at normal speed.  
3.3.2.2 Gut model medium. 
 
Gut model medium was prepared with chemicals obtained from Sigma-Aldrich, Poole, UK 
unless otherwise stated. In one litre: 5g starch, 5g peptone water, 5g tryptone, 4.5g yeast extract 
(Oxoid, Hampshire, UK), 4.5g NaCl, 4.5g KCl, 4g mucin (porcine gastric type III), 3g casein, 
2g pectin (citrus), 2g xylan from beech wood pure (SERVA, Heidelberg, Germany), 2g 
arabinogalactan (larch wood), 1.5g NaHCO3 (Fischer scientific, Loughborough, UK), 1.25g 
MgSO4·7H2O (Fischer scientific, Loughborough, UK), 1g guar gum, 1g inulin (BENEO-Orafti, 
Tienen, Belgium)., 0.8g L–cystine HCl, 0.5g KH2PO4, 0.5g K2HPO4, 0.4g bile salts No. 3, 
0.15g CaCl2·6H2O, 0.005g FeSO4·7H2O, 0.05g haemin, 10µl vitamin K, 1ml Tween 80 and 
4ml resazarin (0.025g/100ml, pH7).  
 
3.3.2.3 Three stage continuous pH controlled, gut model fermentation 
 
A three stage continuous fermentation culture system was used to simulate the lumenal 
conditions in each of the three distinct regions of the human colon: proximal, transverse, and 
distal colon (V1, V2, and V3) (Macfarlane et al., 1998). Vessels with an operating volume of 
80mL, 100mL, and 120mL were set up in sequence. Autoclaved culture medium (51.43 ml 
(V1), 66.67 ml (V2), 82.5 ml (V3)) were aseptically poured into sterile vessels. This system 
was left overnight with oxygen free nitrogen pumping through the media at a rate of 15mL/min. 
Each vessel was temperature controlled at 37°C and stirred using a magnetic stirrer. Faecal 
slurry at 20% (w/v) was inoculated into the culture vessels (28.57 ml (V1), 33.33 ml (V2), 37.5 
ml (V3)) and left to equilibrate for 24 h as a batch culture system prior to commencing the 
continuous medium flow. Control of pH was achieved by pH meters (Electrolab pH controller, 
Tewksbury, UK) connected to each vessel to regulate pH at 5.4 to 5.6 (V1), 6.1 to 6.3 (V2) and 
6.7 to 6.9 (V3) with the aid of 0.5M HCl and NaOH. Oxygen free nitrogen flow and pH were 
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maintained throughout the whole experiment. 
After 8 turnovers (16 days) of the operating volume (300ml in total) at a medium flow rate of 
6.25ml/hour, SCFA were analysed for three consecutive days to confirm the establishment of 
steady state. Samples were taken for three consecutive days after confirmation of the 
equilibrium for analysis of bacterial populations and metabolite concentrations.  
 
3.3.3 Enumeration of faecal microbial populations by flow cytometry fluorescence in situ 
hybridisation (FISH) 
 
A 750µl sample of fermentation fluid was centrifuged at 11337 × g for 5 minutes to remove 
supernatant. The pellet was then suspended in 375µl filtered 0.1M PBS solution. Filtered 4% 
paraformaldehyde (PFA) at 4°C (1125µl) were added and samples were stored at 4°C for 4 
hours. Samples were then washed thoroughly with PBS to remove PFA and re-suspended in a 
mixture containing 300 µl PBS and 300 µl 99% ethanol. Samples were then stored at -20°C, 
prior to FISH analysis by flow cytometry. FISH by flow cytometry was carried out as described 
by Grimaldi et al. (2017). The probes used in this study are listed below:
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Table 3.2 Name, sequence, and target group of oligonucleotide probes used in this study for FISH of bacterial enumeration 
 
Probe name 
 
Sequence (5’ to 3’) 
 
Targeted groups 
 
Reference 
Non Eub ACTCCTACGGGAGGCAGC Control probe complementary to EUB338  (Wallner et al., 1993) 
Eub338‡ GCTGCCTCCCGTAGGAGT Most bacteria (Amann et al., 1990) 
Eub338II‡ GCAGCCACCCGTAGGTGT Planctomycetales (Daims et al., 1999) 
Eub338III‡ GCTGCCACCCGTAGGTGT Verrucomicrobiales (Daims et al., 1999) 
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. (Langendijk et al., 1995) 
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus and Enterococcus (Harmsen et al., 1999) 
Bac303 CCAATGTGGGGGACCTT Most Bacteroidaceae and Prevotellaceae, some Porphyromonadaceae (Manz et al., 1996) 
Erec482 GCTTCTTAGTCARGTACCG Most of the Clostridium coccoides-Eubacterium rectale group (Clostridium cluster XIVa and 
XIVb) 
(Franks et al., 1998) 
Rrec584 TCAGACTTGCCGYACCGC Roseburia genus (Walker et al., 2005) 
Ato291 GGTCGGTCTCTCAACCC Atopobium cluster (Harmsen et al., 2000a) 
Prop853 ATTGCGTTAACTCCGGCAC Clostridial cluster IX (Walker et al., 2005) 
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii and relatives (Suau et al., 2001) 
DSV687 TACGGATTTCACTCCT Desulfovibrio genus Ramsing et al. (1996) 
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium histolyticum group (Clostridium cluster I and II) Franks et al. (1998) 
EC 1531 CAC CGT AGT GCC TCG TCA TCA Escherichia coli BJ4 (Poulsen et al., 1994) 
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3.3.4 Short chain fatty acid (SCFA) and volatile organic compounds analysis by GC 
Samples (1ml) were collected and extractions performed with some modifications of a method 
from Richardson et al. (1989). Sample (1ml) was transferred into a labelled 100 mm×16 mm 
glass tube (International Scientific Supplies Ltd, Bradford, England) with 50 μl of 2-
ethylbutyric acid (0.1 M, internal standard) (Sigma, Poole, UK). Concentrated HCl (500 µl) 
and 1 ml diethyl ether were added to each glass tube and samples vortexed for 1 minute. 
Samples were centrifuged at 2000 g for 10 minutes. The diethyl ether (upper) layer of each 
sample was transferred to a labelled clean glass tube. Ether extract (400 μl) and 50 μl N-(tert-
butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA, Sigma-Aldrich, Poole, UK) 
were added into a GC screw-cap vial. Samples were left at room temperature for 72 hours to 
allow lactic acid in the samples to completely derivatise. 
 
An Agilent/HP 6890 Gas Chromatograph (Hewlett Packard, UK) using an HP-5MS 
30m×0.25mm column with a 0.25μm coating of crosslinked (5%-Phenyl)-methylpolysiloxane, 
(Hewlett Packard, UK) was used for analysis of SCFA. Temperatures of injector and detector 
were 275°C, with the column temperature programmed from 63°C to 190°C at 15°C min-1 
followed by 190°C for 3 minutes. Helium was the carrier gas (flow rate 1.7 ml min-1; head 
pressure 133 KPa). A split ratio of 100:1 was used.  Quantification of the samples was achieved 
by calibration with lactic, acetic, formic, propionic, butyric, valeric acids and branched SCFA 
(iso-butyric and iso-valeric) in concentrations between 12.5 and 100 mM.  
 
3.3.5 Ammonia Analysis 
Samples were diluted 1 in 50 v/v prior to analysis. Ammonia concentrations in diluted 
fermentation samples were analysed by a Sigma-Aldrich FluoroSELECT™ ammonia kit 
(Sigma-Aldrich, Poole, UK). Reagent was prepared by combining 100 μL assay buffer, 4 μL 
reagent A and 4 μL reagent B provided in the kit. H2O (10 μL) served as a blank and 10 μL of 
each sample were added to glass vials. Reagent (100 μL) was then added to each tube. Samples 
were kept in the dark for 15 minutes at room temperature before they were read in a fluorimeter. 
Ammonia standards were prepared by diluting 20 mmol/L NH4Cl into distilled water and the 
concentration range was 0.25-1 mmol/L).  
 
3.4 Results 
3.4.1 Bacterial Enumeration 
High protein feeding did not affect bacterial numbers in the proximal colon simulation, 
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however the simulated transverse colon of both omnivore and vegetarian models and the 
simulated distal colon of vegetarian models had significantly higher bacterial populations after 
protein feeding (Figure 3.1). After prebiotic feeding total bacterial populations in gut models 
from both omnivore and vegetarian donors were slightly higher, especially at the higher dose 
in the models inoculated with omnivore donors (p<0.001 on all three regions). Meanwhile 
populations of bifidobacteria and lactobacilli were increased by growth on Synergy1 in all 
models (Figure 3.2). Bacteroides. spp, populations displayed trend to increase when grown on 
the protein and decreased significantly when grown on Synergy1 (Figure 3.3). Bacteroides spp. 
are significant propionate producers and a potential proteolytic species (Macfarlane et al., 
1986).  
 
Within Clostridium cluster XIVa and XIVb there are some proteolytic bacteria and this group 
responded to the high protein dose (Figure 3.4): these bacteria from omnivore donors increased 
in all vessels while vegetarians’ microbiota increased in transverse and distal colon simulations 
only. The number of facultatively anaerobic Atopobium cluster from all donors grew through 
all steady states.  
 
Desulfovibrio can reduce dietary sulphate and produce H2S (Gibson et al., 1990). These 
organisms were not affected by the protein containing medium, however, both doses of 
prebiotics decreased numbers of Desulfovibrio (Figure 3.5). In omnivore-inoculated models, 
reduction was significant in the proximal and transverse colon vessels while in vegetarian-
inoculated models the change was only significant in the proximal region with the lower dosage.  
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Figure 3.1 Total bacterial changes with different steady states as log10 CFU/mL in three different vessels as analysed by FISH. Values are mean values over consecutive three days from 3 omnivore 
microbiota (A) and 3 vegetarian microbiota (B) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.05). ** Mean values were highly 
significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.001). 
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Figure 3.2 Bif164 (A and B) and Lab158 (C and D) changes with different steady states as log10 CFU/mL in three different vessels as analysed by FISH. Values are mean values over consecutive 
three days from 3 omnivore microbiota (A and C) and 3 vegetarian microbiota (B and D) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.001). 
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Figure 3.3 Bac303 (A and B) and Prop853 (C and D) changes with different steady states as log10 CFU/mL in three different vessels as analysed by FISH. Values are mean values over consecutive 
three days from 3 omnivore microbiota (A and C) and 3 vegetarian microbiota (B and D) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.001). 
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Figure 3.4 Erec482 (A and B) Rrec584 (C and D) and Fprau655 (E and F) changes with different steady states as log10 CFU/mL in three different vessels as analysed by FISH. Values are mean 
values over consecutive three days from 3 omnivore microbiota (A C and E) and 3 vegetarian microbiota (B D and F) ± standard deviation. * Mean values were significantly different from SS1 
or SS2 (for SS3 and SS4) (p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean values were significantly different from SS1 or 
SS2 (for SS3 and SS4) (p<0.001). 
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Figure 3.5 DSV687 (A and B) and Chis150 (C and D) changes with different steady states as log10 CFU/mL in three different vessels as analysed by FISH. Values are mean values over consecutive 
three days from 3 omnivore microbiota (A and C) and 3 vegetarian microbiota (B and D) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.001). 
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Figure 3.6 Ato291 (A and B) and EC1531 (C and D) changes with different steady states as log10 CFU/mL in three different vessels as analysed by FISH. Values are mean values over consecutive 
three days from 3 omnivore microbiota (A and C) and 3 vegetarian microbiota (B and D) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) 
(p<0.001). 
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3.4.2 Organic Acids 
 
Acetate concentrations decreased with protein treatment and increased significantly in all three 
regions after prebiotic steady state, which can be correlated with the higher total bacteria 
numbers in both prebiotic treatments (Figure 3.7). Specifically, a higher number of 
bifidobacteria would be expected to promote acetate production.  
 
Concentrations of propionic acid were reduced by protein supplementation and further reduced 
by prebiotic supplementation (Figure 3.7). This can be explained by a decreased population of 
Bacteroides in the gut models.  
 
Butyric acid was significantly increased in the later steady states (SS3 and SS4) when grown 
on Synergy1, which could be explained by increases in butyrate producing Clostridium 
coccoides-Eubacterium rectale group (Figure 3.7).  
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Figure 3.7 Acetate (A and B) propionate (C and D) and butyrate (E and F) (mM) with different steady states in three different 
vessels as analysed by GC. Values are mean values over consecutive three days from 3 omnivore microbiota (A C and E) and 
3 vegetarian microbiota (B D and F) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for 
SS3 and SS4) (p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** 
Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.001).  
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Bacterial metabolism of valine and leucine produces iso-butyrate and iso-valerate respectively 
and these two metabolites indicate gut bacterial proteolysis (Macfarlane et al., 1992a). Both 
isovaleric acid and isobutyric acid concentrations increased after extra protein was added to all 
three vessels (Figure 3.8). This increased production on the protein was inhibited by prebiotic 
supplementation, especially in vegetarian-inoculated models in the proximal colon simulation 
(p<0.01), where the BCFA concentration was lower than the baseline steady state 1.  
 
 
 
Figure 3.8 Changes in Isobutyrate (A and B) and Isovalerate (C and D) (mM) with different steady states in three different 
vessels as analysed by GC. Values are mean values over consecutive three days from 3 omnivore microbiota (A and C) and 3 
vegetarian microbiota (B and D) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for SS3 
and SS4) (p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean 
values were significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.001).  
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3.4.3 Volatile Organic Compounds 
 
Three potentially detrimental volatile organic compounds (indole, p-cresol and skatole) were 
quantified (Figure 3.9). Concentrations of skatole were under the detection limit. Production 
of these compounds displayed high individual variation, as evidenced by high standard 
deviations these data. Indole was produced in low amounts and not decreased after Synergy1 
addition. p-cresol concentrations were significantly higher in the transverse and distal vessels 
after steady state 2, however the inhibitory effect of prebiotics was only observed in vegetarian-
inoculated models in distal colon simulations (p<0.05). 
 
 
 
Figure 3.9 Changes in indole (A and B) and p-cresol (C and D) (µg/ml) with different steady states in three different vessels 
as analysed by GC. Values are mean values over consecutive three days from 3 omnivore microbiota (A and C) and 3 
vegetarian microbiota (B and D) ± standard deviation. * Mean values were significantly different from SS1 or SS2 (for SS3 
and SS4) (p<0.05). ** Mean values were highly significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01).  
3.4.4 Ammonia  
 
Ammonia is considered a major metabolite of the fermentation of protein by faecal bacteria 
as a result of deamination of amino acids. Addition of protein to the colonic model 
significantly increased the production of ammonia in all three regions, especially in the 
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transverse and distal vessels (Figure 3.10). The higher prebiotic supplementation dose 
suppressed ammonia production to a greater degree, with significant differences in the 
transverse regions of all six models, and distal colon in omnivore-inoculated models. 
 
 
Figure 3.10 Changes in ammonia concentration (mM) with different steady states in three different vessels. Values are mean 
values over consecutive three days from 3 omnivore microbiota (A) and 3 vegetarian microbiota (B) ± standard deviation. * 
Mean values were significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.05). ** Mean values were highly 
significantly different from SS1 or SS2 (for SS3 and SS4) (p<0.01). *** Mean values were significantly different from SS1 or 
SS2 (for SS3 and SS4) (p<0.001). 
 
3.5 Discussion 
 
Three subjects following omnivore diets and three following vegetarian diets were recruited to 
donate their faecal samples for inoculation of the colonic models. Among these six donors, 
some different patterns of microbiota were observed. At the genus level, faecal bacterial 
composition differences between omnivores and vegetarians was not clearly seen, however 
metabolic activities of their microbiota may differ. After feeding standardised medium until the 
fermentation equilibrated, total bacteria counts were lower in vegetarian models compared to 
omnivore models, and this difference persisted in all steady states. A possible explanation for 
in vitro culture differences is that this three-stage continuous culture system has been 
previously validated with six sudden death subjects which most probably were not vegetarians 
(Macfarlane et al., 1998). Therefore, carbohydrate and protein content in vegetarians’ digesta 
can be different from the validated medium used by Macfarlane et al., (1998) resulting in 
differing bacteria growth in the gut model. In the present study, some bacterial groups from 
omnivore- and vegetarian-inoculated models displayed different responses on protein and 
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prebiotic addition indicating that, at genus level at least, bacteria have different metabolic 
activities. With various food sources entering the digestive tract, bacteria from different 
individuals adapt and may possess different metabolic activities (Giraud et al., 2001).  
 
 According to Gibson (1988), SRB population are not always present in human populations 
because some individuals possess methanogens to dispose of hydrogen in the gut instead of 
SRB which may explain the high variation of SRB count in this study. Hydrogen sulphide 
possibly contributes to the pathogenesis of ulcerative colitis, potentially offering a role for 
prebiotics in management of this disease (Roediger et al., 1997). In this study, SRB counts 
were slightly higher in the proximal region, which is the opposite of that described in another 
three stage continuous fermentation study looking at mucin metabolism, sulphate reduction 
and methanogenesis (Gibson et al., 1988). By analysing colonic contents from three sudden 
death subjects, it was found in subjects without methanogenic activity that sulphate reduction 
rates decreased gradually from the proximal to the distal colon (Macfarlane et al., 1992b).  
 
VOCs had similar pattern as SRB: concentrations were variable in different models, therefore 
changes in VOCs production were not significant. When comparing changes at individual 
response levels, prebiotic based inhibition was seen in two out of three omnivore models. 
Indole production was not as high as p-cresol, and addition of Synergy1 did not affect 
production. Indole is a quorum sensing molecule for many biological organisms including 
bacteria, and recent studies investigated the positive role of this signalling molecule on host 
epithelial cell barrier function and hormone secretion modulation (Bansal et al., 2010, Shimada 
et al., 2013, Chimerel et al., 2014).  
 
The current study confirmed that the main proteolysis regions in the colon are the transverse 
and distal regions (Macfarlane et al., 1988, Macfarlane et al., 1992b). Both BCFA and ammonia 
were detected at the highest concentration in the distal colon simulation. This can result from 
accumulation of metabolites due to a lack of absorption in this in vitro continuous culture 
system. When comparing concentration differences, the transverse colon had the highest 
production of BCFA and ammonia. The simulated transverse vessel has a pH of 6.2 which is 
close to the optimum pH of proteolytic enzymes (Macfarlane et al., 1992b).  
 
One study on rats revealed that protein dose was correlated with negative consequences of 
colonic DNA damage, but DNA damage was not seen with whey protein (Toden et al., 2007a). 
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A human intervention study with 3g or 10g of prebiotic galactooligosaccharides (GOS) fed to 
5 healthy subjects with a sequential design: proteolysis inhibitory effects of GOS were seen, 
however, there was no difference between 3g and 10g of GOS per day (Tanaka et al., 1983). 
This may due to huge variation among the volunteers, small sample size (n=5) and short time 
of intervention (1 week). A better proteolysis inhibitory effect of higher dose ITF was seen in 
this in vitro study, which may result from elimination of variation by standardised medium flow.  
 
Vegetarian models had lower production of ammonia and p-cresol than omnivore models. 
Potentially, vegetarian diet has less protein content and vegetarians’ gut bacteria had adapted 
to relatively low protein diet. Therefore it is likely that there was less potential for proteolytic 
metabolism within the microbiota. In terms of gut health, this may indicate vegetarian diet is 
beneficial.  
 
In conclusion, supplementation of prebiotic Synergy1 to three stage, continuous, pH controlled, 
colonic fermentation models shifted the microbiota to a more favourable profile by stimulating 
bifidobacteria and lactobacilli while repressing bacteroides, and Desulfovibrio spp. The 
prebiotic addition also significantly decreased the concentration of protein metabolites 
(ammonia and BCFA), however, inhibitive effect of Synergy1 on VOCs production was only 
seen with vegetarians.  
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Chapter 4 The effect of prebiotic oligofructose enriched inulin 
supplementation on microbiota, protein metabolism and gastrointestinal (GI) 
symptoms in people consuming high protein diets 
 
Abstract 
Dietary protein levels are increasing worldwide and high protein consumption can be 
detrimental due to the generation of various toxic metabolites from gut bacterial fermentation. 
On the contrary, consumption of prebiotic carbohydrates allows specific microbiota changes, 
which may confer benefits upon host wellbeing and health. A double-blind, crossover, placebo 
controlled, randomised study in healthy individuals aged 18-60 years old was performed to 
evaluate the effects of prebiotic use (oligofructose enriched inulin) on gut bacterial proteolysis. 
 
Volunteers were recruited from the Reading local community and 43 people completed the trial. 
Fasting blood, 24 hour urine and fresh faecal samples were collected at the University of 
Reading. Gastrointestinal symptoms and defaecation records were taken throughout the trial. 
 
Bacteria were enumerated by fluorescence in situ hybridisation-flow cytometry. A significant 
increase in bifidobacteria was observed with the addition of prebiotic treatment (p<0.0001). 
Urine, blood plasma and faecal water metabolite changes were monitored by 1H-NMR. There 
were lower concentrations of aromatic metabolites in urine and lower concentrations of lipids 
in blood plasma with prebiotic treatment, however, differences were not significant between 
the two interventions. Stool frequency was significantly (p<0.01) higher with prebiotic 
supplementation comparing to the placebo group and stool consistency had a trend towards 
softness as based on the Bristol scale (p=0.06). Mild symptoms of bloating and flatulence were 
reported with the prebiotic, however these were tolerable. Total bacteria and bifidobacteria 
changes during interventions were significantly correlated with stool frequency (p≤0.05).  
4.1 Introduction 
 
Western European populations typically ingest 105g/d protein, according to the Food and 
Agriculture Organization (FAO, 2017). A proportion of dietary protein enters the large 
intestine which, together with endogenous sources, may be metabolised by colonic bacteria. 
Deamination and decarboxylation of amino acids generates ammonia and amines, which are 
toxic by either affecting barrier function or enhancing N-nitrosamine formation (Hughes et al., 
2008, Tricker, 1997). Utilisation of aromatic amino acids by gut bacteria can form phenol, 
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indole and p-cresol. In healthy adults, these metabolites are readily absorbed by the colonocyte 
and conjugated mainly by sulphation in either the gastrointestinal tract or the liver (Teubner et 
al., 2007, Riches et al., 2009). Sulphated phenols and indoles are then excreted in urine, 
therefore, urinary indoxyl sulphate and p-cresol sulphate levels reflect these aromatic 
metabolites production in the colon (Verbeke et al., 2015). Phenol and p-cresol can damage 
epithelial cell barrier function in vitro at physiologically relevant concentrations (Hughes et 
al., 2008, Cerini et al., 2004). Indoxyl sulphate and p-cresol sulphate can inhibit human cell 
proliferation and wound repair, and induce oxidative stress in vitro (Dou et al., 2004, Dou et 
al., 2007). Their effect on the healthy population is yet to be confirmed, but this may explain 
the correlation between urinary indoxyl sulphate and p-cresol sulphate levels and renal disease 
progression (Vanholder et al., 2014).  
The International Agency for Research on Cancer (IARC), an agency under the World Health 
Organization (WHO), published a press release in October 2015: where it classified red meat 
as “probably carcinogenic to humans”, and processed meat as “carcinogenic to humans”, with 
concerns over colorectal cancer (IARC, 2015). It is not clear if the risk was connected with 
protein consumption or other dietary components in the meat, however Kato et al. (1997) found 
a correlation between total protein intake and colo-rectal cancer (CRC) risk in a New York 
female population, whereas a European cohort study revealed that heterocyclic amines were 
related to CRC risk (Rohrmann et al., 2009). Protein consumption may be associated with other 
colonic diseases: e.g. animal protein has been associated with increased risk of Inflammatory 
Bowel Disease (IBD) in Japanese and French studies (Shoda et al., 1996, Jantchou et al., 2010). 
A prebiotic is defined as “a substrate that is selectively utilized by host microorganisms 
conferring a health benefit” (Gibson et al., 2017). Inulin type fructans (ITF) are naturally 
present in many plant based foods, such as onion, Jerusalem artichoke, chicory, banana, wheat, 
and asparagus. ITF has been tested in humans for its effect on gut microbiota modulation with 
favourable bacteria changes, such as increased growth of bifidobacteria, being reported 
(Gibson et al., 1995, Vandeputte et al., 2017). ITF was found to improve mineral absorption in 
human subjects, particularly calcium, (Coudray et al., 1997, van den Heuvel et al., 1999a, van 
den Heuvel et al., 2009). Satiety can be positively affected by ITF supplementation in both 
healthy and obese volunteers, possibly by modulating the secretion of certain gut hormones, 
for instance, increasing levels of glucagon-like peptide 1(GLP-1) and peptide YY (PYY), and 
decreasing levels of ghrelin (Piche et al., 2003, Archer et al., 2004, Cani et al., 2006, Antal et 
al., 2008, Parnell and Reimer, 2009). ITF can promote short chain fatty acid (SCFA) production, 
and SCFA receptors GPR41 and GPR43, also known as free fatty acid receptors (FFA3 and 
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FFA2), affect human energy intake and adipogenesis (Xiong et al., 2004, Karaki et al., 2008).  
According to a recent national dietary survey, British adults consume 14g dietary fibre daily, 
which is below the UK Dietary Reference Value (DRV) of 30g per day (Food Standards Agency, 
2016, The Scientific Advisory Committee on Nutrition, 2015). EFSA recommended 
consumption of 25g of dietary fibre to maintain regular defaecation (EFSA Panel on Dietetic 
Products and Allergies, 2010a). Native chicory inulin has been recognised as having health 
benefits through “maintenance of normal defecation by increasing stool frequency” by EFSA, 
and SACN in the UK claimed that FOS and inulin have bulking capacity of “1 to 1.5g increase 
in faecal wet weight per 1g intake” (EFSA Panel on Dietetic Products and Allergies, 2015, The 
Scientific Advisory Committee on Nutrition, 2015). ITF were seen to be positive regarding 
increasing faecal weight, colon motility and decreasing colonic transit time (Roman et al., 2008, 
Waitzberg et al., 2013, Vandeputte et al., 2017, Micka et al., 2017). Short chain fatty acids 
(SCFA) produced by prebiotic fermentation affect colon motility: propionate increased muscle 
contraction frequency in rats, possibly linked to FFA2 and FFA3 (Tazoe et al., 2008).  
The aim of the present study was to investigate the effect of inulin-type fructans (ITF) on the 
negative consequences of colonic fermentation in individuals consuming high protein diets. 
The hypothesis to be tested is that their action promotes bacterial carbohydrate metabolism at 
the expense of bacterial protein metabolism. Three biofluids (urine, blood, and faecal water) 
were monitored to evaluate the effects on bacterial composition and mechanism. In addition, 
bowel function was assessed.   
4.2 Subjects and methods 
4.2.1 Subjects 
Healthy adults, both men and women, were recruited from the Reading area. Inclusion criteria 
were subjects aged 18-60, no evidence of lactose intolerance or gluten allergy, without history 
or evidence of intestinal disease within the previous 5 years and good general health. Exclusion 
criteria were antibiotic treatment in the 6 months preceding the study, anaemia, chronic or acute 
diseases, smoking and a history of alcohol or drug misuse. Volunteers were also excluded if 
pregnant, lactating or planning pregnancy. Eligible volunteers were asked to fill food frequency 
questionnaire to calculate their protein intake; subjects with lower than 75g /d protein intake 
were excluded. Any intake of drugs active on gastrointestinal motility, probiotic/prebiotic 
supplements or any class of laxative was not permitted. Volunteers were instructed not to alter 
their usual diet or fluid intake during the trial. The study was a double-blinded, randomised, 
placebo controlled, crossover trial registered at Clinicaltrials.gov as NCT02827760. The study 
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was given a favourable ethical opinion by the University of Reading’s Research Ethics 
Committee (16/17). All participants gave written informed consent prior to study entry. 
 
The primary outcome measure was bifidobacterial population as log10 CFU/g wet faecal sample 
by fluorescence in situ hybridisation. It was calculated that a total of 43 patients were required 
to enrol this placebo controlled crossover study. This allows an 80% probability that the study 
could detect 0.5 log10 CFU/g wet faecal sample difference in colonic bifidobacterial population 
at a two-sided 0.05 significance level based on the assumption of a 0.8 log10 CFU/g wet faecal 
sample bificobacteria within subject standard deviation (Kruse et al., 1999). Thus, fifty 
volunteers were recruited to allow for drop out.  
 
43 volunteers completed the trial (23 females and 20 males, BMI 24.24 ± 3.58 kg/m²), aged 
between 18 to 60, and the average age was 33.82±10.91 years old.  
 
Figure 4.1 Participant flow diagram of the study 
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4.2.2 Study design 
 
Enrolled volunteers were asked to undergo a two week run-in period before the study 
commenced. During this period, they were required to start restricting prebiotics probiotics or 
synbiotics (in food products or as supplements) if there were any in their diet (see Appendix 
4.7). Randomisation was stratified by sex, and allocation occurred to one of the two treatment 
groups using a 1:1 ratio. Fifty volunteers were divided into group A (female; n=26) and B (male; 
n=24) and each group randomly distributed between groups I and II (A-I: n=13, A-II: n= 13 
and B-I: n=12, B-II: n=12). Three female and four male volunteers dropped out before the end 
of the study. In total, 43 volunteers completed the study (A-I: n=11, A-II: n= 12 and B-I: n=10, 
B-II: n=10. Subjects started with the first intervention with either prebiotic (n=22) or placebo 
(n=21), followed by a further 3 week washout period, followed by crossover to the alternative 
intervention of placebo (n=22) or prebiotic (n=21), and then another 3 week washout period.  
 
The IFT food supplement (supplied by the Beneo company) is a chicory inulin powder 
produced in Belgium. Prebiotic treatment (inulin-type fructan) was a mixture of oligofructose 
and inulin: 50%±10% DP (degree of polymerisation) 3-9 and 50%±10% DP≥10 
(Orafti®Synergy 1, BENEO-Orafti, Tienen, Belgium). The placebo control food supplement 
was maltodextrin (Maltodextrin DE 19, Agrana Starch, Austria). The products were provided 
as a powder (served in sachets) and identical in texture, appearance and taste. The Beneo 
company provided barcoded sachets, blinded to investigators and volunteers. After all 
volunteers had completed their study visits and all samples had been analysed by researchers, 
Beneo company provided information about barcoded sachets. Participants were asked to take 
2 sachets of 7.5g supplement daily, and were encouraged to take the sachet at the same time 
each day. Compliance to food supplement (prebiotic or placebo) was assessed by recording 
intake in GI diaries and participants were also asked to return any unused sachets to the 
researchers at the end of the each 6-week intervention period. Participants considered 
compliant and therefore included in the study, were required to take the food supplement or 
placebo at least 6 out of every 7 days of the trial for the 6 week period. 84 sachets were given 
to each volunteer, and volunteers returning less than 14 sachets at the end of the intervention 
were considered as compliant.  
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Figure 4.2 Study design of a randomised, controlled, crossover study in which 50 healthy volunteers received 15g ITF or 
maltodextrin daily for a period of 6 weeks each, following a 3-week washout period after each intervention. Fasting blood, 24 
hour urine, and fresh stool sample were collected at each visit.  
 
Volunteers were asked to keep diaries throughout the study to record stool frequency, 
consistency according with the Bristol chart (see Appendix 4.7) (constipation, hard, formed, or 
soft stool or diarrhoea), abdominal pain (none, mild, moderate or severe), intestinal bloating 
(none, mild, moderate or severe) and flatulence (none, mild, moderate or severe) daily. Any 
medication or adverse events were also recorded. 
4.2.3 Sample collection and preparation 
 
On the visit day, fasting blood samples were taken through venepuncture by trained 
phlebotomists. Blood samples were extracted into sodium heparin tubes (kept on ice). Samples 
were then centrifuged at 1700 × g for 10 min at 4°C to obtain plasma. 24 hour urine samples 
were collected 24 hours before the visit day in containers with frozen cool packs. Urine samples 
were then transferred into 15ml tubes on ice and centrifuged at 1700 × g for 10 min at 4°C to 
remove any particulate material. Blood plasma and urine samples were then stored at −80 °C 
for subsequent metabolic profiling.  
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Volunteers were instructed on how to collect fresh faecal samples in sterile plastic containers, 
kept in 2.5L Oxoid™ AnaeroJar™ (Oxoid, Hampshire, United Kingdom) with Oxoid™ 
AnaeroGen™ 2.5L Sachet (O2 <0.1%; CO2: 7-15%). These were brought to the university 
within 1 hour of voiding. Samples were diluted 1:10 (w:w) in anaerobic phosphate-buffered 
saline (PBS, 0.1 M; pH 7.4), then homogenised using a stomacher (460 paddle beats/min) for 
2 min. Samples were vortexed with 3 mm diameter glass beads for 30 s before being 
centrifuged at 400 x g for 2 min at room temperature. Supernatant (1ml) was centrifuged at 
11337 × g for 10 min and the aqueous layer stored at −80 °C for metabolic profiling. Another 
supernatant sample (375 μl) was fixed in 4% (w:v) paraformaldehyde (1125 μl) for 4 h at 4 °C. 
To wash the cells of paraformaldehyde, samples were centrifuged at 11337 × g in 1 ml PBS for 
5 min at room temperature and this centrifugation and washing was repeated two more times. 
Samples were re-suspended in 150 μl PBS and stored in ethanol (1:1, v:v) at −20 °C for 
fluorescence in situ hybridisation (FISH). 
 
4.2.4 Enumeration of faecal microbial populations by flow cytometry fluorescence in situ 
hybridisation (FISH) 
 
FISH by flow cytometry was carried out as described by Grimaldi et al. (2017). Probes used in 
this study are listed in Table 1. The number of cells is presented as per gram of wet fresh faeces.  
 
Table 4.1. Name, sequence, and target group of oligonucleotide probes used in this study for FISH of bacterial enumeration  
 
Probe name 
 
Sequence (5’ to 3’) 
 
Target groups 
 
Reference 
Non Eub ACTCCTACGGGAGGCAGC Control probe complementary to EUB338  (Wallner et al., 1993) 
Eub338 GCTGCCTCCCGTAGGAGT Most Bacteria (Amann et al., 1990) 
Eub338II GCAGCCACCCGTAGGTGT Planctomycetales (Daims et al., 1999) 
Eub338III GCTGCCACCCGTAGGTGT Verrucomicrobiales (Daims et al., 1999) 
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. (Langendijk et al., 1995) 
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus and Enterococcus (Harmsen et al., 1999) 
Bac303 CCAATGTGGGGGACCTT Most Bacteroidaceae and Prevotellaceae, some 
Porphyromonadaceae 
(Manz et al., 1996) 
Erec482 GCTTCTTAGTCARGTACCG Most of the Clostridium coccoides-Eubacterium 
rectale group (Clostridium cluster XIVa and XIVb) 
(Franks et al., 1998) 
Rrec584 TCAGACTTGCCGYACCGC Roseburia genus (Walker et al., 2005) 
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Ato291 GGTCGGTCTCTCAACCC Atopobium cluster (Harmsen et al., 2000a) 
Prop853 ATTGCGTTAACTCCGGCAC Clostridial cluster IX (Walker et al., 2005) 
Fprau655 CGCCTACCTCTGCACTAC Feacalibacterium prausnitzii and relatives (Suau et al., 2001) 
DSV687 TACGGATTTCACTCCT Desulfovibrio genus Ramsing et al. (1996) 
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium histolyticum group 
(Clostridium cluster I and II) 
Franks et al. (1998) 
CFB286 TCCTCTCAGAACCCCTAC Prevotella group and Bacteroides splanchnicus (Weller et al., 2000) 
 
4.2.5 Metabolic profiling using 1H-NMR spectroscopy 
 
A phosphate buffer (pH 7·4 sodium phosphate with 0.2M Na2HPO4, 0.04M NaH2PO4 in 
deuterium oxide 99·9 %) was prepared, with 1mM 3-(trimethylsilyl)propionic acid-d4 sodium 
salt (TSP) and 3mM sodium azide in the solution. Urine and faecal water samples were thawed 
at 0-4°C, and 400 μl of each sample were mixed with 200 μl buffer. Samples were then 
centrifuged at 11337 × g for 10 min, and 550 μl aliquots of supernatant were collected to fill 5 
mm NMR tubes.  
 
A 0.9% w/v saline solution containing 20% deuterium oxide (v:v) and 3mM sodium azide was 
prepared for blood plasma samples. Samples (200 μl) were mixed with 400 μl buffer before 
centrifugation at 11337 × g for 10 min. Aliquots (500 μl) of supernatant were collected to fill 
5 mm NMR tubes.  
 
All 1H-NMR spectroscopy data were acquired on a Bruker Avance DRX 500 MHz NMR 
spectrometer (Bruker Biopsin, Germany) operating at 500.13 MHz. Urine and faecal water 
spectra were acquired using a standard 1D pulse sequence [recycle delay (RD)-90◦-t1-90◦-Tm-
90◦-acquire free induction decay (FID)] with water suppression applied during RD of 2 s, a 
mixing time Tm of 100ms and a 90o pulse set at 7.70 µs. For each spectrum, a total of 128 
scans were carried out with a spectral width of 14.0019 ppm. The FIDs were multiplied by an 
exponential function corresponding to 0.3 Hz line broadening. 
 
Spectra of blood plasma samples were acquired by using Carr-Purcell-Meiboom-Gill (CPMG) 
spin echo 1H-NMR spectroscopy, which allows reduction of broad high molecular weight 
protein signals and generates spectra on smaller molecular metabolites. For each spectrum, a 
total of 128 scans were carried out with a spectral width of 14.0019 ppm. The FIDs were 
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multiplied by an exponential function corresponding to 0.3 Hz line broadening. 
 
All spectra were manually phased, baseline corrected and calibrated to the chemical shift of 
TSP or glucose using TopSpin (Bruker Biopsin, Germany). NMR spectroscopy data were 
digitalised by Matlab R2017b, and normalised by using Matlab R2017b normalisation scripts 
by total area normalisation. Supervised OPLS-DA (orthogonal projections to latent structures 
discriminant analysis) modelling of 1H-NMR spectroscopy data was performed by SIMCA 
14.1 to compare metabolic changes in different experimental groups.  
4.2.6 Correlation of bacterial population and bowel movement 
 
Bacterial log10 populations and stool frequency results from visits 2, 3, 4 and 5 were extracted. 
Correlations between total bacteria, specific bacterial groups and stool frequency were 
analysed by using SPSS version 24 (SPSS Inc, Chicago, IL). Bacterial changes before and after 
each intervention were calculated. A bivariate Pearson correlation coefficient was calculated 
for all attribute combinations and two-tailed probability was assessed to determine the 
significance. In correlations summary tables, correlation coefficients significant at the 0.05 
level are identified with *, and those significant at the 0.01 level are identified with **. 
 
4.3 Results 
4.3.1 Bacterial Enumeration 
 
Changes in populations of total bacteria and 11 specific faecal microbial groups in the human 
GI tract were monitored in this study by FISH. Each intervention response was compared at its 
start and end. Placebo supplementation for six weeks did not change total bacterial counts 
significantly and all the bacteria groups that were analysed in this study were unaffected by six 
weeks of maltodextrin treatment (Table 4.2). Compared to baseline, after prebiotic intervention, 
total bacteria numbers were slightly elevated, bifidobacterial counts were significantly higher, 
while sulphate-reducing bacteria (Desulfovibrio) numbers were reduced significantly. No other 
significant changes were recorded. 
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Eub338 Bif164 Lab158 Bac303 Erec482 Rrec584 Ato291 Prop853 Fprau655 DSV687 Chis150 CFB286 
Pre-placebo 
intervention 
9.12 ± 
0.51 
7.69 ± 
0.92 
6.70 ± 
0.77 
6.38 ± 
0.69 
8.33± 
0.56 
7.59± 
0.60 
7.17± 
0.79 
7.30 ± 
0.69 
7.37 ± 
0.86 
6.05 ± 
1.02 
6.39 ± 
0.70 
7.00 ± 
0.58 
After-
placebo 
intervention 
9.15 ± 
0.36 
7.84 ± 
0.77 
6.72 ± 
0.65 
6.14 ± 
0.78 
8.32 ± 
0.45 
7.43 ± 
0.56 
7.26± 
0.68 
7.20 ± 
0.62 
7.31± 
0.76 
5.96 ± 
1.04 
6.26± 
0.81 
6.94± 
0.55 
Pre-prebiotic 
intervention 
9.08 ± 
0.53 
7.73 ± 
0.88 
6.60 ± 
0.78 
6.24± 
0.80 
8.30 ± 
0.57 
7.55 ± 
0.78 
7.08 ± 
0.82 
7.30 ± 
0.82 
7.41 ± 
0.66 
5.86 ± 
0.97 
6.18 ± 
0.92 
6.91 ± 
0.56 
After-
prebiotic 
intervention 
9.27 ± 
0.36* 
8.25 ± 
0.80*** 
6.69 ± 
0.68 
6.04 ± 
0.94 
8.20 ± 
0.84 
7.55± 
0.71 
7.30 ± 
0.83 
7.22 ± 
0.91 
7.23 ± 
0.76 
5.42 ± 
1.29* 
6.01± 
1.04 
6.99 ± 
0.46 
Table 4.2 Total bacteria and 11 specific gut bacteria group counts as log10 CFU/g wet faeces in subjects’ faeces as determined 
by FISH, before, and after each intervention. Values are mean values ± standard deviation. * Mean values were significantly 
different from pre intervention (p<0.05). *** Mean values were highly significantly different from pre intervention (p<0.001). 
 
4.3.2 Metabolic profiling of biofluids 
SCFA are the main metabolites that can be identified in faecal water by 1H-NMR in this study. 
Aromatic metabolites including indole and p-cresol had very weak signals in the spectra, and 
BCFA signals were absent, see Figure 4.3. Faecal water metabolite differences between the 
placebo and prebiotic interventions were mainly SCFA, such as acetate, propionate and 
butyrate (Figure 4.4). Concentrations of SCFA were non-significantly higher in the faecal 
samples after placebo intervention compared to samples after prebiotic intervention, however, 
this does not indicate the production of SCFA in the lumen since faecal sample are excreted 
after nutrients absorption in the large intestine. These 24 hours one pot samples do not indicate 
daily output.  
 
Figure 4.3 1H-NMR spectrum from a pooled faecal water sample of all visits of 43 subjects.  
 
Succinate 
Butyrate 
Acetate 
Propionate 
Water 
Unknown 
TSP 
Aromatic metabolites 
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Figure 4.4 OPLS-DA model of 1H-NMR spectra data from all faecal water samples comparing SCFA concentrations between 
prebiotic intervention and placebo intervention. Peaks pointing up are metabolites that were with high concentration in samples 
after the prebiotic intervention, and peaks pointing down are metabolites that were with high concentrations in samples after 
the placebo intervention. X axis is chemical shifts in ppm. Y axis is covariance of two intervention groups. Axis on the right 
shows the discriminatory strength: red is the strongest and blue is the weakest.  
 
Comparison of spectra from blood plasma samples did not show any significant differences in 
the general metabolism post prebiotic and post placebo (Q2= -0.44). The OPLA-DA model 
(Figure 4.5) showed partial separation between two groups; and it revealed some trending 
differences of blood lipid profiles. Between the placebo and prebiotic groups: after prebiotic 
treatment, volunteers had lower concentrations of lipids in their blood, especially, VLDL and 
LDL. Besides, higher concentration of blood plasma lactate was found in the prebiotic group 
(Figure 4.5 and 4.6).  
 
Butyrate 
Butyrate 
Acetate Butyrate Propionate 
Metabolites increased in prebiotic intervention 
Metabolites increased in placebo intervention 
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Figure 4.5 OPLS-DA model of 1H-NMR spectroscopy data from blood plasma samples comparing lipids concentrations 
between prebiotic intervention and placebo intervention. Peaks pointing up are metabolites that were with high concentrations 
in samples after the prebiotic intervention, and peaks pointing down are metabolites that were with high concentrations in 
samples after the placebo intervention. X axis is chemical shifts in ppm. Y axis is covariance of two intervention groups. Axis 
on the right shows the discriminatory strength: red is the strongest and blue is the weakest.  
 
 
Figure 4.6 OPLS-DA model of 1H-NMR spectra from blood plasma samples comparing lactate concentration between 
prebiotic intervention and placebo intervention. Peaks pointing up are metabolites that were with high concentrations in 
samples after the prebiotic intervention, and peaks pointing down are metabolites that were with high concentrations in samples 
after the placebo intervention. X axis is chemical shifts in ppm. Y axis is covariance of two intervention groups. Axis on the 
right shows the discriminatory strength: red is the strongest and blue is the weakest.  
 
Lipid Lipid 
Metabolites increased in placebo intervention 
VLDL 
Metabolites increased in prebiotic intervention 
LDL VLDL 
Lactate 
Lactate 
Metabolites increased in placebo intervention 
Metabolites increased in prebiotic intervention 
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Spectra from 24 hour urine samples did not identify any significant differences between post 
prebiotic and post placebo groups (Q2= -0.28). The OPLA-DA model (Figure 4.7) showed 
partial separation between two groups; and with OPLA-DA model of spectra some trending 
differences were seen in urine samples. Colonic bacterial fermentation-driven changes were 
evident in urine samples post prebiotic treatment. Urinary aromatic metabolites, such as p-
cresol and its conjugated form, are gut bacteria derived metabolites from aromatic amino acids. 
Concentrations of these metabolites reflect bacterial aromatic amino acid metabolism in the 
gut. Aromatic amino acid derived metabolites were lower in the prebiotic group and hippurate 
was in lower concentration after prebiotic intervention.  
 
 
 
Figure 4.7 OPLS-DA model of 1H-NMR spectra from 24 hour urine samples comparing urinary aromatic metabolites 
concentrations between prebiotic intervention and placebo intervention. Peaks pointing up are metabolites that were with high 
concentrations in samples after the prebiotic intervention, and peaks pointing down are metabolites that were with high 
concentrations in samples after the placebo intervention. X axis is chemical shifts in ppm. Y axis is covariance of two 
intervention groups. Axis on the right shows the discriminatory strength: red is the strongest and blue is the weakest.  
 
4.3.3 Bowel habit and function 
Subjects’ faecal voiding frequencies, measured as number per day and stool consistency 
measured as Bristol score, are listed in Table 4.3. Self-reports were collected during 
intervention and wash-out periods and data were compared between prebiotic and placebo 
groups. Compared to the placebo supplementation period, prebiotic treatment significantly 
increased stool frequency. Consistency of volunteers’ faeces did not differ significantly 
however, but there was an increasing trend of softer stools during the prebiotic intervention.  
Hippurate Aromatic metabolites 
p-cresyl sulphate 
Creatinine Metabolites increased in prebiotic intervention 
Metabolites increased in placebo intervention 
142 
 
 
Treatment Placebo intervention Post placebo Prebiotic intervention Post prebiotic 
Stool frequency 1.26+0.56 1.27+0.53 1.42+0.63** 1.32+0.61 
Bristol score 3.67+1.10 3.59+1.28 3.99+0.99 (p=0.06) 3.50+1.128 
Table 4.3 Stool frequency per day and stool consistency score based on Bristol scale reported by volunteers during the trial. 
Values are mean values ± standard deviation. ** Mean values were significantly different from placebo intervention (p<0.01).  
 
Gastrointestinal symptoms were recorded daily during the trial to track bowel function changes 
(Table 4.4). 0, 1, 2, and 3 refer to none, mild, moderate or severe symptoms and each was 
averaged. During the placebo intervention slight symptoms were seen, but abdominal pain, 
bloating and flatulence became more noticeable in the prebiotic intervention. However, average 
severity of these symptoms was below mild, which was tolerable.  
 
Abdominal Pain Stomach or intestinal bloating Flatulence 
Placebo intervention 0.07±0.10 0.12±0.20 0.34±0.39 
Prebiotic intervention 0.31±0.59** 0.40±0.71* 0.76±0.68*** 
Table 4.4 Gastrointestinal symptoms reported by volunteers during interventions. Values are mean values ± standard deviation. 
* Mean values were significantly different from placebo intervention (p<0.05). ** Mean values were significantly different 
from placebo intervention (p<0.01). *** Mean values were significantly different from placebo intervention (p<0.001). 
 
Table 4.5 summarises significant correlations between bacterial numbers in faeces and stool 
frequency at visits 2, 3, 4, and 5. Clostridial cluster XIVa and XIVb, and Roseburia numbers 
were positively correlated with stool frequency with high significance (p< 0.001). 
Faecalibacterium prausnitzii numbers were also significantly associated with stool frequency 
albeit at lower p-value (p=0.0207). These are the three butyrate producers that were monitored 
in this study, and this may indicate butyrate’s role in bowel movement.  
 
Table 4.6 summarises significant correlation between bacterial changes before and after the 
intervention in faeces and stool frequency after interventions of all volunteers. Total bacteria 
and bifidobacteria changes were positively correlated with stool frequency with significance 
(p= 0.05 and 0.031 respectively). Changes of three butyrate producers Clostridial cluster XIVa 
and XIVb, Roseburia, and Faecalibacterium prausnitzii had a trending positive correlation (p= 
0.059, 0.059, and 0.055 respectively). 
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Correlations of bacterial numbers at each visit and bowel movement 
 
Eub338 Bif164 Lab158 Bac303 Erec482 Rrec584 Ato291 Prop853 Fprau655 DSV687 Chis150 CFB286 
Stool 
frequency 
Pearson 
Correlation 
0.07121981 -
0.056375893 
0.047943077 0.017498493 0.262** 0.278** -0.11783068 0.067213431 0.197* 0.115853373 0.017744085 -2.56465E-
05 
Significance 0.408226089 0.512894383 0.58369004 0.845186925 0.002001688 0.001007836 0.173487015 0.436874867 0.020726344 0.234704593 0.842420974 0.999769848 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
Table 4.5 Correlation between bacterial numbers in faecal samples and stool frequency of all volunteers at visit 2, 3, 4, and 5. Pearson correlation coefficient gives strength of the correlation, and 
significance values were marked with two levels.   
 
Correlations of bacterial numbers at each visit and bowel movement 
 
Eub338 Bif164 Lab158 Bac303 Erec482 Rrec584 Ato291 Prop853 Fprau655 DSV687 Chis150 CFB286 
Stool 
frequency 
Pearson 
Correlation 
0.234* 0.256* 0.113 -0.084 0.225 0.209 0.225 0.19 0.228 0.025 0.163 0.042699 
Significance 0.05 0.031 0.349 0.486 0.059 0.08 0.059 0.113 0.055 0.839 0.175 0.617709 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
Table 4.6 Correlation between bacterial changes in faecal samples during both interventions and stool frequency of all volunteers. Pearson correlation coefficient gives strength of the correlation, 
and significance values were marked with two levels.  
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4.4 Discussion 
Gut microbiota analyses are achieved by molecular technologies that no longer require 
culturing viable bacteria. The basis for many of these techniques is the use of the 16S ribosomal 
RNA gene (16S rRNA) which can be used to specifically identify bacterial groups (Case et al., 
2007). FISH involves hybridisation of a specific fluorescent probe which is designed to bind 
to a precise region of a specific bacterial group to 16S rRNA while maintaining structure of the 
cell (Amann et al., 1990). The number of bacterial cells can be obtained by using flow 
cytometry (Amann et al., 1990).  
 
In this trial, it was confirmed that ITF modulates gut microbiota composition, especially 
enhancing the growth of bifidobacteria. This prebiotic effect has been consistently observed in 
both in vitro and in vivo human intervention studies of various target groups (Wang and Gibson, 
1993, Williams et al., 1994, Gibson et al., 1995, Bouhnik et al., 1999, Kruse et al., 1999, 
Guigoz et al., 2002, Vandeputte et al., 2017). Modulation of other bacterial groups are not 
consistent in reported studies: Kleessen et al. (1997) found reduction of clostridia and 
lactobacilli together with an increase of enterococci after inulin consumption; supplementation 
of both Jerusalem artichoke inulin and chicory inulin suppressed growth of 
Bacteroides/Prevotella and Clostridium histolyticum after three weeks intervention. A recent 
study using 16s rDNA microbiota composition profiling found that 4 weeks of inulin 
consumption increased the abundance of Bifidobacterium and Anaerostipes and decreased the 
abundance of Bilophila (Vandeputte et al., 2017). It has been shown in various trials together 
with this one that ITF has a laxative effect which decreases colonic transit time and increases 
faecal volume output. The improvement of stool frequency was significantly correlated with 
increased numbers of bifidobacteria, which suggests that the laxative effect of ITF is related to 
the microbiota community and metabolic activity.  
 
In previous inulin research, 10 volunteers who consumed 9 g inulin per day for two weeks had 
lower numbers of Clostridium cluster XIVa and XIVb (Erec482 probe by FISH analysis, 
(Harmsen et al., 2002). In this current study, a slight decrease of Clostridium cluster XIVa and 
XIVb was also observed in the prebiotic treatment, however without statistical significance 
(p=0.16). Within the Clostridium cluster, there are proteolytic species such as C. indolis and C. 
symbiosum. A prolonged effect of long chain inulin has been observed in an in vitro comparison 
of fermentation of oligofructose, long chain inulin and a mixture of both (Synergy1), (Gomez 
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et al., 2010). This prolonged effect may result in a saccharolytic fermentation in the distal colon, 
where most bacterial proteolysis in the gut occurs.  
 
Sulphide has been found to damage DNA and inhibit the ability of epithelial cells to utilise 
energy derived from butyrate oxidation. Its toxic effects have been thought to cause energy 
deficiency in colonocytes and mucosal inflammation which may contribute towards 
pathogenesis of the Inflammatory Bowel Disease (IBD), ulcerative colitis (Attene-Ramos et 
al., 2006, Roediger et al., 1993, Gibson et al., 1991). Desulfovibrio is one of the dominant SRB 
in the human gut and increasing evidence has suggested that activity of this bacterial group 
correlates with IBD (Gibson et al., 1991, Figliuolo et al., 2017). This trial showed positive 
effects in that the prebiotic reduced SRB. This agrees  with a randomised, double-blind, 
placebo-controlled, crossover trial showing the inhibitory effect of inulin on Desulfovibrio spp. 
by 16s rDNA profiling in 29 subjects (Holscher et al., 2015). Prebiotics may therefore be 
applied usefully to IBD studies. Moreover, Desulfovibrio abundance has been found to be 
increased in the gut microbiota of autistic children, suggesting a further application for 
prebiotics (Finegold, 2011). Unlike the association of bifidobacterial change and bowel 
movement, the change of Desulfovibrio numbers was not correlated with other bacteria changes 
or bowel movement (see Appendix 4.4).  
 
Metabolism of ITF in the gut generates SCFA in vitro (Wang and Gibson, 1993). Consumption 
of inulin and xylo-oligosaccharide mixtures showed elevated concentration of total SCFA and 
propionate compared to a parallel placebo group (Lecerf et al., 2012a). A randomised 
controlled, cross over study revealed higher concentration of butyrate in faecal water after 
intervention with a synbiotic composed of ITF and Bifidobacterum longum (Macfarlane et al., 
2013). However, some human trials have not shown an effect of ITF on faecal water SCFA 
concentrations, even when significant increases in bifidobacterial growth were recorded, which 
may be expected to enhance SCFA production (Gibson et al., 1995, Kleessen et al., 1997, 
Brighenti et al., 1999, Kruse et al., 1999, Kleessen et al., 2007). SCFA in the lumen are rapidly 
and extensively (>95%) absorbed and subsequently metabolised by the colonocyte and their 
concentrations in the distal colon can be affected by transit, moisture and digesta mass (Topping 
and Clifton, 2001). Faecal water SCFA concentrations show SCFA losses after absorption and 
utilisation by the host but not in vivo production and they do not necessarily reflect SCFA 
absorption by the gut (Verbeke et al., 2015). Therefore, faecal water SCFA levels recorded in 
this study do not indicate that less SCFA was generated during prebiotic supplementation. In 
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blood plasma, a higher concentration of lactate was found in the prebiotic group, which may 
correlate with an increase of bifidobacteria as they produce lactate via the bifidus pathway.  
 
Some human studies have found that ITF could modulate energy regulatory hormones such as 
elevation of blood GLP-1 and PYY, which both down-regulate energy intake and have the 
potential to reduce LDL-cholesterol (Piche et al., 2003, Parnell and Reimer, 2009). A proposed 
mechanism is that ITF promote SCFA production resulting in activation of FFA2 and FFA3 
with an effect on energy intake and lipogenesis (Xiong et al., 2004, Karaki et al., 2008). LDL-
cholesterol and triacylglycerol lowering effects of ITF are not always consistent. Significant 
changes have been reported with studies using particular target groups such as diabetic subjects, 
volunteers with moderately raised total plasma cholesterol and triacylglycerol levels, or obese 
subjects (Yamashita et al., 1984, Jackson et al., 1999, Antal et al., 2008, Dehghan et al., 2013). 
A trend towards an improved lipid profile was seen in the current study, but non-significance 
may be due to the wide range of age and BMI and diverse baseline lipid profiles.  
 
Urinary aromatic metabolites such as p-cresol and its conjugated form are gut bacteria derived 
metabolites from aromatic amino acids. Different levels of 4-cresol sulphate after ITF 
intervention were recorded in this study. A lack of significant difference between prebiotic 
intervention and placebo group may be due to baseline differences between volunteers; De 
Preter et al. (2007b) found subjects with high baseline p-cresol had a higher inhibitory response 
resulting from prebiotic intervention. In addition, dietary differences before each visit may 
contribute to varying aromatic metabolite levels.  
 
Hippurate had a trend to be higher in the placebo group compared to the prebiotic intervention 
in this study. Hippurate is a colonic bacterial metabolite derived from plant phenolic 
compounds, aromatic amino acids and benzoic acid (Phipps et al., 1998). There have been two 
studies demonstrating that hippurate may be positively associated with diabetes (Messana et 
al., 1998, Kumari and Sharma, 2016). The causal relation of hippurate and physiological 
diseases is not fully understood.  
 
Fermentation of ITF in in vitro studies does not result in appreciable production of gas, however 
in vivo there are a few volunteer trials that reported increased gastrointestinal flatus and 
bloating after supplementation (Wang and Gibson, 1993, Bouhnik et al., 1999, Kruse et al., 
1999). Inulin consumption is usually either well tolerated, or only causes issues at a high dose 
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(>20g/d). In the current study, symptoms were increased on prebiotic consumption, however 
were still classed as less than mild, which would be recognised as well tolerated. There was 
one volunteer drop out in the study due to prebiotic supplement intolerance, however, some 
complaints of gas production were also noted during the placebo period. A possible reason is 
volunteers were having a placebo effect: they felt gastrointestinal symptoms while taking 
supplements and reporting these symptoms in the daily questionnaire. 
 
In conclusion, daily supplementation of 15g ITF can shift the microbiota to a more favourable 
profile by stimulating bifidobacteria and repressing Desulfovibrio spp. It may also lower the 
number of proteolytic Clostridium cluster XIVa and XIVb. SCFA concentrations in faecal water 
were not promoted by ITF, however, ITF had a trend on boosting blood lactate concentrations. 
Urinary aromatic amino acids metabolites concentrations were lower, and improved lipid 
profiles in blood plasma was found in this study. A significant bulking and laxative effect was 
seen together with all bacterial and metabolic changes. This shows that gut bacterial 
metabolism in the large intestine can be shaped towards a more saccharolytic community by 
ITF, and this change in microbiota exerted beneficial effect on host health.  
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Chapter 5 General discussion and future perspectives 
 
5.1 General discussion 
Protein supply worldwide is growing gradually, and it reached 81.23g/capita/day in 2013 
according to the FAO (2017). In Europe and Northern America, it is rather stable, however, 
with protein supply in these two regions at 96g/capita/day and 109g/capita/day respectively 
since 1993 (FAO, 2017). Sometimes, supply does not necessarily relate with consumption. 
Dietary survey data indicates that, in European countries, protein intakes range from 67 to 114 
g/d in adult men and 59 to 102 g/d in women (EFSA Panel on Dietetic Products and Allergies, 
2012). Meanwhile, protein reference values are not as high as the actual intake. The 
recommended dietary allowance (RDA) is 56g/d for men and 46g/d for women in the US; 
EFSA concludes that the Population Reference Intake (PRI) is 0.66 g/kg body weight per day 
(Institute of Medicine (U.S.). Committee on Use of Dietary Reference Intakes in Nutrition 
Labeling., 2005, EFSA Panel on Dietetic Products and Allergies, 2012). Existing data show an 
association between high fat diet and cardiovascular disease risk; high sugar consumption is 
positively related to serum triglyceride levels and inversely related to insulin response; 
therefore, for these two macronutrients, fats and carbohydrates, reference values are given with 
both lower and upper limit (EFSA Panel on Dietetic Products and Allergies, 2010b, EFSA 
Panel on Dietetic Products and Allergies, 2010a). Though there are insufficient data to 
determine a Tolerable Upper Intake Level (UL) for protein, there are data indicating that high 
consumption of protein can induce negative consequences to host health, especially by bacterial 
fermentation. As discussed in previous chapters, bacterial proteolysis may produce potentially 
harmful metabolites such as ammonia, amines and p-cresol. In both Chapter 2 and Chapter 
3, protein fermentation metabolites production in in vitro models were monitored. Ammonia 
and BCFA concentrations were found to be significantly higher in high protein treatment. 
Phenols and indoles also had an increasing trend in both experiments with high protein diet 
simulation. Besides, gut microbiota may shift to a more proteolytic one with a long-term high 
protein habitual diet. In the continuous three stage fermentation, feeding high protein for more 
than two weeks not only promoted higher production of proteolysis metabolites, but also 
boosted the number of clostridia group. These possibly deleterious effects of a high protein diet 
could be significant in populations following special diets. Athletes and body-builders take 
protein supplements to help with their training and muscle gain. For example, endurance and 
strength-trained athletes are recommended to have 1.2-1.7 g/kg body weight per day of protein 
(Rodriguez et al., 2009). There are some popular weight-loss diets that are high in protein. The 
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Atkins diet and other high protein diets with restriction of carbohydrate intake are followed in 
order to lose weight (WebMD, 2012, Naude et al., 2014). With such high amounts of protein 
ingested, residual dietary protein, together with endogenous proteins that are secreted from the 
digestive tract, could enter the colon and provide substrate for bacterial metabolism.  
Metabolism of ITF promotes specific bacterial changes in the colon, and its fermentation can 
boost the saccharolytic activity of the microflora. The main objective of this project was to 
investigate the effect of prebiotic inulin type fructans on potential negative consequences of 
gut bacterial proteolysis. In both Chapter 2 and 3, ammonia and BCFA were found in 
significantly lower amounts with ITF supplementation comparing to the high protein treatment. 
Phenols and indoles concentrations had a trend to be lower with ITF addition comparing to 
high protein diet simulations. In the human study, urinary aromatic metabolites were found in 
lower amounts with the prebiotic intervention. Besides, ITF modulated the bacteria 
composition towards a more saccharolytic community, with suppression of proteolytic bacteria 
groups. Bifidogenic effect was seen in all experiments, while enhancement of lactobacilli was 
only observed in in vitro batch cultures and continuous culture gut models. Reduction of the 
bacteroides group after ITF treatment was found in continuous cultured gut models. 
Clostridium coccoides-Eubacterium rectale group had a decreasing trend in the human trial 
which were not seen in in vitro fermentations. SCFA is the main end product of carbohydrate 
fermentation by gut bacteria. In batch cultures, prebiotics led to an increase in propionate, and 
in the continuous three staged culture, butyrate levels were elevated with ITF addition. 
Production of SCFA by gut bacteria in humans is difficult to track in faecal water due to 
absorption, circulation, and incorporation with host metabolism. After being absorbed, 
circulatory metabolites in blood can indicate some colonic production in healthy populations. 
Higher concentration of lactate in blood plasma with the prebiotic treatment was found. Both 
metabolic activity and microbiota composition were affected by ITF fermentation, and its 
supplementation shaped the microflora into more a saccharolytic one.  
Another potential benefit of ITF that was seen in this thesis is its influence on SRB. Reduction 
of Desulfovibrio was seen in both in vitro experiments, although in batch culture the change in 
Desulfovibrio was not significant. This inhibitory effect of ITF on sulphate reducing bacteria 
was then confirmed in the in vivo human study. Desulfovibrio is one of the dominant SRB in 
the human gut and increasing evidence has suggested that activity of this bacterial group 
correlates with IBD (Gibson et al., 1991, Figliuolo et al., 2017). 
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Improvement of bowel movement with ITF has been mostly studied in constipated subjects, 
and changes of transit time and faecal voiding were more noticeable in this target group 
(Roman et al., 2008, Waitzberg et al., 2013, Vandeputte et al., 2017). Decreased colonic transit 
time, increased stool frequency and volume has been documented in other in vivo trials in 
healthy populations, and this was confirmed again with 15g ITF per day in healthy population 
in this thesis.  
Vandeputte et al. (2017) discovered that the beneficial effect of ITF on bowel function was 
positively correlated with Bifidobacterium and Anaerostipes populations, and negatively 
correlated with Bilophila population from 16s rDNA profiling data. In this study, 
bifidobacterial numbers were significantly higher with the ITF treatment and its change 
positively correlated with improvement of stool frequency, which was also significantly higher 
after the ITF intervention. This correlation of bifidobacterial change in number and bowel 
movement was the first time being observed in a human study. 
 
According to a recent national dietary survey, British adults consume 14g dietary fibre daily, 
which is less than half of the UK Dietary Reference Value (DRV) of 30g per day (Food 
Standards Agency, 2016, The Scientific Advisory Committee on Nutrition, 2015). EFSA 
recommends consumption of 25g of dietary fibre to maintain regular defaecation (EFSA Panel 
on Dietetic Products and Allergies, 2010a). Normal healthy people should be able to benefit 
from ITF supplementation due to low dietary fibre intake in the general population. Besides, 
EFSA has a favourable opinion on dietary fibre effects on reducing blood lipids (EFSA Panel 
on Dietetic Products and Allergies, 2010a). ITF could modulate energy regulatory hormones 
such as elevating blood GLP-1 and PYY, which both down-regulate energy intake and have the 
potential to reduce LDL-cholesterol (Piche et al., 2003, Parnell and Reimer, 2009). Blood lipids 
decreased after the prebiotic supplementation in Chapter 4, though not significantly. 
In conclusion, all three experiments found favourable bacterial and metabolic changes with 
ITF supplementation. Furthermore, with the in vivo human trial, bowel function was 
significantly improved with ITF intervention. ITF had inhibitory effects on colonic microbial 
proteolysis, and could improve health and wellbeing, especially for Northern American and 
Western European populations who have high protein supply. Athletes, bodybuilders, and 
people following high protein diets for weight management could also benefit from ITF 
supplementation. Due to inadequate dietary fibre intake in the general population, in order to 
maintain regular defaecation and improve blood lipid profile, ITF can be supplemented.  
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5.2 Limitation and future perspectives 
 
In Chapters 2 and 3, in vitro models were applied to study mechanisms and efficacy of ITF 
on reducing proteolysis in the colon before further investigation on human subjects. Batch 
culture fermentation is a way to test multiple substrates over a short period of time, which 
allows initial screening for more complicated models. Proteolysis of four dietary proteins were 
compared with batch culture fermentation in Chapter 2: different metabolism patterns were 
seen not only among various protein sources, but also between vegetarian and omnivore groups; 
this led to further testing of vegetarian and omnivore responses by use of a three stage 
continuous model. Casein was chosen to be the substrate for two reasons: dairy products are 
widely consumed by both vegetarians and omnivores; casein resulted in the highest production 
of aromatic metabolites in batch culture and it would be easier to reveal the inhibitory effect of 
ITF on aromatic metabolite production. In a human study, p-cresol production in subjects with 
high baseline of p-cresol were found to be suppressed better by the prebiotic intervention (De 
Preter et al., 2007b). The three stage continuous fermentation culture system simulating all 
distinct regions of the human colon was done in Chapter 3. It was shown that protein 
fermentation happened mostly in the distal end of the colon, which would be difficult to 
research via non-invasive human studies. The in vitro models used here do not include 
absorptive function: in batch culture systems, metabolites accumulate towards the end of the 
fermentation; while in continuous culture gut model systems, metabolites accumulate from the 
proximal to the distal end. Generally, in vitro models can simulate the gut to aid early research 
screening, however, they lack host interactions such as absorption, secretion, and immune 
responses (Macfarlane and Macfarlane, 2007).  
 
The FISH technique was used in this project to enumerate cell numbers with target bacteria 
groups that are dominant in faecal microbiota and functionally relevant (Franks et al., 1998). 
Initially in Chapters 2 and 3, EC1531 was included to analyse Escherichia coli. No noticeable 
change of E. coli was detected in either batch culture or gut model experiments; E. coli counts 
were relatively low. Its insignificance led to the removal from the groups targeted and the 
introduction of more relevant bacteria groups in subsequent work. Hoyles and McCartney 
(2009) discovered that bacteroides were underestimated while using the Bac303 probe and the 
CFB286 probe can compensate for this. Furthermore, CFB286 can detect the Prevotella group 
and Prevotella was found with higher abundance in populations with high levels of plasma 
trimethylamine N-oxide (TMAO) which is a bacterial derived cardiovascular risk factor (Koeth 
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et al., 2013). Therefore, in Chapter 4 CFB286 was used to monitor this bacteria group instead 
of E.coli in Chapter 2 and 3.  
In Chapter 2, bacterial and metabolic responses varied in fermentations with three different 
donors. The donors were selected with restriction of antibiotics and drug use, disease and 
injuries, however, there are many other factors that impact on the gut microbiota and its 
metabolic activity: stress, lifestyle, and dietary habit (Nicholson et al., 2012). In this context, 
dietary habit may play a very important role in microbiota function. A simple questionnaire 
with what are the protein sources in their diet was given to these donors: one omnivore donor 
consumes far less dairy products and more soy bean; one vegetarian donor does not consume 
dairy products at all. Two fermentation that were inoculated with these two donors’ faecal 
samples had different responses to those relevant protein sources comparing to other batches. 
Further advice for conducting in vitro fermentation is not only restricting age and lifestyle, but 
also indications of dietary habit.  
 
In this thesis, BCFA, ammonia, phenolic compounds, and indolic compounds were determined 
as protein fermentation metabolites. Gamma-aminobutyric acid (GABA) can be produced by 
gut bacteria from glutamate by glutamate decarboxylase, and is a neuro inhibitor which has 
shown a potential in improving host health from dietary intake (Mazzoli and Pessione, 2016). 
Neurotransmitter serotonin is generated from tryptophan mainly by enterochromaffin cells and 
some bacteria (O'Mahony et al., 2015). Increasing evidence suggests that gut microbiota may 
regulate serotonin production in many ways (O'Mahony et al., 2015). The effect, and regulatory 
mechanism of microbiota composition and metabolic activity on these neurotransmitters are 
yet to be discovered.  
 
The cholesterol lowering effect of dietary fibre is not only associated with SCFA production, 
but also bile acid regulation in the gut. Some colonic commensal bacteria such as bifidobacteria, 
that are promoted by ITF, can assimilate bile salts (Pereira and Gibson, 2002a). Soluble dietary 
fibre such as β-glucan in oat is found to prevent bile acid reabsorption, and enhance faecal 
secretion (Gunness and Gidley, 2010). Bile acid profiles of faeces, urine, and blood samples 
can possibly provide useful information of cholesterol lowering effects seen here. 
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In the human trial, metabolite changes were not always significant which may be due to 
metabolism variation of gender, age, BMI, and baseline; therefore, further stratification of 
samples by grouping different gender, BMI range, or age range may help understand those 
metabolic changes better. Current data correlated health outcome and microbial changes, 
therefore, further analyses of metabolic and microbial changes associations may reveal relevant 
biological pathways, and how ITF affect colonic proteolysis.  
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Appendices 
Appendix 4.1 Age distribution of the human study 
 
Age distribution of the human study.  
Appendix 4.2 Ethnic groups of the human study 
 
Ethnic groups of the human study.  
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Appendix 4.3 Weight control of the human study. There was no significant change 
of weight during the whole trial 
  
Before XZ After XZ Before XX After XX 
Volunteer’s 
weight in kg 
70.93±15.48 70.88±15.52 70.76±15.23 70.67±14.91 
Weight control of the human study. There was no significant change of weight during the whole trial. 
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Appendix 4.4 Full correlations results 
Correlations of bacteria numbers and stool frequency  
EUB Bif Lab Bac Erec Rrec Ato Prop Fprau DSV Chis CFB Stool 
Frequenc
y 
EUB 1 .638*
* 
.616** .504
** 
.539*
* 
.611*
* 
.579*
* 
.642*
* 
.597*
* 
.263*
* 
.325*
* 
.650*
* 
0.071 0.097 
 
0.000 0.000 0.00
0 
0.000 0.000 0.000 0.000 0.000 0.003 0.000 0.000 0.408 0.240 
158 158 154 148 158 158 155 157 158 124 146 150 137 148 
Bif .638** 1 .493** .322
** 
.238*
* 
.212*
* 
.591*
* 
.456*
* 
.313*
* 
0.171 .198* .405*
* 
-0.056 -0.051 
0.000 
 
0.000 0.00
0 
0.003 0.007 0.000 0.000 0.000 0.058 0.016 0.000 0.513 0.539 
158 158 154 148 158 158 155 157 158 124 146 150 137 148 
Lab .616** .493*
* 
1 .599
** 
.329*
* 
.401*
* 
.531*
* 
.564*
* 
.511*
* 
.439*
* 
.430*
* 
.657*
* 
0.048 0.053 
0.000 0.000 
 
0.00
0 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.584 0.528 
154 154 154 146 154 154 151 153 154 122 143 146 133 142 
Bac .504** .322*
* 
.599** 1 .437*
* 
.381*
* 
.365*
* 
.386*
* 
.594*
* 
.592*
* 
.609*
* 
.711*
* 
0.017 0.081 
0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.845 0.352 
148 148 146 148 148 148 146 147 148 120 138 140 127 135 
Erec .539** .238*
* 
.329** .437
** 
1 .629*
* 
.202* .255*
* 
.486*
* 
.317*
* 
.323*
* 
.238*
* 
.262** .297** 
0.000 0.003 0.000 0.00
0 
 
0.000 0.012 0.001 0.000 0.000 0.000 0.003 0.002 0.000 
158 158 154 148 158 158 155 157 158 124 146 150 137 148 
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Rrec .611** .212*
* 
.401** .381
** 
.629*
* 
1 .310*
* 
.417*
* 
.592*
* 
.214* .300*
* 
.377*
* 
.278** .330** 
0.000 0.007 0.000 0.00
0 
0.000 
 
0.000 0.000 0.000 0.017 0.000 0.000 0.001 0.000 
158 158 154 148 158 158 155 157 158 124 146 150 137 148 
Ato .579** .591*
* 
.531** .365
** 
.202* .310*
* 
1 .622*
* 
.299*
* 
.271*
* 
.236*
* 
.564*
* 
-0.118 -0.086 
0.000 0.000 0.000 0.00
0 
0.012 0.000 
 
0.000 0.000 0.003 0.004 0.000 0.173 0.302 
155 155 151 146 155 155 155 154 155 121 145 148 135 146 
Prop .642** .456*
* 
.564** .386
** 
.255*
* 
.417*
* 
.622*
* 
1 .464*
* 
.251*
* 
.290*
* 
.600*
* 
0.067 0.070 
0.000 0.000 0.000 0.00
0 
0.001 0.000 0.000 
 
0.000 0.005 0.000 0.000 0.437 0.402 
157 157 153 147 157 157 154 157 157 124 145 149 136 146 
Fprau .597** .313*
* 
.511** .594
** 
.486*
* 
.592*
* 
.299*
* 
.464*
* 
1 .457*
* 
.342*
* 
.513*
* 
.197* .310** 
0.000 0.000 0.000 0.00
0 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.021 0.000 
158 158 154 148 158 158 155 157 158 124 146 150 137 148 
DSV .263** 0.171 .439** .592
** 
.317*
* 
.214* .271*
* 
.251*
* 
.457*
* 
1 .597*
* 
.418*
* 
0.116 .212* 
0.003 0.058 0.000 0.00
0 
0.000 0.017 0.003 0.005 0.000 
 
0.000 0.000 0.235 0.024 
124 124 122 120 124 124 121 124 124 124 117 116 107 114 
Chis .325** .198* .430** .609
** 
.323*
* 
.300*
* 
.236*
* 
.290*
* 
.342*
* 
.597*
* 
1 .484*
* 
0.018 0.104 
0.000 0.016 0.000 0.00
0 
0.000 0.000 0.004 0.000 0.000 0.000 
 
0.000 0.842 0.226 
146 146 143 138 146 146 145 145 146 117 146 138 128 138 
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CFB .650** .405*
* 
.657** .711
** 
.238*
* 
.377*
* 
.564*
* 
.600*
* 
.513*
* 
.418*
* 
.484*
* 
1 0.000 0.043 
0.000 0.000 0.000 0.00
0 
0.003 0.000 0.000 0.000 0.000 0.000 0.000 
 
1.000 0.618 
150 150 146 140 150 150 148 149 150 116 138 150 129 139 
Stool 
Frequency 
0.071 -
0.056 
0.048 0.01
7 
.262*
* 
.278*
* 
-
0.118 
0.067 .197* 0.116 0.018 0.000 1 1 
0.408 0.513 0.584 0.84
5 
0.002 0.001 0.173 0.437 0.021 0.235 0.842 1.000 
  
137 137 133 127 137 137 135 136 137 107 128 129 137 148 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
Pearson correlation coefficient and correlation significance of bacteria population and stool frequency of all volunteers of visit 2, 3, 4, and 5. 
Correlations of bacterial changes and stool frequency  
EUB Bif Lab Bac Erec Rrec Ato Prop Fprau DSV Chis CFB Stool 
Frequency 
EUB Pearson 
Correlation 
1 .817** .584** .368** .718** .675** .561** .593** .738** 0.206 .253* .484** .234* 
Sig. (2-tailed) 
 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.057 0.019 0.000 0.050 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Bif Pearson 
Correlation 
.817** 1 .499** .483** .549** .508** .475** .544** .562** 0.120 .224* .485** .256* 
Sig. (2-tailed) 0.000 
 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.270 0.039 0.000 0.031 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Lab Pearson 
Correlation 
.584** .499** 1 .533** .449** .460** .295** .527** .540** .379** .384** .345** 0.113 
Sig. (2-tailed) 0.000 0.000 
 
0.000 0.000 0.000 0.006 0.000 0.000 0.000 0.000 0.001 0.349 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Bac Pearson 
Correlation 
.368** .483** .533** 1 .314** 0.209 0.141 .456** .341** .394** .320** 0.178 -0.084 
Sig. (2-tailed) 0.000 0.000 0.000 
 
0.003 0.053 0.196 0.000 0.001 0.000 0.003 0.100 0.486 
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N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Erec Pearson 
Correlation 
.718** .549** .449** .314** 1 .597** .396** .476** .615** .319** .291** .285** 0.225 
Sig. (2-tailed) 0.000 0.000 0.000 0.003 
 
0.000 0.000 0.000 0.000 0.003 0.007 0.008 0.059 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Rrec Pearson 
Correlation 
.675** .508** .460** 0.209 .597** 1 .483** .568** .723** .281** .343** .290** 0.209 
Sig. (2-tailed) 0.000 0.000 0.000 0.053 0.000 
 
0.000 0.000 0.000 0.009 0.001 0.007 0.080 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Ato Pearson 
Correlation 
.561** .475** .295** 0.141 .396** .483** 1 .535** .587** 0.072 .240* .589** 0.225 
Sig. (2-tailed) 0.000 0.000 0.006 0.196 0.000 0.000 
 
0.000 0.000 0.508 0.026 0.000 0.059 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Prop Pearson 
Correlation 
.593** .544** .527** .456** .476** .568** .535** 1 .745** .465** .368** .418** 0.190 
Sig. (2-tailed) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 0.113 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Fprau Pearson 
Correlation 
.738** .562** .540** .341** .615** .723** .587** .745** 1 .338** .372** .398** 0.228 
Sig. (2-tailed) 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 
 
0.001 0.000 0.000 0.055 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
DSV Pearson 
Correlation 
0.206 0.120 .379** .394** .319** .281** 0.072 .465** .338** 1 .351** -
0.016 
0.025 
Sig. (2-tailed) 0.057 0.270 0.000 0.000 0.003 0.009 0.508 0.000 0.001 
 
0.001 0.881 0.839 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Chis Pearson 
Correlation 
.253* .224* .384** .320** .291** .343** .240* .368** .372** .351** 1 -
0.001 
0.163 
Sig. (2-tailed) 0.019 0.039 0.000 0.003 0.007 0.001 0.026 0.000 0.000 0.001   0.991 0.175 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
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CFB Pearson 
Correlation 
.484** .485** .345** 0.178 .285** .290** .589** .418** .398** -0.016 -
0.001 
1 .277* 
Sig. (2-tailed) 0.000 0.000 0.001 0.100 0.008 0.007 0.000 0.000 0.000 0.881 0.991   0.020 
N 86 86 86 86 86 86 86 86 86 86 86 86 71 
Stool 
frequency 
Pearson 
Correlation 
.234* .256* 0.113 -0.084 0.225 0.209 0.225 0.190 0.228 0.025 0.163 .277* 1 
Sig. (2-tailed) 0.050 0.031 0.349 0.486 0.059 0.080 0.059 0.113 0.055 0.839 0.175 0.020   
N 71 71 71 71 71 71 71 71 71 71 71 71 71 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
Pearson correlation coefficient and correlation significance of bacteria changes and stool frequency of all volunteers in both intervention
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Appendix 4.5 Consent Form for IFT study 
          Please initial boxes  
 
1. I confirm that I have read and understand the Participant Information Sheet dated 
______________for the above study, which was explained by 
_________________________. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason.   
 
3. I authorise the Investigator to inform my General Practitioner of my participation in the study. 
 
4. I have received a copy of this Consent Form and of the accompanying Participant Information 
Sheet. 
 
5. I consent to an initial blood sample being taken for screening purposes, followed by a series 
of blood samples throughout the study at the times indicated on the accompanying Participant 
Information Sheet. 
 
6. I have had explained to me that consent for my contact details and personal information to be 
added to the Hugh Sinclair Unit of Human Nutrition Volunteer Database is entirely voluntary.  
Accordingly I consent as indicated below: 
 
• I consent to my contact details being stored on the Nutrition Unit Volunteer 
Database.  
 
• I consent to my screening information (including date of birth, height, weight, 
smoking status, long-term use of medication, and blood test results, such as level 
of cholesterol, triacylglycerol, and glucose) being stored on the Nutrition Unit 
Volunteer Database. 
 
• I wish to receive a summary of the overall results once the study                                               is 
complete and analysed statistically.  
 
 
 
 
 
 
 
Participant details 
 
Name of Participant:                                Date of Birth:                                          
                           
 
Signature:                        Date:         
 
 
 
Address of Participant:  
Hugh Sinclair Unit of  
Human Nutrition 
Department of Food and  
Nutritional Sciences 
University of Reading 
PO Box 226  
Reading  RG6 6AP 
Phone +44 (0)118 378 7771 
 
 
 
 
Yes                No  
 
  
 
Yes               No  
 
  
 
Yes                No  
 
  
Glenn Gibson 
Tel: 0118 378 8715 
Sciences  Email:    g.r.gibson@reading.ac.uk 
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(Please add if you wish to receive the overall results of the study, and/or you consent to be part of the Hugh 
Sinclair Unit of Human Nutrition Volunteer Database)            
   
 
 
 
 
Telephone number: 
 
 
 
General Practitioner (GP) details 
 
Name: 
 
Address:  
 
 
Telephone:  
 
 
Witnessed by 
 
Name of researcher taking consent:              
 
 
Signature:            Date: 
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Appendix 4.6 Poster 
 
 
 
  
VOLUNTEERS NEEDED  
The happier your bacteria are, the healthier you are? 
We are recruiting volunteers for a study investigating the effects of a 
beneficial prebiotic on bacteria composition and metabolism. 
 
We are looking for: 
Men and women (aged 18-50) who haven't received antibiotics in the past 
six months 
You will be reimbursed for your time and expenses 
This study has been reviewed according to procedures specified by the University Research Ethics Committee and has 
been given a favourable opinion for conduct 
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For further information on the 
IFT Study, please contact 
nutritionvolunteers@reading.ac.uk 
or 0118 378 7771 for IFT study 
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Appendix 4.7 Research ethics application 
 
 
Note  All sections of this form should be completed. 
Please continue on separate sheets if necessary. 
 
 
Principal Investigator: GLENN GIBSON  
School: School of Chemistry Food & Pharmacy 
Email: g.r.gibson@reading.ac.uk 
 
Title of Project: The effect of prebiotic Synergy1 supplementation on microbiota, protein metabolism and 
gastrointestinal (GI) symptoms in people consuming high protein diet (ITF study) 
Proposed starting date: March 2016 ………………………………………… 
 
I confirm that to the best of my knowledge I have made known all information relevant to the Research Ethics 
Committee and I undertake to inform the Committee of any such information which subsequently becomes 
available whether before or after the research has begun. 
 
I confirm that I have given due consideration to equality and diversity in the management, design and conduct of the 
research project. 
 
I confirm that if this project is an interventional study, a list of names and contact details of the subjects in this 
project will be compiled and that this, together with a copy of the Consent Form, will be retained within the School 
for a minimum of five years after the date that the project is completed.  
Signed: 
…………………………………………………….... Date: ……………….………………… 
(Investigator) 
…………………………………………………….... Date: ……………….………………… 
 (Head of School or authorised Head of Department) 
…………………………………………………….... Date: ……………….………………… 
 (Student -where applicable) 
Department of Food and Nutritional Sciences   
Research Ethics Committee 
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Checklist 
 
1. This form is signed by my Head of School (or authorised Head of Department) 
 
2. The Consent form includes a statement to the effect that the project has been reviewed by 
the University Research Ethics Committee and has been given a favourable ethical opinion 
for conduct 
 
3. I have made, and explained within this application, arrangements for any confidential 
material generated by the research to be stored securely within the University and, where 
appropriate, subsequently disposed of securely. 
 
4. I have made arrangements for expenses to be paid to participants in the research, if any, OR, if 
not, I have explained why not. 
 
 
5. EITHER 
 
(a) The proposed research does not involve the taking of blood  
samples; 
 
OR 
 
(b) For anyone whose proximity to the blood samples brings  
a risk of Hepatitis B, documentary evidence of immunity  
prior to the risk of exposure will be retained by the Head of  
School or authorized Head of Department. 
 
Signed: 
 
…………………………………………... Date…………………… 
(Head of School or 
 authorised Head of Department) 
 
 
6. EITHER 
 
(a) The proposed research does not involve the storage of human  
tissue, as defined by the Human Tissue Act 2004; 
  
OR 
 
(b) I have explained within the application how the requirements  
of the Human Tissue Act 2004 will be met. 
 
7.  EITHER 
 
(a) The proposed research will not generate any information  
about the health of participants; 
 
OR 
 
(b) If the research could reveal adverse information regarding  
the health of participants, their consent to pass information 
on to their GP will be included in the consent form and in this circumstance I will inform the 
participant and their GP,  
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providing a copy of the relevant details to each and identifying by date of birth 
 
OR 
 
(c) I have explained within the application why (b) above is not 
 appropriate. 
 
8. EITHER 
  
(a) the proposed research does not involve children under the  
age of 5; 
  
OR 
 
(b) My Head of School (or authorised Head of Department) has given details of the 
proposed research to the University’s insurance officer, and the research will not proceed 
until I have confirmation that insurance cover is in place. 
 
Signed: 
 
…………………………………………... Date………………..… 
(Head of School or authorised Head of Department) 
 
This form and further relevant information (see Sections 5 (b)-(e) of the Notes for Guidance) should be returned, both 
electronically and in hard copy, to: 
 
Dr Mike Proven 
Coordinator for Quality Assurance in Research 
Whiteknights House 
Email:  m.j.proven@reading.ac.uk  
 
You will be notified of the Committee’s decision as quickly as possible, and you should not proceed with the project 
until a favourable ethical opinion has been passed. 
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School of Chemistry Food & Pharmacy 
Application Form 
SECTION 1: APPLICATION DETAILS 
 
1.1  
Project Title: The effect of prebiotic Synergy1 supplementation on microbiota, protein metabolism and 
gastrointestinal (GI) symptoms in people consuming high protein diets (ITF study)  
Date of Submission: February 2016 Proposed start date: March 2016 Proposed End Date: March 2017 
1.2 
Principal Investigator [supervisor name, if student project]:  Glenn Gibson 
Department :Department of Food and Nutritional Sciences  Email:    g.r.gibson@reading.ac.uk  
Office room number:    2.45  Internal telephone: 0118 378 8715 
Other applicants (role):     
Name:  Xuedan Wang Department :Department of Food and Nutritional Sciences  Email:  
X.Wang6@pgr.reading.ac.uk   
Name:  Bob Rastall (Staff) Department :Department of Food and Nutritional Sciences  Email:   
r.a.rastall@reading.ac.uk   Internal telephone:  0118 378 6726 
1.3 
Project Submission Declaration 
I confirm that to the best of my knowledge I have made known all information relevant to the Research 
Ethics Committee and I undertake to inform the Committee of any such information which subsequently 
becomes available whether before or after the research has begun. 
I understand that it is a legal requirement that both staff and students undergo Criminal Records Checks 
when in a position of trust (i.e. when working with children or vulnerable adults).  
I confirm that a list of the names and addresses of the subjects in this project will be compiled and that 
this, together with a copy of the Consent Form, will be retained within the School for a minimum of five 
years after the date that the project is completed. 
 
Signed…………………………… (Principal Investigator)  Date:………… 
Signed…………………………… (Student)   Date:………… 
 
1.4  
University Research Ethics Committee Applications 
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Projects expected to require review by the University Research Ethics Committee must be reviewed by 
the Chair of the School Ethics Committee or the Head of School before submission. 
Signed…………………………… (Chair of School Committee) Date:…………………… 
Signed…………………………… (Head of School)   Date:…………………… 
1.5 
External research ethics committees  
Please provide details below of other external research ethics committees to which this project has been 
submitted, or from whom approval has already been granted [e.g. NHS Committee] 
Name of committee Date of 
submission/approval 
Reference Status 
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SECTION 2: PROJECT DETAILS 
 
2.1 
Lay summary 
[Please provide a lay summary of the project; what is being investigated and why?] 
The composition and metabolism of human gut microbiota play crucial roles in health. Microbial colonisation of the 
gastrointestinal tract varies widely, with the large intestine having not only the highest density of microbes in terms 
of bacterial cells per gram but also the most metabolically active microbial community (1). Genetics, mode of birth, 
infant feeding patterns, antibiotic usage, sanitary living conditions and long term dietary habits contribute towards 
shaping the composition of the gut microbiome. Diet clearly has a major impact on variation in the gut microbiota 
composition, and this can be detected in faecal samples after only a few days (2, 3). The bacterial metabolism of 
dietary components produces much chemical diversity in the large intestine with protective or detrimental effects 
on disease development (3).  
Dietary protein levels are relatively high in western European populations, up to 103g/d, as reported by Food and 
Agriculture Organization (4). This may result in high levels, entering the large gut where it can become a substrate 
for proteolytic bacteria. Protein specifically can provide nutrition for microorganisms but metabolites from bacterial 
protein breakdown can be detrimental. Protein intake from the diet might not be the only source of microbial 
proteolysis; the human body also secretes considerable amounts of protein into the digestive lumen which can 
potentially be used by the microflora. On the contrary, end products of carbohydrate metabolism can be positive 
for health. In this context, prebiotics are carbohydrates that are resistant to digestion and can become available for 
bacteria in the colon to produce SCFAs and inhibit the production of harmful metabolites. A switch towards more 
carbohydrate metabolism in the colon, at the expense of proteolysis therefore has positive capacity through the 
production of more benign metabolites. 
 
Rationale for design 
Prebiotics are dietary ingredients that target carbohydrate digesting bacteria only. Given the high intake levels of 
protein in Western populations, they may be useful to modulate the composition/activity of the microbial gut 
ecology for improved health (5).  
Among prebiotic nutrients, inulin-type fructans (ITF) are well characterized and their administration promotes 
growth of beneficial microorganisms like Bifidobacterium spp. (5).These microorganisms are involved in the 
reduction of intestinal endotoxin concentration, improve glucose tolerance, exert benefits upon immune function 
and inhibit pathogens (6,7). In healthy individuals, ITF intake promotes satiety and modulates gut peptides regulating 
food intake (7, 8). 
The aim of the present study is to investigate the effect of inulin-type fructans (ITF) on the negative consequences 
of colonic fermentation in individuals consuming high protein diets. The hypothesis to be tested is that their action 
promotes carbohydrate degrading bacteria at the expense of protein utilisers. 
 
 
Primary  
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• To investigate the effect of ITF on the faecal microbiota of individuals consuming high protein diets, 
using a culture independent procedure known as Fluorescence in situ Hybridisation (FLOW-FISH). The 
main groups to be enumerated by this method will be: bifidobacteria, lactobacilli, clostridia, 
eubacteria, bacteroides, atopobium, proteobacteria, sulphate-reducing bacteria and E. coli. In 
addition, bacterial DNA will be extracted and used for a fuller microbial diversity (metagenomic) 
analysis. 
• To ascertain the extent of colonic prebiotic fermentation and to investigate the effect on bacterial 
metabolites in faeces, urine and blood. 
Secondary 
•  To conduct an assessment of stool frequency, stool consistency, bloating, flatulence, abdominal pain 
and mood changes in a human study. 
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2.2 
Procedure 
[Outline the project’s research protocol] 
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This will be a crossover, placebo controlled, and randomised study in 50 (18-50 years old) individuals. The study 
consists of 6 week randomised intervention treatment periods with the prebiotic and placebo, following by 3 
weeks wash-out period and another 6 week randomised intervention treatment.  
Study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This trial will investigate the effects of two groups following an intervention diet with a prebiotic food 
supplement or placebo food supplement. The IFT food supplement (supplied by the Beneo company) is a 
chicory inulin powder produced in Belgium. Participants will be required to take 2 sachets of 7.5g prebiotic 
food supplement daily. This will be reconstituted with milk and participants will be encouraged to take the 
sachet at the same time each day. The placebo control food supplement will be maltodextrin DE 19. 
Maltodextrin is a standard placebo product for use in human studies involving prebiotics and has been used in 
similar trials by ourselves for the last 20 years. The products will be provided as a powder (served in sachets) 
and identical in texture, appearance and taste. The Beneo company will produce and provide barcoded 
sachets, blinded to the investigators and volunteers. After all volunteers have completed their study visits and 
all samples has been analysed by researchers, Beneo company will provide information about barcoded 
sachets. Compliance to food supplement (prebiotic or placebo) will be assessed by recording intake in GI 
diaries and participants will also be asked to return any unused sachets to the researchers at the end of the 
each 6-week intervention period. For participants to be considered compliant and therefore included in the 
study, they will be required to take the food supplement or placebo at least 6 out of every 7 days of the trial 
for the 6 week period and also return completed questionnaires. Primary outcome measures for the trial are 
microbial analysis of stools and metabolite analyses of faeces, blood and urine. It will also be essential for 
participants to provide these samples as described in the Trial Procedure section of this protocol. In order to 
be eligible for inclusion in the trial, the following drugs or therapies will not be permitted during the four weeks 
prior to commencing the trial and for its duration: 
✓ Antibiotics  
✓ Prebiotics or probiotics (in food products or as supplements)  
n=50 
days 
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✓ Other dietary supplements or drugs that may affect the luminal microenvironment of the intestine 
(e.g. Orlistat, Lactulose) 
Primary efficacy parameters 
The faecal microbiota of volunteers will be characterised, using FLOW-FISH, to determine the effectiveness of 
treatment in increasing the numbers of beneficial groups (e.g. bifidobacteria) at the expense of less beneficial groups 
(e.g. clostridia, sulphate-reducing bacteria, E. coli). In addition, a detailed study of the microbiota will be performed 
on total faecal DNA extracts, using16SrRNA sequencing.  
The concentration of SCFA and lactate in faecal samples will be determined to ascertain the extent of colonic 
prebiotic fermentation. Other bacterial metabolites will be measured in faeces, urine and blood by metabolomic 
(NMR based) analysis in order to generate a detailed picture of microbial fermentation profiles. 
Secondary efficacy parameters 
Gastrointestinal symptoms (e.g. abdominal pain, flatulence or bloating), number of bowel movements and 
consistency of stools, will be assessed daily in a volunteer diary. (Appendix E).  
Once consent has been obtained, participants will be randomised and included in the trial.  We will over recruit by 
10% to cover for drop-outs. 
Randomisation will be stratified by sex and allocation will occur to one of the two treatment groups using a 1:1 ratio. 
The method of minimisation will be used to ensure treatment arms are balanced with respect to the number of 
patients in each group (https://www-users.york.ac.uk/~mb55/guide/minim.htm). Participants are free to withdraw 
from the study at any time, without providing a reason, if they wish to cease participation. Should this occur, all 
efforts will be made to report the reason for withdrawal as thoroughly as possible. Allowance has been made for 
withdrawal of 10% subjects in the sample size calculation. Data from withdrawn participants will be included in the 
intention to treat analysis.   
Screening: 
Participants identified as potentially suitable from the University of Reading database or by the local groups and 
societies will be contacted, and screened against inclusion and exclusion criteria if interested in being involved. 
Volunteers will provide a baseline blood sample at a pre-screening visit to check for anaemia, and a stool sample to 
check microbiota composition. Faecal and blood samples will be collected at site visits at the Department of Food 
and Nutritional Sciences. Once consent has been obtained, all eligible participants will be asked to fill in a 4-day food 
diary, a food frequency questionnaire, and complete a brief medical history questionnaire. Based on the food diary, 
protein consumption will be calculated to evaluate if the volunteer meet the criterion. The volunteers will then be 
randomised and requested to participate in the run-in period. 
 Trial Day Stage of Study Treatment 
-2 weeks Pre-trial meeting 
 
• Briefing about the study 
• Distribution of trial information sheets and 
preliminary discussions with volunteers 
• Provide blood and stool samples for screening 
• Provide food diary for screening 
 
 
0 
 
Baseline 
(Visit 1) 
• Provide baseline faecal sample, urine sample and 
a blood sample (50ml; 5 dessert spoons) for 
baseline measurements  
• Distribution of test sachets for the 6w treatment 
Volunteer diaries (diaries for bowel habit and 
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mood questionnaire) will be distributed for the 42 
day treatment 
 
 
6 weeks 
 
 
Treatment period 
(Visit 2) 
• Consume two sachets for every day of 6w 
treatment period 
• During the treatment (prebiotic or placebo), 
complete dietary, bowel habit and mood 
questionnaires and record any concomitant 
medication or adverse events during the trial  
• Provide faecal sample, urine sample and blood 
sample after 6w (Visit 2) 
 
 3 weeks 
 
Washout period 
(Visit 3) 
• Refrain from consuming probiotic and prebiotic 
supplements.  
• Do not take any product sachets 
• Provide faecal sample, urine sample and blood 
sample after 3w (Visit 3) 
 
 
 
15 weeks 
 
 
Treatment period 
(Visit 4) 
• Consume two sachets for every day of 6w 
treatment period 
• During the treatment (prebiotic or placebo), 
complete dietary, bowel habit and mood 
questionnaires and record any concomitant 
medication or adverse events during the trial  
• Provide faecal sample, urine sample and blood 
sample after 6w (Visit 4) 
 
 18 weeks 
 
Washout period 
(Visit 5) 
• Continue to refrain from consuming probiotic and 
prebiotic supplements.  
• Do not take any product sachets 
• Provide faecal sample urine sample and blood 
sample  after 3w (Visit 5) 
 
 
END OF THE STUDY 
 
 
Those researchers working with blood, urine and faeces will be up to date with Hepatitis A and B vaccinations. 
• Bacterial enumeration 
Freshly voided faecal samples will be diluted 1 in 10 (w/w) with anaerobic phosphate buffer and mixed in a 
stomacher for 2 min. Changes in faecal bacterial populations will be assessed through the use of a culture 
independent procedure that assesses molecular changes in the microbiota (FLOW-FISH and metagenomics) 
• Short chain fatty acids (SCFA) 
Samples of the faecal slurry [1 in 10 (w/w) dilution of faeces] will be taken for determination of SCFA (end 
products of bacterial metabolism) by gas chromatography. 
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All investigators coming into contact with faecal matter will have completed a Hepatitis A vaccination course. 
Any individuals coming into contact with faecal samples will abide by good general laboratory procedures. 
• Metabolites 
A blood sample to check for anaemia and baseline measurements will be taken during screening (50ml – 5 
dessert spoons)). 5 subsequent blood samples will be taken during the trial. Volunteers will be asked to 
provide a venous, fasting (fasted for 10 hours), blood sample. Blood will be collected through venepuncture 
by a trained phlebotomist.  
 
Blood will be extracted into sodium heparin tubes (kept on ice), diluted and centrifuged to gain plasma (for 
metabolites analysis).  
Plasma and serum samples will be labelled as a biohazard and stored at -80oC. 
Samples of the faecal slurry, blood plasma and urine will be kept for metabolites determination by 1H-NMR 
based metabolomics 
The Department of Food and Nutritional Sciences is fully licensed under the Human Tissue Act 2004 and as 
such will adhere to the guidelines necessary for the storage of all biological material. A detailed log will be 
kept to record when the sample was taken, its place of storage, when analysis was conducted on the sample 
and how and when the sample was disposed of. 
 
Early withdrawal 
• Withdrawal Criteria: 
Volunteers will be informed in the consent form and also in the volunteer information sheet that they have the 
right to withdraw from the study at any time without giving a reason and without prejudice. In addition they may 
be withdrawn at the Investigator’s discretion at any time. 
 
• Volunteers may be withdrawn by the Investigator due to: 
An adverse event for which the Investigator does not consider continuing study participation safe. 
Recurrent illness. 
Poor tolerance 
Poor adherence.  
Description of the test product 
The product used in this study will be Orafti®Synergy1. The placebo will be Maltodextrin DE 19 (a powdered 
carbohydrate that looks and tastes identical to the test) served in sachets. The products will be provided as a 
powder in sachets, therefore it can be kept at room temperature.  
  
Serving:  2 serving per day (1 sachet: 7.5g) 
Instruction of use: Sprinkle all powder of the sachet over a bowl of cereal, or take with milk, just before 
consumption. Be sure to ingest all powder content.  
 
Visit schedule and assessments 
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Screening/Pre-Trial meeting (Baseline visit) 
Informed consent will be obtained prior to the performance of any study related activities/assessments. 
Inclusion/exclusion criteria will be reviewed for volunteer eligibility. Here, volunteers will undergo the following 
evaluations: 
• Demography 
• Past/current medical conditions 
• Weight/ Height 
• Concomitant medication 
• Smoking history 
• Blood sample collection  
• Food diary and protein consumption 
Note: Blood sample collections can be arranged for another day should volunteer prefer. 
In addition, volunteers deemed eligible and who want to participate will be given food and drink diary and 
instructed on how to complete the diary. 
 
The volunteer will either be excluded or, if fully meeting the inclusion criteria and willing to take part in the 
study, will be randomised and enrolled. On Day 1, the study volunteer will be given the correct number of 
sachets for the first treatment period. Food and drink diaries will be collected and diary cards will be issued and 
the volunteer will be instructed on how to complete these diaries. Volunteers will keep a daily diary noting the 
number of bowel movements and the average consistency of the stools using the Bristol stool chart (hard, solid, 
loose or watery), as well as the occurrence of abdominal discomfort, flatulence or bloating and mood changes. 
Furthermore the diary will include an area for noting any illness experienced including colds and respiratory 
infections. 
Visit 1: Initiation of the study 
Volunteers meeting the inclusion/exclusion criteria will be given the correct number of sachets for the first 6 
weeks of the treatment. Food and drink diaries will be collected and daily diary cards will be delivered and the 
volunteer will be instructed on how to complete the diary cards. Volunteers will provide blood (50ml; 5 
dessertspoons) urine and faecal samples. Concomitant medications will be checked and the volunteer’s weight 
recorded.  
 
Blood sample collection 
Volunteers will be asked to provide a venous, fasting (having fasted for 10 hours, drinking only water – 
but no water 1hr before arrival) blood sample (50ml; 5 dessertspoons) at each visit. Blood samples will be 
collected by an experienced and trained phlebotomist in the Hugh Sinclair Unit of Human Nutrition 
(Department of Food and Nutritional Sciences).  
 
Faecal sample collections 
Volunteers will be asked to provide a fresh faecal sample at each visit. The volunteers will be provided 
with an appropriate vessel for sample collection at the University. If unable to do so, they will be given the 
option to come in on following days until production is possible. No new treatment will be issued until stool 
has been provided. Samples will be processed immediately for microbial and metabolites analyses. 
 
Urine sample collections 
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Volunteers will be asked to provide a 24h urine sample at each visit. Volunteers will be provided with an 
appropriate container for the 24h urine sample collection at the University. Samples will be processed 
immediately for metabolite analysis. 
 
Visits 2: 6-weeks treatment period 
At Visit 2, volunteers will provide blood, urine and faecal samples. Adverse events will be addressed, 
concomitant medications will be checked and the diary card will be reviewed with the volunteer.  New diary 
cards and the correct number of sachets for the 6 weeks of the treatment will be given. In the event of withdrawal, 
all evaluations will be performed as per the end of the study, provided the subject is willing.  
 
Visit 3: wash-out period 
At Visit 3, volunteers will provide blood (50ml; 5 dessertspoons), urine and a faecal sample. Adverse events will 
be addressed, concomitant medications will be checked, weight will be recorded and the diary card will be 
reviewed with the volunteer. New diary cards will be distributed and volunteers will not be supplied with feeding 
sachets at this visit as they will enter 3 weeks of washout period. All unused products will be collected at this 
visit. In the event of withdrawal, all evaluations will be performed as at the end of the study, provided the subject 
is willing.  
 
Visits 4: 6-weeks treatment period 
 
At Visit 6, volunteers will provide blood (50ml; 5 dessertspoons), urine and faecal samples. Adverse events will 
be addressed, concomitant medications will be checked, weight will be recorded and the diary card will be 
reviewed with the volunteer. New diary cards will be distributed and volunteers will be supplied with sachets for 
the 6 weeks of the treatment – different from the product they received for the first 6 weeks. 
 
Visit 5: wash-out period 
At Visit 5, volunteers will provide blood (50ml; 5 dessertspoons), urine and a faecal sample. Adverse events will 
be addressed, concomitant medication will be checked, weight will be recorded and the diary card will be 
reviewed with the volunteer. All unused products will be collected at this visit. In the event of withdrawal, all 
evaluations will be performed as at the end of the study, provided the subject is willing.  
Visit 5 finalises the study. 
 
Statistical analysis: 
Faeces: 
Bacterial numbers will be compared after transformation to log counts. This will be done using a repeat 
measure ANOVA test analysing repeat measures over time using the factors: Treatment group 0 (placebo) 
or 1 (treatment). 
Volunteer diaries: 
We will use a  χ  2 test which compares two factors to see if they are independent from each other (in this 
case the placebo and treatment values): of stool frequency, consistency, abdominal pain and intestinal 
bloating. 
(Note: All questionnaires or interviews should be appended to this application) 
2.3 
Location 
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Where will the project take place?  
The project will take place within the Department of Food and Nutritional Sciences building, within the Hugh 
Sinclair Unit. 
If the project is to take place in Hugh Sinclair Unit of Human Nutrition, please confirm that you have informed 
Ms Sarah Elizabeth Hargreaves (s.e.hargreaves@reading.ac.uk). Yes, Ms Sarah Elizabeth Hargreaves has been 
informed. 
2.4  
Funding 
Is the research supported by funding from a research council or other external sources (e.g., charities, 
business)? [If yes, please check for any particular requirements of the funder regarding ethical review]Yes 
B E N E O     
BENEO GmbH 
Maximilianstrasse 10 
68165 Mannheim 
Germany 
General Management: Hildegard Bauer, Andreas Herber, Dominique Speleers 
Register Court: County Mannheim - No. HRB 701800 - VAT DE 253691060 
2.5 
Ethical Issues 
[Please outline any potential ethical issues in the project, and how these will be addressed in the research 
protocol] 
It is not anticipated that there will be any risk to participant safety. Synergy 1 has been used in a number of 
different feeding trials with various groups of volunteers and was well tolerated by all. Participation in the 
study does not pose any significant risk. However, same people who have taken similar prebiotics have 
reported an increase in gas production, with slight bloating feelings, some flatulence and mild diarrhoea. Cases 
of this are very rare. Volunteers will be questioned about adverse events on a weekly basis on the telephone.  
Please refer to Appendix H for further information 
 
2.6 
Deception 
Will the research involve any element of intentional deception at any stage (i.e. providing false or misleading 
information about the study, or omitting information)? No 
[If so, this should be justified. You should also consider including debriefing materials for participants, which 
outline the nature and the justification of the deception used] 
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2.7 
Payment 
Will you be paying your participants for their involvement in the study? 
[Will there be pro rata payments if participants withdraw early?] 
Time Task Payment Total Payment 
2 hours Assessment and instruction £ 8.50 / h £ 17 
6 hours Sample collection £ 7.00 / h £ 42 
13 hours Record keeping £ 7.00 / h £ 91 
Total 21 hours   £ 150 
Volunteers will be paid £150 for completion of the trial. Those who withdraw will have their payment pro-
rated according to time spent. Reserve volunteers will be paid for assessment and instruction if they are not 
required to participate in the treatment phases of the trial. 
Note: excessive payment may be considered coercive and therefore unethical. Travel expenses will not be 
provided. 
2.8 
Data storage, data protection and confidentiality 
[Please outline plans for the handling of data to ensure data protection and confidentiality, i.e. how and 
where will the data (results data, consent forms) be stored? Do any samples fall under the jurisdiction of the 
Human Tissue Agency act?] 
Confidentiality will be maintained by allocating volunteers an identification code, which will be used to identify 
all samples and data obtained. Volunteer’s names will not be used in any reports or publications. All data 
generated from the study will be held securely within a password protected file, only the study investigators 
will have access to this.  A record of the names of the volunteers will not be held on the same file. Information 
matching volunteer names with identification codes will be kept in a locked filing cabinet, the investigators will 
only use identification codes. The only time data will be matched with volunteer names is for those volunteers 
that request to have their personal results discussed with them. A request for individual results to be discussed 
will include a review of all sample results for the individual volunteer. A list of the names and addresses of the 
subjects in this project will be compiled, this, together with a copy of the Consent Form, will be retained within 
the Department for five years after the date that the project is completed. 
 
 
2.9  
Consent 
[Please outline procedures for obtaining consent from participants] 
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Potential volunteers may contact the study investigator if they are interested in participating, or if they would like any 
further information or to discuss any concerns. A meeting will be arranged to talk to the participants before 
commencement of the trial. Participants are free to withdraw from the trial at any time without giving reasons. Those 
who wish to participate in the study will attend a pre-trial assessment, in which informed consent will be obtained. 
Consent will be obtained after volunteers are asked questions about inclusion and exclusion criteria. Volunteers are 
free to ask the investigator questions at any point during / following this process. 
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SECTION 3: PARTICIPANT DETAILS 
3.1 
Sample Size 
[What is your target sample size? Provide statistical (or otherwise) justification for this number] 
By the use of a statistical power calculation it can be observed that at significance level of 5% (two-sided) 
will be that, a log change of 0.5 can be detected at a power of 80% with 43 volunteers. (This calculation is 
based on the assumption that the within volunteers standard deviation is 0.8, which was as observed by 
Kruse et al., 1999). Therefore 43 volunteers (18-50 years old) will be recruited for participation in this study. 
We will over recruit by 10% to cover for drop-outs. 
18-50 year old individuals will be screened according the inclusion and exclusion criteria. From this 
screening we will select individuals (equal numbers of men and women) to enrol in the trial. 
 
3.2 
Will the research involve vulnerable adults (e.g., adults with mental health problems or neurological 
conditions)? No 
[If so, you will need to consider carefully issues around working with this population, e.g. consent 
procedures, Criminal Records Bureau disclosures. It is highly likely that you will also need approval from an 
NHS Research Ethics Committee for your project]  
 
3.3 
Will your research involve young people under the age of 18 years? No 
Will your research involve children under the age of 5 years? No 
[If so, you will need to consider carefully issues around working with these constituencies, e.g. consent 
procedures, Criminal Records Bureau disclosures. You may need to consider age appropriate information 
sheets] 
 
3.4 
Will your research involve NHS patients or Clients of Social Services? No 
[If so, you will need approval from an NHS Research Ethics Committee for your project. In the case of NHS 
staff, this is only required if their recruitment is by virtue of their professional role. Ideally, approval will 
have been received from the NHS committee prior to being submitted to the University committee. Please 
attach original NRES application and, where relevant, approval documents] 
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3.5  
Recruitment 
[Please describe recruitment procedures (e.g. advertising, databases) and attach any recruitment materials, 
such as posters, emails, letters, etc.] 
Posters with study information will be distributed around the Reading area. Potential volunteers may then 
contact the study investigator if they are interested in participating, or if they would like any further 
information or to discuss any concerns. Potential participants will have a minimum of two weeks to decide 
whether they want to be involved in the study. A meeting will be arranged to talk to participants before 
commencement of the trial prior to informed consent. Participants are free to withdraw from the trial at any 
time. Advertisements may also be emailed, put in newspapers and on walls in and around the University.  
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Appendix A: CONSENT FORM 
 
 
        Consent Form 
1. I have read and had explained to me by ……………………………………………..…  
 
the accompanying Information Sheet relating to the project on: 
 
 
 ……………………………………………………………………………………………....  
 
2. I have had explained to me the purposes of the project and what will be required of me, and any questions I 
have had have been answered to my satisfaction.  I agree to the arrangements described in the Information 
Sheet in so far as they relate to my participation. 
 
 
3. I understand that participation is entirely voluntary and that I have the right to withdraw from the project any 
time, and that this will be without detriment. 
 
 
4. Researcher to delete (a) and (b) if GP will not be contacted, or (b) if no response from GP is required 
 
a) I authorise the Investigator to consult my General Practitioner, and provide their name and address details 
overleaf. 
 
b) I authorise my General Practitioner to disclose any information which 
    may be relevant to my proposed participation in the project. 
 
 
5. I agree to the interview/session being video/audio taped. (delete if not applicable) 
 
6. This application has been reviewed by the University Research Ethics Committee and has been 
approved by UREC.  It has been given a favourable ethical opinion for conduct. 
 
 
7. I have received a copy of this Consent Form and of the accompanying Information Sheet.  
 
 
Name: ……………………………………………………………………………… 
 
Date of birth [if GP details given]: ……………………………………………… 
 
Signed: ……………………………………………...……………………………… 
 
Date: ………………………………………………………...……………………… 
 
GP details 
 
Name: ……………………………………………………………………………… 
 
Address: ……………………………………………………………………… 
 
…………………………………………...……………………………… 
 
               
Department of Food and Nutritional Sciences 
Xuedan Wang: X.Wang6 @pgr.reading.ac.uk 
Whiteknights 
PO Box 266, Reading RG6 6AP, UK 
Telephone 07840031309 
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Appendix B 
 
GP letter 
 
Dear Name of GP, 
 
Name of Patient (and date of birth) has expressed an interest in participating in a dietary intervention trial at The 
University of Reading. The trial will investigate the effect of a prebiotic Synergy1 on on protein metabolism by gut 
bacteria in healthy adults. 
 
This will be a double-blind, crossover, placebo controlled, randomised study in individuals aged 18-50 years old. The 
study will consist of a treatment period (prebiotic or placebo for 6 weeks), a wash-out period (3 weeks) and another 
treatment period (prebiotic or placebo for 6 weeks). The subject information sheet has been enclosed for your 
information. 
The product used in this study will be Synergy1 served in sachets, twice daily. The placebo will be maltodextrin served 
in sachets, twice daily. Synergy1 and maltodextrin are completely safe. As such the trial is not considered of risk to the 
volunteers. 
 
This human study has been subject to ethical review, according to the procedures specified by the University Research 
Ethics Committee, and has been given a favourable ethical opinion for conduct. 
 
The trial will commence on (Trial start date) 
 
If you have any questions about the trial please do not hesitate to contact me. 
We appreciate your help. 
Yours sincerely, 
 
Xuedan Wang 
 
 
 
 
Department of Food and Nutritional Sciences 
Xuedan Wang: X.Wang6 @pgr.reading.ac.uk 
Whiteknights 
PO Box 266, Reading RG6 6AP, UK 
Telephone 07840031309 
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Appendix C 
  
PARTICIPANT INFORMATION SHEET 
 
The effect of prebiotic Synergy1 supplementation on microbiota, protein metabolism and gastrointestinal (GI) 
symptoms in people consuming high protein diet (ITF study) 
You are being invited to take part in a research study. Before you decide if you want to take part it is important that 
you understand what is involved. Please read the following information and discuss with others if you wish. Please ask 
us if there is anything you do not understand or if you would like any additional information. Take time to decide 
whether or not you wish to take part. 
 
Aim 
The aim of this study is to evaluate the effects of prebiotic Synegy1 on intestinal bacteria and protein metabolism in 
individuals aged 18-50 years. About 50 volunteers will take part in this study. In addition, a further 5 volunteers will 
be recruited as reserves. Equal numbers of men and women will be included in the study cohort. 
 
Before you decide whether to take part in the study, please read the following information carefully. If you want to 
know anything about the study, which is not written here, please ask the investigator. 
 
What are prebiotics? 
• Prebiotics are non-digestible carbohydrates that exert bacteria changes in the intestine and bring about health 
benefits 
• They are used in foods to increase gut bacterial numbers 
• They have been found to improve the intestinal bacterial composition of the general population 
• They are safe for human consumption 
• They have been consumed by humans for hundreds of years 
• The prebiotic used in this study Orafti®Synergy1 is produced by Beneo company which is also sponsoring this study.  
 
Proposed benefits of prebiotics 
• Reduce the number / activities of disease causing bacteria 
• Influence satiety 
• Improve immune response 
• Reduce risk of gastrointestinal illness such as travellers’ diarrhoea, irritable bowel syndrome, infections 
• Increase absorption of minerals 
Why is this study being carried out? 
There is an increasing shift towards use of diet to control protein metabolism and other health parameters. Prebiotics 
are safe interventions that could help. 
Department of Food and Nutritional Sciences 
Xuedan Wang: X.Wang6 @pgr.reading.ac.uk 
Whiteknights 
PO Box 266, Reading RG6 6AP, UK 
Telephone 07840031309 
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Inclusion criteria/exclusion criteria 
Inclusion criteria- If the following applies to you, you will be considered for participation in the trial: 
• Aged between 18 and 50 years of age. 
• Willing to participate in the entire study (signed informed consent required). 
• Subjects will be eligible for the study if male or female (non pregnant), aged 18– 50 years, with high consumption 
of protein (105g/day).  
 
Exclusion criteria - If the following applies to you, you will be unable to participate in the trial: 
• History or evidence of intestinal disease; such as tumour, Irritable Bowel Syndrome, etc., within the previous 5 
years. 
• Received antibiotics in the previous six months 
• Not willing to cease the consumption of probiotic or prebiotic preparations for the duration of the study 
• Former participation in another study involving prebiotic or probiotic preparations within the previous 2-weeks, or 
intention to use such products during the course of the study (please note sensory evaluations may be still permitted 
after discussion with the Investigator) 
• History of malignancy within the previous 5 years (with exception of well-treated basal cell carcinoma or in situ 
cervical carcinoma).  
• Diabetes 
• Smoker 
• Lactose intolerant 
• Allergic to gluten  
• Currently prescribed immunosuppressive drugs. Participants will be required to withdraw should they begin taking 
any of the ineligible medication. 
• Intention to use regularly other medication which affects gastrointestinal motility.  
• History of alcohol or drug misuse. 
• Using statins  
• Suffer from any major conditions involving the following: 
✓ Head, Ears, Eyes, Nose and Throat 
✓ Dermatological/Connective tissue 
✓ Neurological 
✓ Lymphatic  
✓ Urogenital/Rectal 
✓ Abdominal 
✓ Respiratory  
✓ A previous cardiovascular event within the last 6 months, presence of secondary dyslipemia related to thyroid 
dysfunction, used any drug affecting lipid metabolism in previous 3 months, a history of alcohol abuse. 
 
What will I be asked to do? 
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• All participants will be asked to fill out a health screening questionnaire and inclusion/exclusion criteria will be 
reviewed for volunteer eligibility. 
• Informed consent from yourself will be required  
• On giving consent and passing initial screening, participants’ height and weight will be measured and they will be 
required to give a blood sample to screen for anaemia and baseline measurements (50ml; 5 dessertspoons)  
• Once the study begins, participants will be randomly allocated to consume the prebiotic supplement or a placebo 
(maltodextrin) for 6 weeks and after the first wash out period participants will switch to placebo or prebiotic 
supplement. Neither you nor investigator will know which of the supplements you are taking. After the each 6 
weeks (placebo or treatment) there will be a 3 week washout period where no product will be consumed.  
• Participants will be required to consume the product as two doses before breakfast and after dinner. The products 
will be provided as a powder in sachets, therefore can be kept at room temperature, and also can be taken abroad. 
• Participants will provide one stool sample on weeks 0, 6, 9, 15 and 18 of the study to look for changes in gut 
bacteria. The same times will be used for blood sampling to assess blood metabolites. 
• Volunteers will be asked to provide a 24h urine sample at each visit.  
• Volunteers will be given a container for faecal collection and shown to private facilities within the department to 
give a stool sample. If unable to do so, they will be given the option to come in the days following until production 
is possible. No new treatment will be issued until stool has been provided. 
• All blood samples will be taken in the Hugh Sinclair unit of the Department of Food and Nutritional Sciences 
• Maintenance of normal dietary patterns throughout the study is essential and participants will be required to 
complete food and drink logs throughout the study 
• Any adverse medical events which occur during the trial (e.g. headache, gut symptoms) should be recorded in a 
diary along with medication taken  
• All incidence of respiratory infections and colds should also be reported 
• Daily stool habit should be recorded in a diary 
• Please note that participants will be removed from the study if they develop acute gastrointestinal illness (e.g. 
food poisoning) or intolerance to the supplement or if they do not comply to above stated restrictions 
 
Are there any risks? 
The product used in this study will be the prebiotic Synergy1, the placebo will be maltodextrin served in sachets, twice 
daily. Synergy1 and maltodextrin do not pose any risk to participants.  
 
Blood samples will be collected by experienced staff trained for this purpose at the University (Hugh Sinclair Unit). 
There is a chance of a little discomfort and bruising when having blood taken but every care will be taken to minimise 
this. 
 
Confidentiality 
Confidentiality will be maintained by allocating volunteers an identification code, which will be used to identify all 
samples and data obtained. Volunteer’s names will not be used in any reports or publications. All data generated from 
the study will be held securely within a password protected file, only the study investigators will have access to this a 
record of the names of the volunteers will not be held on the same file. 
Information matching volunteer names with identification codes will be kept in a locked filing cabinet, the investigators 
will only use identification codes. The only time data will be matched with volunteer names is for those volunteers 
that request to have their personal results discussed with them. A request for individual results to be discussed will 
include a review of all sample results for each volunteer. A list of the names and addresses of the subjects in this 
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project will be compiled, this, together with a copy of the Consent Form, will be retained within the School for a 
minimum of five years after the date that the project is completed. 
 
Restrictions during testing 
• Participants must not consume pre- or probiotic supplements or food products containing them during the study. 
Examples of these food products are: 
• Danone Actimel yoghurt drink 
• Yakult milk drink 
• Danone Activia yoghurt 
• Kellog’s Rice Crispies multigrain 
• Weetabix  
• Muller Vitality Yoghurt/Drinks 
• Warburton’s healthy inside bread 
 
General Information 
• You will receive £150 for completing the trial and £20 if you are a reserve volunteer who does not receive a 
treatment. Volunteers that drop out will have their payment pro-rated to cover the part of the study completed.  
• Stool sample pots will be provided and advice on how to take stool samples will be given 
• Analysis of faecal, urine, and blood samples will occur at the University of Reading 
• You will be provided with breakfast on visit days 
• If at any time you wish to withdraw from the study you are completely free to do so without giving a reason 
The information collected will be used for research purposes only. All information will be confidential and 
individuals’ names will not be used in any reports resulting from this work. 
• Once the study has been completed you can request your results 
• All unused samples will be destroyed after the completion of the study and sample analysis. 
 
The University has appropriate insurance and is well used to carrying out these types of trials. If there is a complain 
then this should be addressed to Professor Glenn R Gibson, Head of FMSU, University of Reading     
g.r.gibson@reading.ac.uk 
The investigators thank you for taking time to read this. If you have any queries please feel free to contact: 
 
Xuedan Wang          X.Wang6@pgr.reading.ac.uk 
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Study Timetable 
Proposed dates Stage of Study Treatment 
 Baseline 
Pre-trial meeting/ 
Screening 
• Briefing about the study 
• Provide screening blood and stool samples  
• Dispensing food and drink diary cards 
Weeks 0 Visit 1 
Start of study 
• Provide base-line faecal, urine and blood samples  
• Collecting food and drink diary cards 
• Dispensing diary cards 
• Dispensing product 
• During the 6 week period – product will be taken twice 
daily 
• Diaries to be completed daily 
 
Weeks 1-6 
(interim period) 
 ) 
Visits 2  
6 Week 
Treatment  
period 
• Diaries to be submitted  
• Provide faecal, urine and blood samples and given 
new diary cards. No product provided for washout 
period.  
• Dispensing diary cards 
• Diaries to be completed daily 
Weeks 6-9 Visit 3 
3 week 
Post Washout 
period 
• Provide faecal, urine and blood samples (visit 3)  
• Diaries to be submitted 
• Dispensing diary cards 
• Dispensing product 
• During next 6 week period – product will be taken 
twice daily 
• Diaries to be completed daily  
 
Weeks 9-15 
(interim period) 
Visits 4  
6 Week 
Treatment  
period 
• Diaries to be submitted  
• Provide faecal, urine and blood samples and given 
new diary cards. No product provided for washout 
period.  
• Given new diary cards 
• Diaries to be completed daily  
 
Weeks 15-18 
(end of  
treatment 
period) 
Visit 5 
3 week 
Post Washout 
period 
• Provide faecal, urine and blood samples (visit 3)  
• Diaries to be submitted 
 
 
Note: Volunteers will take all treatments during the course of the study but not at the same time. Volunteers will be 
provided with breakfast on visit days. 
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Appendix D: Pre-study Questionnaire 
 
Pre-study General Health Questionnaire and Volunteer details 
 
Name: _______________________________________ 
 
 
DOB:  _______________________________________ 
 
Gender: ______________________________________ 
 
Address: _____________________________ 
 
  ________________________ 
 
  ________________________ 
 
  ________________________ 
 
  ________________________ 
 
Telephone: ____________________________________ 
 
 
  
Height: _______________________________________ (cm) 
 
Weight: _______________________________________ (kg) 
 
Waist circumference: ____________________________ (cm) 
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Questions to assess general health   
Does the following apply to you? 
 Yes  No Don’t know If Yes – Please describe 
History of drug or alcohol abuse     
Excessive Alcohol consumption * 
*Should not drink regularly (most days 
or everyday) more than : 
Men: 3-4 Units a day (not more than a 
pint of strong lager,beer or cider;) 
Women: 2-3 Units a day (not more than 
a standard 175 ml glass of wine) 
    
Smoker     
Lactose intolerance     
Pregnancy, lactation or planning 
pregnancy 
    
Involvement in drug/ medication study 
in last month 
    
Intake in pre or probiotics within last 
month 
    
Gluten allergy      
Use of antibiotics in previous 6 months     
Colonic irrigation (within last 3 
months)? 
    
Medication active on GI tract (within 
last 3 months) 
    
Family history of colorectal cancer in 
under 50’s 
    
Please state any prescribed medication you are currently taking below: 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
________________________________________________________________________________ 
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Do you suffer from any conditions involving the following? 
 
 Yes No Don’t 
know 
If Yes – Please describe 
Dermatological/Connective tissue     
Head, Ears, Eyes, Nose and Throat     
Cardiovascular     
Respiratory     
Abdominal     
Urogenital/Rectal     
Gastroenterological     
Lymphatic     
Neurological     
Coeliac disease     
 
 
All details will be kept strictly confidential  
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Appendix E: Volunteer diaries 
 
Volunteer Diary 
 
Page 1 of 10 
 
 
Volunteer No. _______________________ 
 
 
 
Period No. _____________________ Day No. to Day No. 
 
 
Please fill in the diary carefully and completely for each day. If you are unsure how to answer, please 
give the best information you can. Please return completed diary to Xuedan Wang on your next visit. 
 
To be filled in by investigator only! 
 
Date started at: 
 
Next visit at: 
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Page 2 of 10  
 
 
 
 
 
 
The Bristol stool chart provides a scale 
relating to stool consistency, please use 
this chart to rate your stool consistency 
1-7 (solid – liquid) in your daily diary. 
 
E.g. a rating of 4 – used in the diary 
example would relate to “like a sausage 
or snake, smooth and soft”) 
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Page 3 of 10        Volunteer No.  
Study 
day 
Date 
d/m 
Number of 
stools 
Stool consistency as per 
Bristol chart(page 2) 
Abdominal pain 
  If 0 please 
include 
Stool 1 Stool 2 Stool 3 none mild moderate severe 
e.g. 15/01 1 4 x x     
1          
2          
3          
4          
5          
6          
7          
8          
9          
10          
11          
12          
13          
14          
15          
16          
17          
18          
19          
20          
21          
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 Page 4 of 10       Volunteer No.  
Study day Date d/m  
Stomach or intestinal bloating 
 
Flatulence 
  none mild moderate severe none mild moderate severe 
e.g. 15/01         
1          
2          
3          
4          
5          
6          
7          
8          
9          
10          
11          
12          
13          
14          
15          
16          
17          
18          
19          
20          
21           
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Page 5 of 10       Volunteer No. _______________ 
Study day Date 
d/m 
 
Happy  
 
Alert 
  Less than 
normal 
Normal More than 
normal 
Less than 
normal 
Normal More than 
normal 
e.g. 15/1       
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15        
16        
17        
18        
19        
20        
21        
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Page 6 of 10       Volunteer No. _______________ 
Study day Date 
d/m 
 
Energetic 
 
Stressed 
  Less than 
normal 
Normal More than 
normal 
Less than 
normal 
Normal More than normal 
e.g 15/01       
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15        
16        
17        
18        
19        
20        
21        
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Page 7 of 10                     Volunteer No.  
Medication 
Please enter the intake of any medication taken during the study with name, dosage per day, date 
started and date stopped. 
Medication Dosage Date started - stopped 
e.g1. paracetamol 500mg twice 15/1 – 15/01 
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   
11   
12   
13   
14   
15   
16   
17   
18   
19   
20   
21   
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Page 8 of 10                                                                Volunteer No.  
Adverse Events 
Please enter the occurrence of all adverse events and any respiratory infections, colds or flu-like 
symptoms with start and end date and time. 
Adverse Event Date – started Date – stopped 
e.g1. headache 15/01 15/01 
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   
11   
12   
13   
14   
15   
16   
17   
18   
19   
20   
21   
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Page 9 of 10       Volunteer No. _______________ 
 Date: 
  
Time Food/drink  
 
Details Amount 
E.g. 6.30 
 
   
    
7.30 
 
Cereal Weetabix 3  
 Semi-skimmed milk  1 mug full 
 
 
Toast Wholemeal 2 slices 
 
 
Tea Tea, Milk 1 mug full 
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Page 10 of 10       Volunteer No. _______________ 
 
Final Questions 
Did you experience any of the following after taking your product: 
 
 
Did you experience an after taste? 
 
 Yes   No   
 
 
Did you experience a feeling of fullness? 
 
 Yes   No   
 
 
Did you experience difficulty in taking the product? 
 
 Yes   No   
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Appendix F: Advertisement 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Department of Food and Nutritional Sciences 
Xuedan Wang: X.Wang6 @pgr.reading.ac.uk 
Whiteknights 
PO Box 266, Reading RG6 6AP, UK 
Telephone 07840031309 
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                                                                    Appendix G 
Recruitment Letter 
 
Dear  
 
We are looking to recruit men and women aged 18-50 years old, who haven’t received any antibiotics 
for the past 6 months , on to a dietary intervention trial at The University of Reading. The product we 
will be using is a prebiotic called Synergy1. Prebiotics are non-digestible fibre and safe for human 
consumption. This trial will investigate the effect of the prebiotic on gut bacteria and protein 
metabolism. 
  
The study will consist of a 4 month randomised crossover treatment period with prebiotic or 
placebo.  
 
Please review the enclosed information sheet and contact myself (study investigator) if you are 
interested in participating, or would like any further information or to discuss any concerns. There will 
be a minimum of two weeks to decide whether you would like to be involved in the study and a 
meeting will be arranged before the commencement of the trial prior to giving informed consent. 
Participants are free to withdraw from the trial at any time. 
 
The trial will commence on (Trial start date) 
 
If you have any questions about the trial please do not hesitate to contact me. 
 
We appreciate your help. 
 
Yours sincerely, 
 
 
Xuedan Wang 
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Appendix H 
 
Information relating to safety aspects of the prebiotic 
Please find attached the pdf file from Beneo confirming both prebiotic and placebo in this study is 
safe to take. Any concerns/questions, please feel free to call at any time. 
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